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A B S T R A C T
Background
Trachoma is the world’s leading infectious cause of blindness. In 1996, WHO launched the Alliance for the Global Elimination of
Trachoma by the year 2020, based on the ’SAFE’ strategy (surgery, antibiotics, facial cleanliness, and environmental improvement).
Objectives
To assess the evidence supporting the antibiotic arm of the SAFE strategy by assessing the effects of antibiotics on both active trachoma
(primary objective), Chlamydia trachomatis infection of the conjunctiva, antibiotic resistance, and adverse effects (secondary objectives).
Search methods
We searched relevant electronic databases and trials registers. The date of the last search was 4 January 2019.
Selection criteria
We included randomised controlled trials (RCTs) that satisfied either of two criteria: (a) trials in which topical or oral administration of
an antibiotic was compared to placebo or no treatment in people or communities with trachoma, (b) trials in which a topical antibiotic
was compared with an oral antibiotic in people or communities with trachoma. We also included studies addressing different dosing
strategies in the population.
Data collection and analysis
We used standard methods expected by Cochrane. We assessed the certainty of the evidence using the GRADE approach.
Main results
We identified 14 studies where individuals with trachoma were randomised and 12 cluster-randomised studies.
Any antibiotic versus control (individuals)
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Nine studies (1961 participants) randomised individuals with trachoma to antibiotic or control (no treatment or placebo). All of these
studies enrolled children and young people with active trachoma. The antibiotics used in these studies included topical (oxy)tetracycline
(5 studies), doxycycline (2 studies), and sulfonamides (4 studies). Four studies had more than two study arms. In general these studies
were poorly reported, and it was difficult to judge risk of bias.
These studies provided low-certainty evidence that people with active trachoma treated with antibiotics experienced a reduction in
active trachoma at three months (risk ratio (RR) 0.78, 95% confidence interval (CI) 0.69 to 0.89; 1961 people; 9 RCTs; I2 = 73%)
and 12 months (RR 0.74, 95% CI 0.55 to 1.00; 1035 people; 4 RCTs; I2 = 90%). Low-certainty evidence was available for ocular
infection at three months (RR 0.81, 95% CI 0.63 to 1.04; 297 people; 4 RCTs; I2 = 0%) and 12 months (RR 0.25, 95% CI 0.08
to 0.78; 129 people; 1 RCT). None of these studies assessed antimicrobial resistance. In those studies that reported harms, no serious
adverse effects were reported (low-certainty evidence).
Oral versus topical antibiotics (individuals)
Eight studies (1583 participants) compared oral and topical antibiotics. Only one study included people older than 21 years of age.
Oral antibiotics included azithromycin (5 studies), sulfonamides (2 studies), and doxycycline (1 study). Topical antibiotics included
(oxy)tetracycline (6 studies), azithromycin (1 study), and sulfonamide (1 study). These studies were poorly reported, and it was difficult
to judge risk of bias.
There was low-certainty evidence of little or no difference in effect between oral and topical antibiotics on active trachoma at three
months (RR 0.97, 95% CI 0.81 to 1.16; 953 people; 6 RCTs; I2 = 63%) and 12 months (RR 0.93, 95% CI 0.75 to 1.15; 886 people;
5 RCTs; I2 = 56%). There was very low-certainty evidence for ocular infection at three or 12 months. Antimicrobial resistance was
not assessed. In those studies that reported adverse effects, no serious adverse effects were reported; one study reported abdominal pain
with azithromycin; one study reported a couple of cases of nausea with azithromycin; and one study reported three cases of reaction to
sulfonamides (low-certainty evidence).
Oral azithromycin versus control (communities)
Four cluster-randomised studies compared antibiotic with no or delayed treatment. Data were available on active trachoma at 12 months
from two studies but could not be pooled because of reporting differences. One study at low risk of bias found a reduced prevalence
of active trachoma 12 months after a single dose of azithromycin in communities with a high prevalence of infection (RR 0.58, 95%
CI 0.52 to 0.65; 1247 people). The other, lower quality, study in low-prevalence communities reported similar median prevalences of
infection at 12 months: 9.3% in communities treated with azithromycin and 8.2% in untreated communities. We judged this moderate-
certainty evidence for a reduction in active trachoma with treatment, downgrading one level for inconsistency between the two studies.
Two studies reported ocular infection at 12 months and data could be pooled. There was a reduction in ocular infection (RR 0.36, 0.31
to 0.43; 2139 people) 12 months after mass treatment with a single dose compared with no treatment (moderate-certainty evidence).
There was high-certainty evidence of an increased risk of resistance of Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia
coli to azithromycin, tetracycline, and clindamycin in communities treated with azithromycin, with approximately 5-fold risk ratios
at 12 months. The evidence did not support increased resistance to penicillin or trimethoprim-sulfamethoxazole. None of the studies
measured resistance to C trachomatis. No serious adverse events were reported. The main adverse effect noted for azithromycin (~10%)
was abdominal pain, vomiting, and nausea.
Oral azithromycin versus topical tetracycline (communities)
Three cluster-randomised studies compared oral azithromycin with topical tetracycline. The evidence was inconsistent for active
trachoma and ocular infection at three and 12 months (low-certainty evidence) and was not pooled due to considerable heterogeneity.
Antimicrobial resistance and adverse effects were not reported.
Different dosing strategies
Six studies compared different strategies for dosing. There were: mass treatment at different dosing intervals; applying cessation or
stopping rules to mass treatment; strategies to increase mass treatment coverage. There was no strong evidence to support any variation
in the recommended annual mass treatment.
Authors’ conclusions
Antibiotic treatment may reduce the risk of active trachoma and ocular infection in people infected with C trachomatis, compared to
no treatment/placebo, but the size of the treatment effect in individuals is uncertain. Mass antibiotic treatment with single dose oral
azithromycin reduces the prevalence of active trachoma and ocular infection in communities. There is no strong evidence to support
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any variation in the recommended periodicity of annual mass treatment. There is evidence of an increased risk of antibiotic resistance
at 12 months in communities treated with antibiotics.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for trachoma
What is the aim of this review?
The aim of this Cochrane Review was to find out if antibiotics work for treating trachoma, either in individuals or communities.
Cochrane researchers collected and analysed all relevant studies to answer this question and found 26 studies.
Key messages
The review shows that antibiotic treatment of people and communities with trachoma leads to less eye infection due to trachoma and
less eye disease. Mass treatment of communities with antibiotics is associated with increased antimicrobial resistance.
What was studied in the review?
Trachoma is caused by a kind of bacterial infection of the outer eye which, if not treated, can lead to blindness. This germ is known
as Chlamydia trachomatis, which thrives where water is scarce and hygiene is poor. Trachoma is the most common infectious cause of
vision loss and usually affects people living in poor communities. Repeated bouts of conjunctivitis (inflammation of the membrane that
covers the surface of the eyeball and inside of the eyelids) known as ’active trachoma’ caused by this eye infection can lead to inward
turning of the upper eyelid. The eyelashes rub the clear front part of the eye (cornea) leading to pain, scarring, and blindness.
The World Health Organization (WHO) has developed the SAFE strategy to eliminate trachoma.
• Surgery for inward-turning eyelids
• Antibiotics to clear the eye infection
• Facial cleanliness to stop the eye infection being passed on
• Environmental improvement, in particular clean water and sanitation
This review considers the A part of the SAFE strategy. Antibiotics can be used to treat the eye infection and may be given as an
ointment or by mouth. The two antibiotics commonly used for the treatment of trachoma are azithromycin (single dose by mouth)
and tetracycline (ointment applied to the eye over several weeks).
What are the main results of the review?
Cochrane researchers found 26 relevant studies.
Fourteen studies enrolled people with trachoma. These studies took place in the following WHO regions (one study took place in two
regions): African Region (three studies), Eastern Mediterranean Region (five studies), Region of the Americas (four studies), South-
East Asian Region (one study), and Western Pacific Region (two studies). Most of the studies enrolled children and young people with
active trachoma.
These studies showed that:
people with trachoma treated with antibiotics may have less active trachoma and eye infection at three and 12 months after treatment
(low-certainty evidence);
there may be little or no difference in active trachoma between oral and topical antibiotics at three months and 12 months (low-
certainty evidence) but there was only very low-certainty evidence on eye infection at three and 12 months;
there were no reports of serious adverse effects. The most common adverse effect reported was nausea with azithromycin.
Twelve studies enrolled communities in areas where trachoma is common and treated the whole community (’mass treatment’). These
studies took place mainly in the African Region (10 studies), with one study in the Eastern Mediterranean Region (Egypt) and one
study in the Western Pacific Region (Vietnam).
These studies showed that:
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communities treated with azithromycin had less trachoma (active trachoma and eye infection) 12 months after a single dose treatment
(moderate-certainty evidence);
there was no strong evidence to support changing from the currently recommended strategy of mass treatment of affected communities
every year;
there was an increased risk of antimicrobial resistance in treated communities (high-certainty evidence).
How up-to-date is this review?
Cochrane researchers searched for studies that had been published up to 4 January 2019.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotic versus control for trachoma: individuals
Patient or population: people (any age) with act ive trachoma
Settings: people resident in a trachoma endemic area
Intervention: ant ibiot ics, including (oxy)tetracycline, doxycycline, sulfonamides
Comparison: control (no treatment or placebo)




Certainty of the evidence
(GRADE)




act ive trachoma de-
f ined as TF, TI, or both






800 per 1000 624 per 1000
(552 to 712)






750 per 1000 555 per 1000
(413 to 750)
Ocular C trachomatis in-
fection
Posit ive test for C tra-
chomatis infect ion iden-
t if ied by culture, stain-
ing on conjunct ival
smears, or nucleic acid
amplif icat ion methods






500 per 1000 405 per 1000
(315 to 520)



















































































Proport ion of samples
showing evidence of re-
sistance to ant ibiot ic
Any t ime point None of the studies addressed this outcome.
Adverse effects Any t ime point 4 studies made no comment on adverse ef fects.
3 studies noted no untoward react ions (sulfonamides) or only trivial react ions
(tetracycline, sulfonamide)
1 study of 155 students noted 3 adverse react ions to sulfonamide (severe
purpura associated with marked thrombocytopenia, 2 cases of drug rash)
1 study of 122 children noted anorexia, nausea, vomit ing, or diarrhoea in 3
children. 2 of these children were receiving doxycycline, and the disturbances





* The assumed risk is the median risk in control groups in the included studies (rounded to nearest 10 per 1000). The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; TF: t rachomatous inf lammation-follicular; TI: t rachomatous inf lammation-intense; RR: risk rat io
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for serious lim itat ions in study design (methods of sequence generat ion, allocat ion concealment, and
masking poorly reported; three studies at high risk of attrit ion bias) and one level for serious inconsistency (risk rat ios
ranged f rom 0.40 to 1.02 and I2 = 73%).
2Downgraded one level for serious lim itat ions in study design (methods of sequence generat ion, allocat ion concealment, and
masking poorly reported; two studies at high risk of attrit ion bias) and one level for serious inconsistency: risk rat ios ranged
f rom 0.50 to 1.05 and I2 = 90%). We did not addit ionally downgrade for imprecision, although the upper conf idence interval
was 1.00, as we felt that this imprecision probably ref lects lim itat ions in study design and inconsistency.
3Downgraded one level for serious lim itat ions in study design (methods of sequence generat ion and allocat ion concealment
poorly reported; two studies at high risk of attrit ion bias) and one level for serious imprecision (95% CI 0.63 to 1.04 include
null ef fect 1).
4Downgraded two levels for very serious lim itat ions in study design (only one small study with poorly reported methods of











































































5Downgraded one level for very serious lim itat ions in study design (methods of sequence generat ion, allocat ion concealment,
and masking poorly reported; three studies at high risk of attrit ion bias) and one level for imprecision, as the studies were not












































































B A C K G R O U N D
Description of the condition
Trachoma is the world’s leading infectious cause of blindness
(WHO 2018). In 2015, there were an estimated 398,000 peo-
ple blind due to trachoma (80% uncertainty intervals 114,000 to
851,000) (Flaxman 2017). Trachoma is a disease of poverty and is
associated with poor water supplies and sanitation (Garn 2018).
The age-standardised all-ages prevalence of blindness due to tra-
choma varies from 0% in most high-income countries to 0.23%
(0.07% to 0.42%) in East sub-Saharan Africa and 0.19% (0.06%
to 0.35%) in West sub-Saharan Africa (Flaxman 2017).
There are two phases of trachoma. In the first phase, most fre-
quently seen in infancy and childhood, there are repeated rounds
of conjunctivitis caused by the bacterium Chlamydia trachomatis.
The conjunctivitis is characterised by the presence of follicles on
the under surface of the upper eyelid and by vascular changes and
is known as active trachoma. Active trachoma is associated with
discharge from the eyes and nose that is particularly noticeable on
the faces of children, but the active stage may also be asymptomatic
in children and adults. When symptomatic, symptoms may persist
for months after the infection is cleared. C trachomatis is thought
to be transmitted from child to child and from child to mother
and back to child through eye-finger-eye contacts, fomites, and
via eye-seeking flies.
Repeated conjunctival infections over a number of years can lead
to the second phase of disease, characterised by scarring and short-
ening of the upper eyelid. Ultimately, the lashes turn inwards to
rub on the cornea, causing pain, corneal abrasions, and secondary
infection. Treatment at this stage is surgery to reposition the eyelid
margin. Blindness results from corneal opacification. The blind-
ing phase affects women more commonly than men (Cromwell
2009), and typically starts in adult life (Burton 2009).
Description of the intervention
Active trachoma has been treated with antibiotics since the 1950s,
and a variety of regimens have been used. The antibiotic can be
applied directly to the conjunctiva (topical) or taken orally (sys-
temic). Topically applied antibiotics are usually in the form of an
ointment, and a variable amount is squeezed onto the inner surface
of the lower eyelid. This route gives a high concentration of the
antibiotic to the conjunctiva but a low dose to the nasopharynx,
which is also a reservoir for the organism. Ointments may cause
stinging eyes and temporary blurred vision, and they are difficult
to apply to small children.
Oral treatment gives a higher dose of antibiotic to sites of infec-
tion outside of the eye, but systemic antibiotics can cause various
adverse effects in the person taking them. Bacteria anywhere in
the body may also develop antibiotic resistance. As the currently
recommended oral antibiotic regimen is a single, directly observed
dose of azithromycin, as compared to six weeks of twice-daily top-
ical tetracycline, oral treatment is likely to have a higher compli-
ance rate than a course of topical antibiotic.
Efforts in trachoma control have used various antibiotic treat-
ment regimens and have also been aimed at different subgroups
within a trachoma endemic area. Examples of subgroups are: only
those individuals with clinical signs of disease (detected actively or
passively); active cases together with family contacts; or high-risk
groups including schoolchildren. Because many individuals har-
bour infection without demonstrating clinical signs, it has been
suggested that trachoma elimination cannot be achieved by an-
tibiotic treatment given only to subgroups of a trachoma endemic
community (Bailey 1993; Kamiya 1956; Sutter 1983). This led to
the concept of community-based interventions, where all residents
of a community should receive treatment irrespective of disease
status.
The desired primary endpoint of any intervention against active
disease is reduction of blindness, but this can only be demonstrated
20 to 30 years after the start of the intervention. The usual surro-
gate outcome measure in trachoma intervention trials is clinically
active disease. In some trials a secondary endpoint is laboratory
evidence of ocular C trachomatis infection.
Why it is important to do this review
International interest in trachoma was given a boost in 1996 when
the World Health Organization (WHO) launched a new initiative
for trachoma control, based on the ’SAFE’ strategy, and in 1998 the
51st World Health Assembly passed a resolution on “Global elim-
ination of blinding trachoma” (WHA 1998). The components of
the SAFE acronym are Surgery, Antibiotics, Facial cleanliness, and
Environmental improvement. Cochrane Reviews on surgery for
trichiasis (Burton 2015), face washing (Ejere 2015), and environ-
mental sanitary interventions have also been completed (Rabiu
2012).
The WHO recommends the following antibiotic treatment for
trachoma: either topical treatment of 1% tetracycline ointment to
both eyes, twice daily for six weeks, or azithromycin, given as a
single oral dose of 1 g in adults and 20 mg/kg of body weight in
children (Solomon 2006).
This review was important to systematically evaluate the safety
and effectiveness of these recommended treatment regimens.
O B J E C T I V E S
To assess the evidence supporting the antibiotic arm of the SAFE
strategy by assessing the effects of antibiotics on both active tra-
choma (primary objective), Chlamydia trachomatis infection of the
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conjunctiva, antibiotic resistance, and adverse effects (secondary
objectives).
(1) What is the effect of antibiotic treatment of the individual on
active trachoma and ocular C trachomatis infection?
• What is the effect of antibiotic treatment versus no
treatment?
• What is the effect of oral versus topical antibiotic?
• What is the effect of oral azithromycin compared to topical
tetracycline?
(2) What is the effect of community treatment with antibiotics
on the prevalence of active trachoma and ocular C trachomatis
infection?
• What is the effect of mass administration of antibiotic
compared to no treatment?
• What is the effect of mass administration of oral
azithromycin versus topical tetracycline?
• What is the effect of annual versus different treatment
frequencies?
(3) What are the adverse effects of antibiotic treatment?
• What are the adverse effects at the individual level?
• What is the effect of mass administration of oral
azithromycin or topical tetracycline on resistance in (i) C
trachomatis and (ii) other bacteria?
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review includes only randomised controlled trials (RCTs) of
antibiotic treatment for active trachoma. We included clinical and
community-based trials. In clinical trials, the unit of randomisa-
tion was the individual with active trachoma, and outcomes were
reported at an individual level. In community-based trials, the unit
of randomisation was a community, in which some individuals
had active trachoma, and outcomes may have been reported at an
individual or a community level.
Types of participants
Participants in the trials were people who were usually resident in
a trachoma endemic area.
Types of interventions
We included trials in which the interventions were:
1. topical or oral administration of an antibiotic at any dose or
frequency compared to placebo or no treatment;
2. topical administration of an antibiotic at any dose or
frequency compared to oral administration of an antibiotic at
any dose or frequency.
We excluded studies if the antibiotic was combined with an envi-
ronmental or educational intervention unless this component was
used uniformly across the trial, and only the antibiotic treatment
varied in the different groups.
We also included studies addressing different dosing strategies in
the population.
Types of outcome measures
We measured outcomes at three, 12, and 24 months after the start
of treatment. Three months was the time at which the maximum
effect on active trachoma was expected, given that clinical signs
take several months to resolve after the clearance of infection (
Grassly 2008). We selected 12 months to represent the period
during which recurrence of infection or relapse would most likely
occur, and 24 months to reflect the expected long-term result of
one course of treatment. A course of treatment may be a single or
multiple doses of an oral antibiotic or interrupted applications of
a topical antibiotic applied over six weeks to several months.
In order to take into account the fact that studies may not have
collected outcomes at these exact times, we defined the following
ranges for each:
• three months, i.e. outcomes measured before six months;
• 12 months, i.e. outcomes measured between six months
and 18 months;
• 24 months, i.e. outcomes measured after 18 months.
If more than one outcome measurement in any of these follow-up
ranges was available, then we selected the nearest measurement to
three, 12, or 24 months.
Primary outcomes
The primary outcome for this review was active trachoma. There
are five main trachoma grading scales (Dawson 1975a; Dawson
1981a; MacCallan 1936; Thylefors 1987; WHO 1962). All these
scales except for MacCallan quantify the number of follicles and
the degree of vascular engorgement of the under surface of the
upper eyelid as seen with low magnification (usually x 2.5). The
Dawson scales subdivide the follicular and papillary activity as F
0 to 3 and P 0 to 3. The Thylefors scale is a simplified version
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defining active trachoma by the grades TF (trachomatous inflam-
mation-follicular) and TI (trachomatous inflammation-intense).
The MacCallan scale is not directly comparable with the other
scales, as scarring is included as an indicator of active disease. The
four more recent scales are broadly comparable. A minor inconsis-
tency between them is that Dawson’s F1 is defined as five or fewer
follicles in zones two and three, and F2 as “more than 5 follicles in
zones 2 and 3 together, but less than 5 in zone 3”; whereas TF is
five or more follicles in zones two and three. This means that the
divisions between F1 and F2 and ’not TF’ and TF do not quite
coincide.
In this review we defined the absence of active trachoma as:
• not TF and not TI (Thylefors scale);
• (P0 or P1 or P2) AND (F0 or F1) (WHO and Dawson
scales).
We defined active trachoma as TF, TI, or both, in the Thylefors
scale; or any other grade for P or F in the WHO or Dawson scales.
Secondary outcomes
The secondary outcome for this review was a positive test for C
trachomatis infection. A variety of tests have been used to demon-
strate presence of the pathogen. Historically, staining of conjunc-
tival cells to show inclusion bodies was the first method of iden-
tifying infection. This was followed by culture of the organism,
which was time consuming and lacking in sensitivity. The demon-
stration of antigen by various antibody staining methods followed,
and finally identification of chlamydial DNA by various nucleic
acid amplification methods. The tests, in order of increasing sen-
sitivity, are:
• culture by C trachomatis isolation in eggs or tissue culture;
• staining of conjunctival smears with Giemsa or iodine;
• direct fluorescent antibody cytology;
• indirect enzyme immunoassay;
• nucleic acid test (NAT);
• nucleic acid amplification tests (NAAT).
For the current update we defined an additional secondary out-
come: resistance: proportion of samples showing evidence of
resistance to antibiotic in (i) C trachomatis and (ii) other bacteria.
We considered any measure of resistance reported in the included
studies. This included genotypic and phenotypic measures for all
organisms and drug classes. We focused on the proportion of sam-
ples that were resistant, but also collected data, where available,
on the proportion of isolates that were resistant.
Adverse effects
We recorded all adverse effects reported in the included studies.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist searched the
following electronic databases for randomised controlled trials and
controlled clinical trials. There were no restrictions on language
or year of publication. The electronic databases were last searched
on 4 January 2019.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2019, Issue 1) (which contains the Cochrane Eyes
and Vision Trials Register) in the Cochrane Library (searched 4
January 2019) (Appendix 1).
• MEDLINE Ovid (1946 to 4 January 2019) (Appendix 2).
• Embase Ovid (1980 to 4 January 2019) (Appendix 3).
• International Standard Randomised Controlled Trial
Number (ISRCTN) registry ( www.isrctn.com/
editAdvancedSearch; searched 4 January 2019) (Appendix 4).
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov ( www.clinicaltrials.gov; searched 4 January
2019) (Appendix 5).
• World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( www.who.int/ictrp; searched
4 January 2019) (Appendix 6).
Searching other resources
We used the Science Citation Index to search for articles that cited
the included studies. We searched the reference lists of included
articles for any other potentially relevant studies. For previous
versions of this review, we also contacted experts in the field, either
directly or through the membership of the WHO workshops,
requesting information on unpublished trials. We did not do this
for the current update, however we did contact individual trialists
for more information.
Data collection and analysis
Selection of studies
For the first publication of this review (Mabey 2005), one review
author assessed the titles identified from the initial searches and
selected all titles that made reference to treatment for trachoma.
For subsequent updates (Evans 2011 and current update), two
review authors screened the search results. The searches also found
references to genital C trachomatis infections and to laboratory
tests on C trachomatis. We excluded titles that clearly referred to
either of these groups at the first screening. Two review authors
independently reviewed the full texts of all potentially relevant
papers and assessed them according to the Criteria for considering
studies for this review.
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Data extraction and management
Two review authors independently extracted data. Any discrepan-
cies were resolved before data were entered into Review Manager
5 (Review Manager 2008).
For the 2011 review update, JE checked the original data collec-
tion and entry. The changes that were made are summarised in
Appendix 7. For the newly identified trials, two review authors
(JE, AWS) independently extracted data, resolving any discrepan-
cies by discussion. Data were entered by both review authors onto
two spreadsheets and cross-checked. Data were cut and pasted into
RevMan from the spreadsheet (JE). For the current update, the
process was repeated by JE/EHE using updated Review Manager
5 (RevMan 5) software (Review Manager 2014).
Assessment of risk of bias in included studies
We assessed risk of bias using Cochrane’s ’Risk of bias’ assessment
tool as described in Chapter 8 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2017). We assessed the
extent to which bias could have been introduced in the following
aspects of study design and execution: sequence generation, alloca-
tion concealment, blinding (masking), incomplete outcome data,
and selective outcome reporting. We considered two additional
criteria for cluster-randomised trials: recruitment bias and baseline
imbalances (Higgins 2011). Two review authors (JE/AWS (2011),
JE/EHE (2019)) independently assessed risk of bias, compared
results, and resolved any discrepancies by discussion.
Measures of treatment effect
The primary outcome for the review was active trachoma, and
the secondary outcomes were ocular C trachomatis infection and
antibiotic resistance. These are dichotomous (adverse) outcomes,
and our preferred effect measure was the risk ratio.
Unit of analysis issues
This review includes trials in which individuals were randomly
allocated to treatment and trials in which communities were the
unit of allocation (cluster-randomised trials). A correct analysis
of cluster-randomised trials includes an adjustment for the fact
that people within a cluster tend to be more similar to each other
than to people from other clusters (i.e. the observations are not
independent). The effect of cluster-randomisation is to increase
the size of standard errors and hence widen the confidence intervals
compared with a study of the same size using individual participant
randomisation (Donner 1982).
Our preferred method of analysis of cluster-randomised studies
was as follows: for those studies that reported the effect measure
using an analysis that properly accounted for the cluster design,
we planned to enter and pool data from different studies using the
generic-inverse variance method in RevMan 5. However, we were
aware that cluster-randomised trials are not always analysed and
reported appropriately. We planned that for those studies that did
not report such an effect measure, we would perform an approxi-
mate analysis (Higgins 2011), as follows:
• calculate a ’design effect’ of 1 + (M − 1) ICC (where ICC =
intracluster correlation coefficient and M = average cluster size);
• multiply the standard error of an analysis at the individual
level by the square root of the design effect.
Estimates from the literature suggest that the ICC can vary from
0.05 to 0.2 (Katz 1988; West 1991). We planned sensitivity anal-
yses using ICC estimates of 0.05, 0.1 and 0.2.
Dealing with missing data
The clinical need to change or discontinue antibiotic therapy (for
an individual undergoing treatment for a single episode of infec-
tion of disease, or a community undergoing a single round of mass
treatment) is likely to be rare. This reduces the potential problems
associated with performing the analysis on an intention-to-treat
basis. More serious problems may arise from losses to follow-up
and non-compliance. Some of the trials have been done in largely
transient populations in which losses to follow-up rapidly accu-
mulate as people move on. Such losses were assumed to be inde-
pendent of the outcome measures, therefore we did not exclude
studies on this basis.
Assessment of heterogeneity
We assessed heterogeneity by considering clinical and study design
differences between trials and by examining the forest plots. We
also considered statistical measures of heterogeneity such as the χ
2 test and I2 statistic.
Assessment of reporting biases
As less than 10 trials were included in the meta-analyses in this
version of the review, we did not assess publication bias. In future
updates that include more trials, we will assess the possibility of
small-study effects, including publication bias, using a funnel plot
(plotting the risk ratio along the x-axis versus standard error along
the y-axis).
We included all trials irrespective of the language of publication,
however we cannot exclude the possibility that negative trials have
been published in less accessible journals (see publication bias
above).
We did not find any evidence of multiple (duplicate) reporting
publication bias. Data from one of our included trials, ACT 1999
The Gambia, were published twice, with ocular C trachomatis
infection being the focus of one publication and active trachoma
the focus of the other, but the relationship of the data was clear
from the publications.
11Antibiotics for trachoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data synthesis
In the original review, the review authors pooled outcomes from
community-based trials in which non-affected and affected cases
were treated with outcomes from individual-based trials in which
only affected cases were treated. The original protocol planned but
did not carry out a sensitivity analysis to determine the effect of
using only data from cases that were active at baseline.
In the updates we considered these community-based and indi-
vidually randomised trials separately, as we believed that they were
asking different questions and were likely to be estimating differ-
ent treatment effects. The individually randomised studies address
the question: what is the effect of antibiotic treatment on individ-
uals? The cluster-randomised trials address the question: what is
the effect of antibiotic treatment on communities? The effect of
treatment in individuals in treated communities may be different
because as well as the individual-level effect, there may be an ad-
ditional impact via reduction in transmission. The following two
objectives were identified.
Where appropriate, data were pooled using a random-effects
model. We used a fixed-effect model if there were three or fewer
trials. In cases where there was substantial heterogeneity or incon-
sistency, that is the individual study estimates were different sides
of the null line and/or confidence intervals did not overlap, with
corresponding high levels of I2, we did not pool the results.
Subgroup analysis and investigation of heterogeneity
We considered type of antibiotic (oral or topical) to be a potential
source of clinical heterogeneity. This subgroup analysis was not
specified explicitly but was implied in the objectives of the origi-
nal protocol, which were to consider oral and topical antibiotics
separately, in particular oral azithromycin and topical tetracycline.
A further subgroup analysis considered just those trials in which
communities were randomised to oral azithromycin, topical tetra-
cycline, or both, where the antibiotic was administered using regi-
mens consistent with WHO guidelines current in 2010, compared
either to each other, placebo, or no treatment.
Sensitivity analysis
As set out above in the Unit of analysis issues section, we considered
the possible effect of assumptions about the size of the intracluster
correlation coefficient (ICC) on the results.
’Summary of findings’ table
’Summary of findings’ tables were introduced in the current up-
date following new Cochrane guidance. As such, these tables are
post hoc, but as fewer than seven outcomes were specified in this
review, and we focused on the key comparisons in individuals and
communities, there were no significant judgements that may have
been influenced by our knowledge of the data in the preparation
of these tables. We graded the certainty of the evidence for the
comparisons and outcomes included in the ’Summary of findings’
tables using the GRADE approach (Schünemann 2017). We con-
sidered risk of bias in the studies contributing data, consistency of
effects, precision of the effect estimate, directness of the evidence,
and possibility of publication bias when grading the evidence. The
initial assessment was done by JE, and this was checked by co-
authors.
R E S U L T S
Description of studies
Results of the search
2011 version
The previous edition of this review published in 2011 included 22
studies. Fourteen of these studies were individually randomised,
and a further eight were cluster-randomised.
2019 update
The searches run in January 2019 yielded a further 1406 records
(Figure 1). After removal of 301 duplicates, the Cochrane Infor-
mation Specialist screened the remaining 1105 records and re-
moved 839 references that were not relevant to the scope of the
review. We screened the remaining 266 references and obtained
51 full-text reports for further assessment. We identified 27 re-
ports of four new cluster-randomised studies (PRET Niger; PRET
Tanzania; PRET The Gambia; Wilson 2018). The searches iden-
tified three new reports for the TEF study and nine new reports
for the TANA study. The total number of included studies was
26; see Characteristics of included studies for further details.
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Figure 1. Study flow diagram.
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We will assess two ongoing studies for potential inclusion when
data become available (NCT03523156; SWIFT 2017), and one
study by Last 2015 is awaiting classification.
We excluded nine reports of the following nine studies: Coulibaly
2013; MORDOR 2018; NCT00286026; NCT00347607;
NCT00347776; NCT01178762; NCT01767506;
NCT02211729; Schachterle 2014. The total number of excluded




Fourteen individually randomised studies are included in the re-
view (Table 1).
Types of participants
These 14 studies took place in the following countries (according
to WHO region) (one study, Cochereau 2007, was conducted in
two regions).
African Region
• The Gambia (Bailey 1993; Bowman 2000)
• Guinea (Cochereau 2007)
Eastern Mediterranean Region
• Egypt (Attiah 1973; Dawson 1997)
• Iran (Darougar 1980)
• Pakistan (Cochereau 2007)
• Saudi Arabia (Tabbara 1996)
Region of the Americas
• USA (Dawson 1969 Sherman; Dawson 1969 Stewart;
Foster 1966; Hoshiwara 1973)
South-East Asian Region
• India (Shukla 1966)
Western Pacific Region
• Australia (Peach 1986)
• Taiwan (Woolridge 1967)
The participants in these studies had active trachoma. The num-
ber of participants randomised ranged from 29, in Dawson 1969
Sherman, to 670, in Cochereau 2007. Almost all of the studies
enrolled children and/or young people (21 years or younger) only,
with the exception of Bailey 1993, which had a wider age range
(9 months to 60 years). Not all studies reported the proportion of
males and females, but in those that did there were approximately
equal proportions. Participants in the studies in USA and Aus-
tralia were from Indigenous communities (Native American and
Aboriginal, respectively).
Types of interventions
Table 2 summarises the comparisons addressed in these studies.
Nine studies compared antibiotic with a no-treatment or placebo
arm. These antibiotics were:
• tetracycline or oxytetracycline applied topically (Attiah
1973; Darougar 1980; Woolridge 1967);
• oral tetracycline (Peach 1986);
• doxycycline (Hoshiwara 1973);
• sulfonamides (Dawson 1969 Sherman; Dawson 1969
Stewart; Foster 1966; Shukla 1966).
Four studies compared oral azithromycin with topical tetracycline
(Bailey 1993; Bowman 2000; Dawson 1997; Tabbara 1996).
One study compared topical azithromycin with oral azithromycin
(Cochereau 2007).
Azithromycin was usually given as a single dose of 20 mg/kg up
to 1 g (for adults). Topical tetracycline was usually the 1% dose,
although there was some variation in treatment schedules. In gen-
eral, the application of topical tetracycline was supervised, or ap-
plied by personnel in the research team. The exceptions were Bailey
1993 and Bowman 2000, where the ointment was administered
by carers and was not supervised.
Types of outcome measures
Reporting of the two main outcome measures for this review is
presented in Table 3.
All studies provided data at around three months (range two to
five months). Six studies had longer follow-up, ranging from six
months (Bailey 1993; Bowman 2000), and 12 months (Darougar
1980; Dawson 1997; Foster 1966) to three years (Woolridge
1967).
All 14 individually randomised studies reported active trachoma at
follow-up. A variety of classification schemes were used for active
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trachoma. The majority of studies used one of the scales described
in Types of outcome measures.
• MacCallan 1936 (Dawson 1969 Sherman; Dawson 1969
Stewart; Woolridge 1967)
• WHO 1962 (Attiah 1973; Shukla 1966)
• Dawson 1975 (Darougar 1980)
• Dawson 1981 (Bailey 1993; Tabbara 1996)
• Thylefors 1987 (Bowman 2000; Cochereau 2007; Dawson
1997)
Three studies used different classifications, but these were likely to
have been based on a similar assessment (Foster 1966; Hoshiwara
1973; Peach 1986). The trachoma grading scales used after 1962
do not have scarring as a feature of active trachoma, and so the
underlying principles in the grades are more or less equivalent in
all of the studies, using only the presence of follicles and papillae
for diagnosis of active disease.
Six of the 14 studies reported assessment of ocular infection
(Bailey 1993; Cochereau 2007; Darougar 1980; Dawson 1997;
Hoshiwara 1973; Tabbara 1996), but comparative data on ocu-
lar infection between intervention groups were not reported by
Cochereau 2007.
None of the studies considered resistance as an outcome. Adverse
effects were reported inconsistently.
Cluster-randomised studies
Twelve community-based studies are included in the review (Table
4).
Types of participants
These 12 studies took place in the following countries (according
to WHO region).
African Region
• The Gambia (ACT 1999 The Gambia; PRET The Gambia)
• Ethiopia (TANA; TEF)
• Niger (NCT00618449; PRET Niger)
• Mali (Resnikoff 1995)
• Tanzania (ACT 1999 Tanzania; PRET Tanzania; Wilson
2018)
Eastern Mediterranean Region
• Egypt (ACT 1999 Egypt)
Western Pacific Region
• Vietnam (Atik 2006)
The inclusion criteria for communities were not always clearly
specified in these studies, and varied where they were speci-
fied. Some studies randomly selected communities in specific
regions (Atik 2006; TEF); some studies specified a cut-point
in terms of prevalence of active trachoma between 5% and
20% (NCT00618449; PRET Niger; PRET Tanzania; PRET The
Gambia); one study included communities that had not received
azithromycin since 2009 with an estimated prevalence of active
trachoma between 5% and less than 10% (Wilson 2018); and
others used logistical considerations (TANA).
All the studies (except Atik 2006) evaluated some form of mass
drug administration and therefore included everyone present in
the communities. The evaluation of the outcome was often done
on a random sample of children and adults, termed a “sentinel”
sample. Where sex was reported, approximately 50% of the pop-
ulation were male.
Most studies were conducted in trachoma endemic areas with high
levels of infection and clinical disease, particularly in children.
The exceptions were Atik 2006, NCT00618449, and PRET The
Gambia, where active trachoma and ocular infection were less than
20%.
Types of interventions
Table 5 summarises the comparisons addressed in the 12 cluster-
randomised studies. Almost all of these studies evaluated mass drug
administration with azithromycin at 20 mg/kg up to 1 g for adults.
Resnikoff 1995 assessed topical tetracycline 1%. Atik 2006 only
treated people with active trachoma and their household members.
Four studies compared antibiotic to no treatment, Resnikoff 1995,
or delayed treatment (TANA; TEF; Wilson 2018).
Four studies compared azithromycin and topical tetracycline
(ACT 1999 Egypt; ACT 1999 Tanzania; ACT 1999 The Gambia;
Atik 2006).
Six studies compared different strategies for mass drug adminis-
tration:
• NCT00618449 compared azithromycin twice (one month
apart) with a single dose of azithromycin;
• the three PRET studies compared enhanced coverage (>
90%) with standard coverage (80% to 90%) (PRET Niger;
PRET Tanzania; PRET The Gambia);
• three studies compared azithromycin twice a year for two or
three years with azithromycin once a year for two or three years
(PRET Niger; TANA; TEF), with only children being treated
twice a year in PRET Niger;
• PRET Tanzania and PRET The Gambia compared
azithromycin annually for three years with a cessation rule.
Specific exclusion criteria were usually given for pregnant women,
children younger than six months, or people with macrolide al-
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lergy. Other treatments offered included oral erythromycin or top-
ical tetracycline.
Types of outcome measures
Table 6 summarises the reporting of the main outcome mea-
sures for this review in these cluster-randomised studies. Follow-
up ranged from six months, in Resnikoff 1995, to 42 months,
in TANA, with most studies reporting at least to 12 months.
Most studies used the classification of trachoma as set out in
Thylefors 1987, the exception being the ACT studies (ACT 1999
Egypt; ACT 1999 Tanzania; ACT 1999 The Gambia), which used
Dawson 1981a. Almost all studies (except Resnikoff 1995) did
some form of assessment of ocular infection using a variety of tech-
niques, but most commonly polymerase chain reaction (PCR).
Five studies assessed resistance (PRET Niger; PRET Tanzania;
PRET The Gambia; TANA; TEF). None of the studies assessed re-
sistance of C trachomatis to antibiotics, but a number of other bac-
teria were considered (Streptococcus pneumoniae, Staphylococcus au-
reas, Escherichia coli), as well as genetic determinants of macrolide
resistance.
Excluded studies
We excluded 63 studies for the following reasons (Characteristics
of excluded studies).
• Types of studies: not RCTs (33 studies).
• Types of participants: not people with trachoma or not
conducted in a trachoma endemic area (4 studies).
• Types of interventions: not a relevant intervention or
comparator (21 studies).
• Types of outcomes: eye outcomes not measured, or assessed
effect of antibiotics on trichiasis only (4 studies).
• Other reason: study not done (1 study), trial report not
found (1 study).
Risk of bias in included studies
See Figure 2 and Figure 3.
Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Twelve studies described adequate methods of generating an un-
predictable sequence, using either computer-generated sequences
or random number tables. We considered that allocation conceal-
ment was not an issue for cluster-randomised trials, and graded
all 12 cluster-randomised studies as at low risk of bias for this do-
main. Three of the individually randomised studies reported ade-
quate methods of allocation concealment. The remaining studies
reported insufficient detail to judge the risk of selection bias.
Blinding
We considered performance and detection bias together, but sep-
arated the two main outcomes (active trachoma and ocular infec-
tion) because we considered that masking would have a different
impact on these two outcomes. We considered that the issues of
performance and detection bias for antimicrobial resistance were
likely to be similar to those for ocular infection, as antimicrobial
resistance is also assessed using laboratory tests.
Individually randomised studies
Active trachoma
In most of the individually randomised studies the treatments were
quite different, either comparisons with no treatment, or compar-
ing oral and topical treatments. Only four studies used placebo
treatments to mask the study arms: three studies compared ac-
tive treatment to placebo (Dawson 1969 Sherman; Dawson 1969
Stewart; Hoshiwara 1973), and one study compared oral and top-
ical azithromycin with equivalent placebo treatments in each arm
(Cochereau 2007). We graded these studies as at low risk of bias
for performance and detection bias for active trachoma. A num-
ber of studies mentioned masking, particularly of outcome asses-
sors. Masking was not well described in general, and we marked
these studies as having an unclear risk of bias for performance and
detection bias for active trachoma, given that the interventions
were so clearly different. We graded studies where masking was
not mentioned as at high risk of bias (Shukla 1966).
Ocular infection
Fewer studies measured ocular infection. Where masking was de-
scribed, these were graded in general as having low risk of bias. Two
of the individually randomised studies did not describe masking
of laboratory samples and so were graded as at unclear risk of bias
(Darougar 1980; Dawson 1997).
Cluster-randomised studies
Active trachoma
All the comparisons in the cluster-randomised studies were obvi-
ously different, and none of the studies reported using placebos.
We therefore graded these studies as at high risk of bias, unless
they reported efforts to mask the assessment of trachoma and/or
attempted to minimise knowledge of the other arms of the study,
in which case we graded them as at unclear risk of bias.
Ocular infection (and antimicrobial resistance where
assessed)
We graded the majority of studies that examined these outcomes
as at low risk of bias, as efforts to mask the laboratory assessment
were generally well described. Three studies described masking
procedures in insufficient detail (NCT00618449; PRET Niger;
Wilson 2018).
Incomplete outcome data
Only eight studies provided data suggesting that incomplete out-
come data were unlikely to bias the results, that is they reported
high follow-up rates (greater than 80%) that were reasonably
equal between intervention groups (Bailey 1993; Bowman 2000;
Dawson 1997; Peach 1986; PRET Niger; TANA; TEF; Woolridge
1967). We graded seven studies with high or unequal loss to fol-
low-up as at high risk of attrition bias (ACT 1999 Egypt; ACT
1999 Tanzania; ACT 1999 The Gambia; Atik 2006; Foster 1966;
Hoshiwara 1973; Resnikoff 1995). In another study, people were
excluded because of inadequate treatment, and it was not clear
to which group this applied (Darougar 1980); this study was also
graded as at high risk of attrition bias. Attrition bias was difficult
to judge for the remaining studies, which we graded as at unclear
risk of bias.
Selective reporting
There was little suggestion of selective outcome reporting. Table 3
and Table 6 show the outcome-reporting grid. In most cases where
an outcome was not reported it was because the study follow-
up was not conducted at that time point, which is unlikely to
introduce bias. TANA did not publish data on active trachoma,
but this information was supplied by the authors. In two studies
(Cochereau 2007; NCT00618449), it was clear that data on ocular
infection had been collected but not reported.
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Other potential sources of bias
Recruitment bias
Recruitment bias can occur when individuals are recruited to the
trial after the clusters have been randomised, as the knowledge of
whether each cluster is an ‘intervention’ or ‘control’ cluster could
affect the types of participants recruited (Higgins 2011). None of
the included studies discussed this issue.
Baseline imbalances
When small numbers of clusters are randomised, there is a possibil-
ity of chance baseline imbalance between the randomised groups
in terms of either the clusters or the individuals (Higgins 2011).
This was a problem with some of the cluster-randomised trials in-
cluded in this review. Four of the trials randomised only two com-
munities to treatment or control (ACT 1999 Egypt; ACT 1999
Tanzania; Atik 2006; Resnikoff 1995). Reporting of the baseline
comparability of clusters or statistical adjustment for baseline char-
acteristics can help reduce concern about the effects of baseline
imbalances (ACT 1999 Egypt; ACT 1999 Tanzania), however
it is difficult to interpret differences in treatment effect between
only two communities because there may be some other unknown
confounding factor that explains the difference in effect. In ACT
1999 The Gambia, eight communities were pair-matched. The
more recent cluster-randomised studies were larger: PRET Niger
(24 communities); PRET Tanzania (32 communities); PRET The
Gambia (48 communities); TANA (48 communities); TEF (16
communities); Wilson 2018 (96 communities).
Effects of interventions
See: Summary of findings for the main comparison Antibiotic
versus control for trachoma: individuals; Summary of findings
2 Oral versus topical antibiotic for trachoma: individuals;
Summary of findings 3 Oral azithromycin compared to control
for trachoma: communities; Summary of findings 4 Oral
azithromycin compared to topical tetracycline for trachoma:
communities
Comparison 1: Any antibiotic versus control
(individuals)
Primary outcome: active trachoma
Analysis 1.1 shows the effect of any antibiotic treatment on active
trachoma at three months. Nine trials randomising 1961 people
contributed to this analysis. There was considerable heterogeneity
between trials (I2 = 73%). The treatment effects observed in the
different trials ranged from a risk ratio of 0.40 (95% confidence
interval (CI) 0.20 to 0.79), Dawson 1969 Stewart, to a risk ratio of
1.02 (95% CI 0.83 to 1.25), Darougar 1980. However, most of the
trials suggested an apparent beneficial effect of treatment on active
trachoma measured at three months follow-up. The pooled risk
ratio was 0.78 (95% CI 0.69 to 0.89). We judged this to be low-
certainty evidence, downgrading for risk of bias and inconsistency
(Summary of findings for the main comparison).
Analysis 1.2 shows the effect of any antibiotic treatment on active
trachoma at 12 months. Four trials randomising 1035 people con-
tributed to this analysis. Again there was evidence of considerable
heterogeneity between trials (I2 = 90%). The treatment effects
observed in the different trials ranged from a risk ratio of 0.50
(95% CI 0.41 to 0.62), Shukla 1966, to a risk ratio of 1.05 (95%
CI 0.88 to 1.24), Foster 1966. However, three of the four trials
showed a statistically significant beneficial effect of treatment on
active trachoma measured at 12 months follow-up. The pooled
risk ratio was 0.74 (95% CI 0.55 to 1.00). We judged this to
be low-certainty evidence, downgrading for serious limitations in
study design and inconsistency (Summary of findings for the main
comparison).
Subgroup analysis: oral antibiotics versus control compared
with topical antibiotics versus control
Analysis 1.3 shows the results separately for the trials that con-
sidered oral antibiotic versus control and the trials that consid-
ered topical antibiotic versus control on active trachoma at three
months. Although statistical heterogeneity was reduced by con-
sidering these trials separately, substantial heterogeneity remained
(I2 of 60% and 68%). The pooled estimate of treatment effect for
oral antibiotics on active trachoma at three months was 0.81 (95%
CI 0.67 to 0.97) and for topical antibiotics 0.82 (95% CI 0.72 to
0.92). A similar picture was seen for active trachoma at 12 months
(Analysis 1.4). Subgroup analyses such as these can be misleading
because there may be other reasons for differences between trials
apart from the type of antibiotic used. Direct comparison of oral
versus topical antibiotic within trials is a more reliable estimate of
relative effect.
Secondary outcome: C trachomatis infection
Analysis 1.5 shows the effect of any antibiotic treatment on ocular
C trachomatis infection at three months. Fewer trials contributed
to this analysis (4 trials, n = 297). However, in contrast to the
effect on active trachoma, there was no evidence of heterogeneity
in treatment effect between trials (I2 = 0%). The treatment effect
appeared to be of a similar order of effect as for active trachoma,
but did not achieve conventional levels of statistical significance
(pooled risk ratio of 0.81, 95% CI 0.63 to 1.04). We judged this to
be low-certainty evidence, downgrading for serious limitations in
study design and imprecision (Summary of findings for the main
comparison).
Analysis 1.6 shows the effect of any antibiotic treatment on C
trachomatis infection at 12 months. Only one trial provided data
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on ocular chlamydial infection at 12 months (Darougar 1980).
The effect was strong, with a risk ratio of 0.25. Although this
was statistically significant, the estimate of treatment effect was
imprecise with a wide confidence interval (0.08 to 0.78), reflecting
the small sample size of the trial. We judged this to be low-certainty
evidence, downgrading for very serious limitations in study design:
one small study at risk of bias.
One source of clinical heterogeneity in these trials was whether
oral or topical antibiotic was used. One of the objectives of this
review was to compare oral and topical treatment, in particular
oral azithromycin and topical tetracycline.
Subgroup analysis: oral antibiotics versus control compared
with topical antibiotics versus control
Data were insufficient to make a reliable comparison of the effects
of oral and topical antibiotics versus control on C trachomatis
infection (Analysis 1.7; Analysis 1.8).
Secondary outcome: antimicrobial resistance
None of the studies assessed antimicrobial resistance.
Adverse effects
Table 7 summarises the information on adverse effects reported in
the individually randomised studies. In 5 of the 14 individually
randomised studies, there was no mention of adverse effects in the
study report.
• In Bailey 1993 abdominal pain was reported more often in
the azithromycin group (26% versus 16%, P = 0.09). Other
effects: diarrhoea, vomiting, fever, headache, body pain, other
similar between two study groups.
• Cochereau 2007 reported no treatment-related adverse
events.
• Dawson 1969 Sherman and Dawson 1969 Stewart noted
“No untoward reactions to sulfonamides”.
• Dawson 1997 reported that azithromycin was well
tolerated, and that only two children (of 125 treated)
complained of nausea.
• Foster 1966 noted three adverse reactions to
sulphamethoxypyridazine in 155 children given the drug.
• Hoshiwara 1973 reported “Anorexia, nausea, vomiting or
diarrhoea...” in two children out of 49 receiving doxycycline.
• Tabbara 1996 reported no adverse effects in 31 people given
azithromycin and 29 given tetracycline.
• Woolridge 1967 noted only trivial reactions.
Comparison 2: Oral versus topical antibiotics
(individuals)
Primary outcome: active trachoma
Analysis 2.1 shows the effect of oral versus topical antibiotic on
active trachoma at three months from within-trial comparisons (6
trials, n = 953). There was considerable statistical heterogeneity (I
2 = 63%). The estimates of effect were spread across the null line,
with three trials reporting a beneficial effect of oral antibiotics, and
three trials reporting a beneficial effect of topical antibiotics. Three
of the six trials had findings consistent with no difference in effect
(Darougar 1980; Dawson 1997; Foster 1966). We judged this to
be moderate-certainty evidence, downgrading one level for serious
limitations in study design and one level for inconsistency as the
study estimates ranged from 0.65 to 1.37 (Summary of findings
2).
Analysis 2.2 shows the effect of oral versus topical antibiotic on
active trachoma at 12 months from within-trial comparisons (5
trials, n = 886). There was considerable statistical heterogeneity (I
2 = 56%). The estimates of effect were spread across the null line,
with three trials reporting a beneficial effect of oral antibiotics, and
two trials reporting a beneficial effect of topical antibiotics. Three
of the six trials had findings consistent with no difference in effect
(Darougar 1980; Dawson 1997; Foster 1966). We judged this
to be low-certainty evidence, downgrading one level for serious
limitations in study design and one level for inconsistency as the
study estimates ranged from 0.66 to 1.15 (Summary of findings
2).
Examining the trials for clinical heterogeneity suggested that the
interventions used in Bowman 2000 were different. In particular,
this study focused on “practical operational conditions”, which
meant that the topical treatments were unsupervised. A post hoc
analysis excluding this trial from the analyses substantially reduced
the observed inconsistency (I2 = 0%) at three months, with a
pooled risk ratio for the remaining five included trials of 1.04 (95%
CI 0.94 to 1.16). Similar improvements in consistency were seen
when Bowman 2000 was excluded from the 12 months’ analyses
(I2 changed from 56% to 29%, pooled risk ratio 1.01 (95% CI
0.85 to 1.20)). In the other trials, application of topical antibiotics
was done by members of the research team or schoolteachers.
Secondary outcome: C trachomatis infection
Similarly for active trachoma at 12 months, there was no consistent
evidence to support either oral or topical antibiotics being more
effective for C trachomatis infection at three (Analysis 2.3) or 12
months (Analysis 2.4) (Summary of findings 2).
Secondary outcome: antimicrobial resistance
None of the studies assessed antimicrobial resistance.
Adverse effects
See Comparison 1 above.
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Comparison 3: Oral azithromycin versus topical
tetracycline (individuals)
Primary outcome: active trachoma
Analysis 3.1 and Analysis 3.2 show the specific comparison be-
tween oral azithromycin and topical tetracycline for active tra-
choma at three and 12 months. There was considerable hetero-
geneity in the results of these studies for active trachoma (Analysis
3.1). As before, excluding Bowman 2000 from the analyses sub-
stantially reduced the inconsistency (I2 = 0%), and the pooled risk
ratio of the two remaining trials was 1.01 (95% CI 0.80 to 1.28).
Only two trials reported data at 12 months. Bowman 2000 re-
ported a beneficial effect of azithromycin compared to tetracycline
(risk ratio 0.66, 95% CI 0.45 to 0.98). Dawson 1997 reported a
smaller effect that was not statistically significant (risk ratio 0.90,
95% CI 0.65 to 1.23).
We have not included data from Bailey 1993 in the graphical anal-
yses because they compared oral antibiotic (single dose azithromy-
cin) with a combination of topical/oral antibiotic (topical tetracy-
cline with oral erythromycin for severe cases). A total of 194 peo-
ple with active trachoma were randomly allocated to treatment, 97
in each group. Approximately 60% of these people were antigen
positive at baseline. At 26 weeks, 21/97 had active trachoma in the
azithromycin group and 27/97 in the tetracycline/erythromycin
group (risk ratio 0.78, 95% CI 0.47 to 1.28). Approximately 42%
of each group were antigen positive. We have also not included data
from Cochereau 2007 in the meta-analyses because they compared
oral azithromycin with two regimens of topical azithromycin, and
treated people accompanying the children to the treatment centre.
They found that trachoma resolved in 93.0%, 96.3%, and 96.6%
of the two-day group, three-day group, and oral treatment group
60 days after treatment.
Secondary outcome: C trachomatis infection
Analysis 3.3 and Analysis 3.4 show the specific comparison be-
tween oral azithromycin and topical tetracycline for C trachoma-
tis infection at three and 12 months. Two studies reported this
outcome at three months. The results of these studies differed:
Dawson 1997 risk ratio 0.57, 95% CI 0.14 to 2.30, favouring
azithromycin, and TANA risk ratio 1.30, 95% CI 0.41 to 4.11,
favouring tetracycline. At 12 months there were only data from
Dawson 1997, but with few events the effect estimate was impre-
cisely estimated (risk ratio 0.50, 95% 0.18 to 1.43).
Secondary outcome: antimicrobial resistance
None of the studies assessed antimicrobial resistance.
Adverse effects
See Comparison 1 above.
Comparison 4: Oral antibiotics versus control
(communities)
Four cluster-randomised community-based trials compared an-
tibiotic to no or delayed treatment: three studies of oral azithro-
mycin (TANA; TEF; Wilson 2018) and one study of topical tetra-
cycline (Resnikoff 1995).
Primary outcome: active trachoma
None of the studies followed up at three months.
Two studies published on active trachoma at 12 months (Resnikoff
1995; Wilson 2018) and one study provided unpublished data
(TANA).
In TANA, 258/634 sentinel children aged 0 to 9 years in 12 com-
munities treated with a single dose of azithromycin had active tra-
choma at 12 months compared with 429/613 children in com-
munities where treatment was delayed to 12 months (risk ratio
0.58, 95% CI 0.52 to 0.65). The results of this study were rea-
sonably robust to assumptions about the intracluster correlation
coefficient (ICC): adjusting for an ICC of 0.2 gave a 95% CI of
0.41 to 0.83.
Wilson 2018 reported data as median community prevalence. At
12 months, the median community prevalence of active trachoma
was 9.3% in communities given one single dose of azithromycin
(range 0 to 38.9%) and 8.2% in communities that had not been
treated (range 0 to 52.9%).
There are several potential reasons for the difference between
TANA and Wilson 2018: (1) The prevalence of active trachoma in
the population of Wilson 2018 was low (median 6%). In TANA
disease prevalence was much higher: over 70% of children had
active trachoma at baseline in the intervention groups; (2) We
judged TANA largely at low risk of bias but Wilson 2018 was a
mixture of unclear and high risk of bias. In particular, the authors
reported that reported that people taking part in the 12-month
follow-up were less likely to report exposure to a face-washing
educational campaign and were less likely to live within 30 minutes
of a water source; (3) the coverage of mass drug administration
was lower in Wilson 2018 at 73% whereas in TANA it was over
80%.
In Resnikoff 1995 four villages were randomly allocated in facto-
rial fashion to treatment with 1% oxytetracycline or health edu-
cation. Individuals treated with tetracycline experienced a higher
cure rate than people who were not, and communities treated with
tetracycline experienced a lower incidence and prevalence of the
disease.
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Secondary outcome: C trachomatis infection
TEF and TANA reported C trachomatis infection at 12 months
(Analysis 4.2). In both studies communities treated with azithro-
mycin were less likely to have C trachomatis infection at 12 months
compared to untreated communities. These studies gave different
estimates of effect (0.61 in Atik 2006 and 0.32 in TANA, I2 =
97%). The pooled risk ratio was 0.35 (95% CI 0.21 to 0.60).
Although it is likely that the size of the pooled effect estimate is
unreliable, given the differences between the studies, both of the
studies indicated a statistically significant beneficial effect of an-
tibiotic treatment on C trachomatis infection. Again, we judged
this to be moderate-certainty evidence, downgrading for inconsis-
tency (Summary of findings 3).
The conclusions did not change as a result of adjusting for the extra
variation introduced by the cluster design of the studies. Adjusting
for an ICC of 0.2 gave a confidence interval for the pooled risk
ratio of 0.20 to 0.63.
In TANA communities were treated at 12 months. However, at a
later stage after four years of mass treatment, communities were
randomised to continuation versus discontinuation of annual or
biannual mass treatment. In the discontinuation arm, the mean
prevalence of infection in children aged 0 to 9 years increased from
8.3% (95% CI 4.2% to 12.4%) at baseline (0 months) to 14.7%
(95% CI 8.7% to 20.8%, P = 0.04) at 36 months. The prevalence
of C trachomatis in communities randomised to continuation of
mass treatment was 7.2% (95% CI 3.3% to 11.0%) at baseline
and 6.6% (95% CI 1.1% to 12.0%, P = 0.64) at 36 months.
Wilson 2018 reported data as median community prevalence. At
12 months, the median community prevalence of ocular infection
was 0% in communities given one single dose of azithromycin
(range 0 to 14.3%) and 0% in communities that had not been
treated (range 0 to 14.3%).
Secondary outcome: antimicrobial resistance
Five studies, all taking place in Africa, assessed antimicrobial re-
sistance (Table 8) (PRET Niger; PRET Tanzania; PRET The
Gambia; TANA; TEF). Three of these studies compared azithro-
mycin with no azithromycin (PRET Tanzania; TANA; TEF). In
PRET Tanzania azithromycin was given once a year for three years;
in TANA azithromycin was given every three months for one year;
and in TEF azithromycin was given twice a year for three years.
Two studies compared different frequencies of azithromycin ad-
ministration. PRET Niger compared azithromycin twice a year
for two years to azithromycin once a year for two years. PRET
The Gambia compared azithromycin once a year for three years
to azithromycin once a year for one year. In all five studies antibi-
otic resistance was assessed in children, although the age ranges
differed.
None of the studies assessed antibiotic resistance inC trachomatis.
Three studies assessed S pneumoniae (PRET The Gambia; TANA;
TEF); one study assessed S aureus (PRET The Gambia); and one
study assessed E coli (PRET Tanzania). Carriage was nasopha-
ryngeal, with the exception of E coli, which was gastrointesti-
nal. Four studies assessed resistance to azithromycin. PRET Niger
and TANA assessed genetic evidence of resistance to macrolides
and azithromycin, respectively. Other antibiotics were also consid-
ered: erythromycin (PRET Tanzania), clindamycin (PRET The
Gambia; TANA), tetracycline (TANA; TEF), penicillin (TANA;
TEF), and trimethoprim-sulfamethoxazole (TMP-SMX) (TEF).
Maximum follow-up (after baseline mass drug administration
(MDA) treatment) was six months (PRET Tanzania), 12 months
(TANA), 24 months (PRET Niger), 30 months (PRET The
Gambia), and 54 months (TEF).
Due to the heterogeneity of studies, outcomes, and reporting,
we did not perform any meta-analysis of antimicrobial resistance
outcomes.
Antibiotic resistance in S pneumoniae
Table 9 show the results of the studies investigating resistance to
S pneumoniae (PRET The Gambia; TANA; TEF).
In PRET The Gambia azithromycin/macrolide resistance was as-
sessed one month before, one month after, and six months after the
third annual round of MDA in two communities. This was com-
pared to antibiotic resistance 30 months after one round of MDA
in six communities. There were few cases of resistance to azithro-
mycin: no cases one month before the third round of azithromy-
cin MDA; 5/417 (1.2%) one month after; and 3/343 (0.9%) six
months after. In the comparator group there was one case of resis-
tance in 400 children (0.3%) 30 months after one annual round
of MDA. The risk ratio comparing intervention (six months after
the third round of mass treatment) and control (30 months after
one annual round of mass treatment) suggested an increased risk
of resistance in the intervention communities (risk ratio 3.5, 95%
CI 0.4 to 33.5). However, wide confidence intervals, due to the
sparse data, were compatible with increased or decreased risk.
TANA compared antibiotic resistance in 12 communities allo-
cated to mass treatment with azithromycin every three months
for 12 months, which was compared to antibiotic resistance in 12
communities that did not receive azithromycin for 12 months.
At baseline in the intervention communities, on average 3.6% of
children were carrying S pneumoniae resistant to azithromycin. At
12 months this had increased to 46.9%. The 12 untreated con-
trol communities were not assessed at baseline, but at 12 months
had an average azithromycin-resistant S pneumoniae carriage risk
of 9.2% (risk ratio 5.1, 95% CI 2.8 to 9.3). These analyses are
based on the proportion of swabbed children who were classified
as resistant. Similar findings were seen for analyses of the propor-
tion of pneumococcal isolates that were classified as resistant (risk
ratio 5.6, 95% CI 3.1 to 9.9). The confidence intervals around the
effect estimate do not take into account the cluster design of the
study. In the study report, confidence intervals were only provided
for risk estimates by group and not for the risk ratio. Comparing
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these with confidence intervals calculated ignoring the cluster de-
sign suggested that any design effect in this study would be less
than 1.5. Repeating the risk ratio calculations assuming a con-
servative design effect of 2 suggests the lower confidence interval
would be not less than 2.
Similar results were seen in TEF. A substantial proportion of chil-
dren in eight communities treated with azithromycin twice a year
for three years were carrying S pneumoniae resistant to azithro-
mycin at follow-up visits: 28.2% at 24 months and 76.8% at 36
months. This proportion decreased after cessation of azithromycin
and was 30.6% at 42 months and 20.8% at 54 months. Data from
eight untreated control communities had a lower risk of resistance:
0.9% at 24 months and 0% at 36 months. Risk ratio was 34.0
(95% CI 4.7 to 244) at 24 months and 183.4 (95% CI 11.5 to
2922) at 36 months. Again, repeating analyses assuming a design
effect of 2, the lower confidence intervals were always well above
1.
In TANA an increased risk of clindamycin resistance was seen in
the intervention communities (risk ratio 4, 95% CI 1.4 to 11.7),
but the prevalence of resistance was lower than in other studies:
13.3% in communities treated every three months compared to
3.3% in untreated communities. Similar results were seen for anal-
yses of isolates of S pneumoniae infection.
Both TANA and TEF investigated penicillin resistance in S pneu-
moniae. There were very few cases (0 or 1 only) in both studies.
Both TANA and TEF investigated tetracycline resistance in S pneu-
moniae. In TANA 10% of children had tetracycline-resistant S
pneumoniae at baseline; this increased to 28.4% in communities
given mass treatment with azithromycin every three months. This
was compared to 17.5% resistance in the non-treated communities
at 12 months (risk ratio 1.6, 95% CI 1.01 to 2.6). An analysis with
design effect of 2 reduced the lower confidence interval to below
1. Similar results were seen when the analyses were restricted to
isolates of S pneumoniae infection. In TEF tetracycline resistance
was seen in 36.5%, 68.7%, 57.2%, and 38.7% of samples at 24,
36, 42, and 54 months, respectively. This was compared to 18.9%
and 15.7% resistance in the control group at 24 months and 36
months (risk ratio 1.9 (95% CI 1.2 to 3.0) and 4.3 (2.8 to 6.6),
respectively). The lower confidence interval for the latter analysis
remained above 1 with a design effect of 2.
TEF was the only study to look at TMP-SMX and found a similar
order of magnitude of resistance in intervention (approximately
8%) and comparator groups (approximately 7% at 36 months)
(risk ratio 1.1, 95% CI 0.5 to 2.8).
Antibiotic resistance in S aureus
Table 10 shows the results of the studies investigating resistance
to S aureus (PRET The Gambia).
Only one study reported resistance to S aureus (PRET The
Gambia). This study compared azithromycin once a year for three
years with azithromycin once a year for one year.
Resistance to azithromycin rose from 8.9% one month before the
third round of mass treatment to 34.1% one month after and
dropped again to 7.3% six months later in two communities. This
was higher than the prevalence of resistance in six comparator
communities (1.6%) that had received 1 dose of azithromycin 30
months previously (risk ratio 4.6, 95% CI 1.9 to 11.0). A similar
change over time was seen with clindamycin (5.8% one month
before third round; 30.7% one month after third round; and 5.8%
six months after third round), with a low risk in comparator com-
munities (0.8% prevalence 30 months after baseline) risk ratio 7.3
(95% CI 2.2 to 24.3).
Antibiotic resistance in E coli
One study reported resistance to E coli (Table 11) (PRET
Tanzania). In the four intervention communities, azithromycin
resistance increased from 16.3% at baseline to 61.2% one month
after mass treatment, thereafter decreasing to 42.1% at three
months, and 31.3% at six months. In the four untreated commu-
nities, azithromycin resistance was lower: 20.8%, 18.7%, 15.9%,
and 20.0% (risk ratio at six months 1.6, 95% CI 0.8 to 3.0). A
similar pattern was seen for erythromycin. In the four interven-
tion communities, erythromycin resistance varied from 26.0% at
baseline to 76.0% at one month after mass treatment, to 54.9%
at three months, and 38.6% at six months. In the four untreated
communities, erythromycin resistance was lower: 22.9%, 28.4%,
23.8%, and 26.0% (risk ratio at six months 1.8, 95% CI 0.8 to
3.9).
Adverse effects
Table 12 summarises the information on adverse effects reported
in the cluster-randomised studies. In TANA data on adverse effects
due to azithromycin were collected systematically:
• 96/671 individuals treated with azithromycin reported an
adverse effect of treatment (14.3%, 95% CI 11.7% to 17.2%);
72 of these 96 people (75%) had gastrointestinal effects
(abdominal pain, vomiting, nausea, diarrhoea, constipation, and
related issues) (10.7% of total sample of 671 people, 95% CI
8.5% to 13.3%);
• no serious adverse events were recorded in this study;
• a specific analysis of childhood mortality suggested that
azithromycin treatment reduced the rate of childhood mortality
in these communities. The mortality rate for children aged 1 to 9
years was 4.1 per 1000 person-years (95% CI 3.0 to 5.7) in the
treated communities compared to 8.3 per 1000 person-years
(95% CI 5.3 to 13.1) in the untreated communities.
• NCT00618449, PRET Tanzania, Tabbara 1996, TEF, and
Wilson 2018 reported that there were no serious adverse events.
Notably, two other large cluster-randomised studies of azithromy-
cin did not comment on adverse events (PRET Niger; PRET The
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Gambia), but in PRET Niger “a data and safety monitoring com-
mittee met annually to review results and serious adverse events”.
Comparison 5: Oral azithromycin versus topical
tetracycline (communities)
Primary outcome: active trachoma
Only one study compared oral and topical community-based treat-
ment for trachoma, the Azithromycin in Control of Trachoma
study (ACT). As this study took place in three different countries
in Africa (Egypt, The Gambia, and Tanzania), it is included in the
analyses as three separate studies.
Even though all three studies had the same interventions and the
one study protocol, there was still considerable heterogeneity of
effect. However, it should be noted that in two locations only two
communities were randomised to oral versus topical treatment
(ACT 1999 Egypt; ACT 1999 Tanzania).
The effect of community-based treatment with azithromycin ver-
sus topical tetracycline on active trachoma is shown in Analysis
5.1 and Analysis 5.2. In ACT 1999 Egypt and ACT 1999 The
Gambia, there was some evidence that azithromycin was more ef-
fective than topical tetracycline in reducing the risk of active tra-
choma at three and 12 months. However, these results were not
very robust to assumptions about the ICC. Adjusting for an ICC
of 0.05 resulted in confidence intervals including 1 for all the re-
sults. In ACT 1999 Tanzania, the findings were less consistent,
with a risk ratio greater than 1 (favouring topical treatment) for
active trachoma at three and 12 months. We judged this to be low-
certainty evidence, downgrading for serious limitations in study
design and inconsistency (Summary of findings 4).
One further study with a more complex design compared targeted
azithromycin combined with surgery versus surgery alone. People
with active trachoma in the control group received tetracycline,
as did non-index cases in the intervention group (Atik 2006).
The proportion of people with active trachoma at 12 months was
21/523 in the intervention group compared with 35/994 in the
control (risk ratio 1.14, 95% CI 0.67 to 1.94). The figures for
ocular infection were: 23/659 vs 68/1192 (risk ratio 0.61, 95%
CI 0.39 to 0.97).
Secondary outcome: C trachomatis infection
The effect of community-based treatment with azithromycin ver-
sus topical tetracycline on active trachoma is shown in Analysis
5.3 and Analysis 5.4. At three months, azithromycin appeared to
be more effective than topical tetracycline in reducing the risk of
C trachomatis infection. However, these results were not very ro-
bust to assumptions about the ICC. Adjusting for an ICC of 0.05
resulted in confidence intervals including 1 for all the results. In
ACT 1999 Tanzania, the findings were less consistent, with a risk
ratio greater than 1 (favouring topical treatment) for C trachomatis
infection at 12 months. We judged this to be low-certainty ev-
idence, downgrading for serious limitations in study design and
inconsistency (Summary of findings 4).
Secondary outcome: antimicrobial resistance
See Comparison 4 above.
Adverse effects
See Comparison 4 above.
Comparison 6: Annual versus different treatment
frequencies
The included studies considered several different dosing strategies.
These fall into three broad categories: applying mass treatment at
different dosing intervals; applying cessation or stopping rules to
mass treatment; and strategies to increase mass treatment coverage.
Mass administration of azithromycin at different dosing
intervals
The WHO recommends annual treatment with antibiotics for
communities where the prevalence of active trachoma in children
aged 1 to 9 years is 10% or more (Solomon 2006; WHO 2014).
Four studies compared different dosing intervals with azithromy-
cin versus annual treatment with azithromycin. The different dos-
ing intervals evaluated were as follows.
• Two doses of azithromycin (day 0 and day 30) compared
with one dose (day 0) for one year (NCT00618449).
• Azithromycin (single dose) every three months for one year
(children aged 1 to 10 years only) (TANA).
• Azithromycin (single dose) every six months for two years
(TEF).
• Azithromycin (single dose) every six months for three years
(children aged 0 to 12 years only) (PRET Niger).
• Azithromycin (single dose) every six months for three years
(TANA).
Two doses of azithromycin (day 0 and day 30) compared
with one dose (day 0) for one year
NCT00618449 compared two doses of azithromycin (day 0
and day 30) with a single dose of azithromycin (day 0) in 10
communities within the Maradi region of Niger with a high
prevalence of clinical active trachoma in children aged 10 years
and younger. This study is unpublished, but study results were
available on the trials register (clinicaltrials.gov/ct2/show/results/
NCT00618449). The results of this study were inconclusive. At
one year, 19/679 (2.8%) participants in the two dose arm had C
trachomatis infection compared with 12/668 (1.8%) in the single
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dose arm (risk ratio 1.56, 95% CI 0.76 to 3.18). The investiga-
tors reported that “Prevalence of infection in communities was
less than predicted, as was return of infection post-treatment, thus
hypothesis could not be evaluated”.
Azithromycin (single dose) every three months for 12 months
TANA evaluated the treatment of children aged 1 to 10 years
every three months for one year in 12 communities in Ethiopia.
Active trachoma was reported for the children-treated arm only.
Table 13 shows results for C trachomatis infection. At 12 months
there was a lower prevalence of infection in children age 1 to 10
years in the communities where children were treated every three
months (3.6%) compared with the communities where everyone
was offered 1 annual dose (14.6%). Similar prevalence of infection
at 12 months was observed in the two groups in people age 11
years and above (8.2% versus 6.2%).
Azithromycin (single dose) every six months
Three studies compared azithromycin mass treatment every six
months with annual treatment (PRET Niger; TANA; TEF). In
PRET Niger, the treatment every six months was targeted at chil-
dren aged 0 to 12 years only. PRET Niger and TANA reported
active trachoma, and results were similar between communities
treated every six months and communities treated annually.
• In PRET Niger, the prevalence of active trachoma at 36
months was 7.8% (95% CI 5.3% to 11.4%) in the communities
where children were treated every six months and 8.0% (95% CI
5.0% to 11.6%) in the communities where everyone was treated
annually.
• In TANA, the prevalence of active trachoma in children
aged 0 to 9 years at 42 months was 35.0% (95% CI 23.9% to
46.1%) in communities treated every six months compared with
31.5% (95% CI 21.6% to 41.3%) in communities treated
annually. The authors reported that they did not detect a
difference at all other time points (12, 18, 24, 30, 36 months) in
children aged 0 to 9 years nor in people aged 10 years or older.
All three studies reported results for C trachomatis (see Table 14).
Overall, there was some evidence of lower prevalence of C tra-
chomatis infection in communities treated every six months, but
the differences were generally small and not statistically signifi-
cant. These data were not pooled due to differences in follow-up
and age groups considered and in reporting (mean community
prevalences).
Annual mass drug administration compared to annual mass
drug administration if evidence of trachoma in the
community (C trachomatis infection or active trachoma)
In PRET Tanzania and PRET The Gambia, annual mass drug
administration was also compared to annual mass drug adminis-
tration if there was evidence of follicular trachoma or infection,
that is the lack of infection was to be used as a stopping rule.
In PRET Tanzania the stopping rule was not applied because in-
fection was observed in all communities after dosing.
In PRET The Gambia there was no evidence of any difference
according to stopping rule on active trachoma (rate ratio 1.17,
95% CI 0.65 to 1.53) or C trachomatis infection (rate ratio 0.78,
95% CI 0.14 to 4.49) at 36 months, but with wide confidence in-
tervals, indicating considerable uncertainty in the effect estimate.
The rate ratios quoted here compare communities allocated to
stopping rule, that is that received only one round of mass drug
treatment, with communities that received three rounds of mass
drug treatment, with confidence intervals adjusted for cluster de-
sign. Communities in the stopping-rule arms only received treat-
ment if there were observed cases of infection or disease in the
community in the previous six months, and this rule was imple-
mented for all communities, hence they received only one round
of mass drug treatment.
Strategies to improve the coverage of mass treatment with
azithromycin
In the three PRET studies (PRET Niger; PRET Tanzania; PRET
The Gambia), annual mass drug administration with single dose
azithromycin and a standard coverage of 80% to 90% was com-
pared to annual mass drug administration of azithromycin with
enhanced coverage of 90% or more. All three studies found little
evidence of a benefit of the additional effort to increase the cover-
age of mass treatment.
• In PRET Niger, the prevalence of C trachomatis infection at
36 months was 7.1% (95% CI 2.7% to 11.4%) in the enhanced-
coverage communities compared with 4.6% (95% CI 0% to
9.5%) in the standard-coverage communities.
• In PRET Tanzania at 36 months (one year after the third
mass drug administration), there was no evidence of any
difference in the prevalence of C trachomatis infection according
to coverage of mass drug administration. The prevalence of
infection was 4.0% in the standard-coverage communities and
5.4% in the enhanced-coverage communities. The authors
reported an adjusted difference of 1.4% (95% CI −1.0% to
3.8%).
• In PRET The Gambia, there was no evidence for an effect
of enhanced coverage on C trachomatis infection (rate ratio 1.03,
95% CI 0.18 to 5.89) or active trachoma (rate ratio 1.15, 95%
CI 0.74 to 1.79), but with wide confidence intervals, indicating
considerable uncertainty in the effect estimate.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Oral versus topical antibiotic for trachoma: individuals
Patient or population: people (any age) with act ive trachoma
Settings: people resident in a trachoma endemic area
Intervention: oral ant ibiot ic, including azithromycin, doxycycline, sulfamethoxypyridazine, and sulfadimethoxine
Comparison: topical ant ibiot ic, including tetracycline and sulfafurazole








Assumed risk Corresponding risk




trachoma def ined as
TF, TI, or both





600 per 1000 582 per 1000
(486 to 696)









Posit ive test for C
trachomatis infect ion
ident if ied by culture,
staining on conjunc-
t ival smears, or nu-
cleic acid amplif ica-
t ion methods




No pooled est imate
due to high hetero-
geneity: Darougar
1980 RR 6.05 (95%CI
0.78, 46.95); Dawson
1997 RR 0.57 (0.14,
2.30); Tabbara 1996
















































































Darougar 1980 RR 2.
59 (95% CI 0.28, 23.




Proport ion of sam-
ples showing evi-
dence of resistance
to ant ibiot ic
Any t ime point None of the studies addressed this outcome.
Adverse effects Any t ime point 3 studies made no comment on adverse ef fects.
1 study of 155 students noted 3 adverse react ions to sulfonamide
(severe purpura associated with marked thrombocytopenia, 2 cases
of drug rash)
1 study of 194 people reported abdominal pain more of ten in
azithromycin group (26% versus 16%, P = 0.09). Other ef fects:
diarrhoea, vomit ing, fever, headache, body pain were sim ilar
between 2 study groups.
1 study of 60 people reported no serious adverse react ions and
that both azithromycin and tetracycline were well tolerated.
1 study of 168 children noted that azithromycin was well tolerated





* The assumed risk is the median risk in control groups in the included studies (rounded to nearest 10 per 1000). The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; TF: t rachomatous inf lammation-follicular; TI: t rachomatous inf lammation-intense; RR: risk rat io
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.












































































1Downgraded one level for serious lim itat ions in study design (only one study reported adequate methods for allocat ion
concealment and masking of outcome assessment) and one level for inconsistency (study est imates ranged f rom 0.65 to
1.37 and I2 = 63%).
2Downgraded one level for serious lim itat ions in study design (only one study reported adequate methods for allocat ion
concealment and masking of outcome assessment) and one level for inconsistency (study est imates ranged f rom 0.66 to
1.15 and I2 = 56%).
3Downgraded one level for serious lim itat ions in study design (methods of sequence generat ion and allocat ion concealment
poorly reported, one study at high risk of attrit ion bias) and two levels for very serious inconsistency (see comment column in
table).
4Downgraded one level for serious lim itat ions in study design (methods of sequence generat ion and allocat ion concealment
poorly reported, one study at high risk of attrit ion bias); one level for serious inconsistency (see comment column in table);
and one level for imprecision (only 16 events in total).
5Downgraded one level for serious lim itat ions in study design (none of the trials reported adequate methods of allocat ion
concealment and masking of outcome assessment, and adverse ef fects were not consistent ly considered and reported) and












































































Oral azithromycin compared to control for trachoma: communities
Patient or population: people (any age) with act ive trachoma
Settings: communit ies in a trachoma endemic area
Intervention: oral azithromycin
Comparison: control (no treatment)




Certainty of the evidence
(GRADE)




act ive trachoma de-
f ined as TF, TI, or both
3 months None of the studies addressed this outcome.





100 per 1000 58 per 1000
(52 to 65)
High- risk population
300 per 1000 174 per 1000
(156 to 195)
Ocular C trachomatis in-
fection
Follow-up: 3 months
Posit ive test for C tra-
chomatis infect ion iden-
t if ied by culture, stain-
ing on conjunct ival
smears, or nucleic acid
amplif icat ion methods

















































































100 per 1000 36 per 1000
(31 to 43)
High- risk population
300 per 1000 108 per 1000
(93 to 129)
Antibiotic resistance
Proport ion of samples
showing evidence of re-
sistance to ant ibiot ic
Any t ime point There was evidence of an increased risk of resistance of S pneumoniae, S aureus,
and E coli to azithromycin, tetracycline, and clindamycin with risk rat ios in
the order of 5 at 12 months. No evidence to support increased resistance to




Adverse effects Any t ime point No serious adverse events reported. Azithromycin associated with reduced
mortality in children. Main adverse ef fect of azithromycin (in approximately




* The assumed risk (medium/ high risk) were based on prevalence est imates used as the basis for recommendations as set out in WHO 2010. The corresponding risk (and its
95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; TF: t rachomatous inf lammation-follicular; TI: t rachomatous inf lammation-intense; RR: risk rat io
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect.
1Downgraded one level for serious inconsistency.
2Downgraded one level for serious inconsistency: I2 = 79%. However, both study est imates were in the same direct ion 0.32












































































Oral azithromycin compared to topical tetracycline for trachoma: communities
Patient or population: people (any age) with act ive trachoma
Settings: communit ies in a trachoma endemic area
Intervention: oral azithromycin
Comparison: topical tetracycline








Assumed risk Corresponding risk




trachoma def ined as
TF, TI, or both




ACT 1999 Egypt RR 0.
52 (95%CI 0.43, 0.64)
; ACT 1999 Tanzania
RR 1.16 (1.00, 1.
36); ACT 1999 The
Gambia RR 0.76 (0.
50, 1.15)




ACT 1999 Egypt RR 0.
74 (95%CI 0.61, 0.90)
; ACT 1999 Tanzania
RR 1.19 (1.02, 1.
40); ACT 1999 The




Posit ive test for C
trachomatis infect ion
ident if ied by culture,
staining on conjunc-
t ival smears, or nu-




ACT 1999 Egypt RR 0.
22 (95%CI 0.11, 0.44)
; ACT 1999 Tanzania
RR 0.68 (0.49, 0.
95); ACT 1999 The












































































cleic acid amplif ica-
t ion methods
37, 0.70)




ACT 1999 Egypt RR 0.
48 (95%CI 0.31, 0.74)
; ACT 1999 Tanzania
RR 1.01 (0.76, 1.
35); ACT 1999 The




Proport ion of sam-
ples showing evi-
dence of resistance
to ant ibiot ic
Any t ime point None of the studies addressed this outcome.
Adverse effects Any t ime point No comment on adverse ef fects in study reports 6002
(3 studies)
-
CI: conf idence interval; TF: t rachomatous inf lammation-follicular; TI: t rachomatous inf lammation-intense; RR: risk rat io
GRADE Working Group grades of evidence
High-certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate-certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low-certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low-certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for serious lim itat ions in study design (three cluster-randomised trials, two of which only randomised
two communit ies to oral/ topical ant ibiot ic; assessment of trachoma was not masked, but assessment of ocular infect ion
was; recruitment bias not addressed and problems with incomplete outcome data; some attempt made to adjust for













































































D I S C U S S I O N
Summary of main results
The trials included in this review provide evidence that individuals
with trachoma benefit from antibiotic treatment (Summary of
findings for the main comparison). Antibiotic treatment reduces
the risk of active trachoma and ocular C trachomatis infection up to
12 months after treatment. The trials included in this review were
clinically and statistically heterogeneous, and most had serious
limitations in their design. This makes it difficult to estimate the
size of the effect - the current best guess would be an approximate
20% risk reduction. We judged the certainty of the evidence to be
low. Oral and topical treatments appeared to have similar effects if
used as prescribed (Summary of findings 2). One study compared
oral antibiotic and unsupervised topical treatment and found the
oral antibiotic to be more effective “under practical operational
conditions”, which may have been due to poor compliance with
the more complex topical treatment regimen (Bowman 2000).
Only three of the more recent trials in individuals used azithro-
mycin, which is the currently recommended oral antibiotic treat-
ment. None of these trials had a no-treatment group. However,
in the individually randomised trials there was no evidence that
azithromycin was less effective than topical tetracycline.
We identified four community-based trials comparing azithromy-
cin versus no treatment. These trials were of variable quality and
size, however there was one large, good-quality trial conducted in
Ethiopia providing moderate-certainty evidence that community-
based treatment with a single dose of azithromycin reduces the
prevalence of active trachoma and ocular chlamydial infection in
children up to 12 months after treatment (Summary of findings
3) (TANA).
Only one trial compared oral versus topical community-based
treatment (Summary of findings 4). This study was conducted
in three countries in Africa and was therefore included as three
separate studies in this review. Data from this study were incon-
sistent. In The Gambia and Egypt, there was some evidence that
oral azithromycin was more effective than topical tetracycline, par-
ticularly with regards to ocular infection. However, after adjust-
ment for the cluster design of the study, these findings were not
statistically significant and were not replicated consistently in the
Tanzanian arm of the study.
The included studies considered several different dosing strategies.
These fall into three broad categories: applying mass treatment at
different dosing intervals; applying cessation or stopping rules to
mass treatment; and strategies to increase mass treatment coverage.
There was no strong evidence to support any variation in the
recommended annual mass treatment.
None of the included trials reported any serious adverse events
associated with either of the currently used antibiotics, azithro-
mycin and topical tetracycline. However, for many of the trials it
was not clear whether data on adverse effects had been collected
systematically. In the one trial that did collect and report these
data systematically, between 10% and 15% of people experienced
symptoms such as nausea and vomiting with azithromycin treat-
ment.
Results from five cluster-randomised trials of mass treatment with
azithromycin provided high-certainty evidence of an increased risk
of resistance of S pneumoniae,S aureus, and E coli to azithromycin,
tetracycline, and clindamycin with risk ratios in the order of 5 at
12 months. There was no evidence to support increased resistance
to penicillin or trimethoprim-sulfamethoxazole (TMP-SMX).
Overall completeness and applicability of
evidence
A strength of the evidence is that the included trials come from
many different countries and populations. However, it is unfortu-
nate that heterogeneity between trial results meant that we could
not estimate with any confidence the size of the effect for treat-
ment of trachoma with oral or topical antibiotics, although it is
likely that both oral and topical treatments have a beneficial effect.
The epidemiology of trachoma has changed over time as pro-
grammes have implemented the SAFE strategy. In March 2019,
the number of people living in areas where the prevalence of tra-
chomatous inflammation-follicular (TF) in children aged 1 to 9
years was ≥ 5% was 142.2 million, down from 1517 million in
2002 (WER 2019). The majority of people living in trachoma
endemic areas are in sub-Saharan Africa. Many of the more recent
trials included in this review took place in countries in the African
Region. The level of endemicity was relatively high in most of
these studies, and the extent to which they are applicable in set-
tings with lower endemicity is unclear.
Almost all the trials in individuals were done in children, and the
generalisability of these findings to adults is uncertain. Data were
reported for adults and children in the community-based trials.
Given the small number of trials, it was not possible to determine
whether the effects are different in these groups, but one study
provided data on ocular infection after mass treatment in both
children and adults (TANA). The observed risk ratio was 0.32
(95% CI 0.26 to 0.40) in children and 0.49 (95% CI 0.33 to
0.71) in adults.
Where azithromycin is not donated, there is a major cost difference
between topical tetracycline and oral azithromycin, but it was not
possible to determine which is the more cost-effective strategy per
extra case cured.
Some populations in which trachoma is endemic are subject to
migration, which may account in part for the low follow-up rates
in the community trials; it may also have implications in deter-
mining the most effective treatment in those populations where
new infected cases migrate into the community.
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Quality of the evidence
The included trials were published from 1966 onwards, and their
quality was variable. The certainty of evidence for most outcomes
was low, particularly for the comparison of antibiotics versus no
treatment (Summary of findings for the main comparison). Re-
porting of sequence generation and allocation concealment was
not good, and it was often difficult to assess the effect of incom-
plete data due to inadequate reporting. There was considerable
heterogeneity of results. However, masking of outcome assessment
was reported for laboratory analyses (less so for clinical assessments
of active trachoma), and there was little evidence of selective out-
come reporting. There was moderate-certainty evidence for the
comparison of oral versus topical antibiotics for the outcome ac-
tive trachoma (Summary of findings 2).
The community-based trials were also of variable methodological
quality (Summary of findings 3; Summary of findings 4). In some
cluster-randomised studies, only two communities were randomly
allocated to treatment. Although adjustment for baseline charac-
teristics can alleviate this problem to some extent, the interpre-
tation of these studies remains problematic. As well as being un-
derpowered, it is difficult to exclude the alternative explanation
that there is some characteristic that is different between the com-
munities (apart from treatment of trachoma) and which may be
the real cause of any observed differences in outcome. There was
also little information on other potential sources of bias in cluster-
randomised trials such as recruitment bias.
Four community-based trials had a ’delayed treatment’ design that
involved randomly selecting clusters for treatment and compar-
ing the prevalence of trachoma 12 months after treatment with a
random selection of untreated clusters, which are then enrolled in
the treatment programme (Resnikoff 1995; TANA; TEF; Wilson
2018). This study design overcomes the ethical dilemma of survey-
ing communities for trachoma and then withholding treatment
for 12 months, but has the disadvantage that baseline data on tra-
choma are not available in the control group.
Potential biases in the review process
This review has been substantially revised for the update. New
methods, such as assessment of risk of bias and subgroup and
sensitivity analyses, and inclusion of antimicrobial resistance as
an outcome, have been incorporated. A new protocol was not
written. It is possible that the update could have been influenced
by knowledge of the trial results.
We found the classification Atik 2006 problematic. In the last
edition of this review we included this trial in the comparison
“azithromycin versus no treatment” but on re-evaluation for the
current edition we considered the trial to be “azithromycin versus
tetracycline”. Although the study was described as azithromycin
versus no azithromycin in fact people with active trachoma in the
control group received tetracycline. The change in classification
of this study did not affect the conclusions of this review.
In the current 2019 update we included studies that compared
different treatment strategies. We added in the additional ques-
tion to our objectives: “What is the effect of annual versus dif-
ferent treatment frequencies?”. We did not repeat the searches for
this additional question. There may be studies that were not in-
cluded in previous editions of the review (for example Schemann
2007), that would have been eligible for the current update. We
do not anticipate that we will have missed many relevant studies
as searches were screened from 2010 onwards.
Agreements and disagreements with other
studies or reviews
We identified a number of non-randomised studies providing data
on antimicrobial resistance. Their results are summarised in Table
15. Overall, the non-randomised studies provided inconsistent ev-
idence on resistance, with some evidence of increased resistance
to azithromycin for S pneumoniae. Three studies considered re-
sistance in C trachomatis after mass treatment and suggest little
evidence of resistance to azithromycin.
A recent systematic review of community-level interventions in re-
ducing the prevalence of active trachoma (published as an abstract
only) identified a similar number of trials as the current review and
came to similar conclusions, that is that mass drug administration
reduces active trachoma and ocular chlamydia infection (Bobba
2018). Diab 2018 concluded that azithromycin eye drops twice
daily for three days may be as efficient as oral azithromycin in
treating active trachoma. This was largely based on the findings of
a non-randomised study, but the authors did identify the one trial
on this topic identified in the current review (Cochereau 2007).
We agree that the trial identified similar rates of cure over 60 days,
but suggest that confirmatory studies are needed to assess longer-
term follow-up.
A recent systematic review of resistance following mass azithro-
mycin distribution drew similar conclusions to the current re-
view (O’Brien 2019), that is that the available evidence suggests
that macrolide resistance to azithromycin is increased after mass
azithromycin distribution, particularly for S pneumoniae.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Oral or topical antibiotic treatment reduces the risk of active tra-
choma and ocular chlamydial infection in people who have active
trachoma, but the size of the treatment effect in individuals is un-
certain. It is likely that oral azithromycin and topical tetracycline
have similar effects if used as prescribed. Mass antibiotic treatment
with single dose oral azithromycin reduces the prevalence of active
34Antibiotics for trachoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
trachoma and ocular infection in communities. There is evidence
of an increased risk of antibiotic resistance in communities treated
with antibiotics.
The evidence provided in this review supports the current “A”
strategy as set out by the World Health Organization (WHO)
(Solomon 2006; WHO 2014), and does not provide convincing
evidence for any alternate regimen.
This review is largely based on studies conducted in areas of rela-
tively high endemicity. It does not provide evidence as to the role
of mass administration of antibiotics as communities approach
elimination of trachoma as a public health problem.
Implications for research
The WHO Alliance for the Global Elimination of Trachoma en-
dorsed the donation of azithromycin for the treatment of tra-
choma, and as of July 2019, over 850 million doses donated by
Pfizer Inc. had been distributed via the International Trachoma
Initiative (ITI) since 1999. Locations that have not yet started
azithromycin mass drug administration would enable community-
randomised trials to be conducted under operational conditions.
Inequities are bound to exist in some settings at start-up, when
resources for antibiotic distribution are generally in limited sup-
ply. Allocating interventions randomly in these circumstances is
reasonable, with roll-out of the intervention to areas initially ran-
domised to ’control’ in later treatment rounds. Such an approach
has been used in several of the trials included in this review. Trials
are required to determine optimal dosage intervals of azithromycin
at various levels of endemicity, test the most appropriate thresholds
for starting and stopping mass treatment, determine minimum
treatment coverage requirements, and to determine which sub-
groups could be treated at various stages of the pathway towards
elimination. Potential strategies to evaluate could be selected on
the basis of recent mathematical modelling work. Cost-effective-
ness per extra case cured should be one of the outcome measures.
The adverse effects of azithromycin and emergence and persistence
of resistance are also areas that should be addressed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ACT 1999 Egypt
Methods Unit of randomisation: community (1 matched pair).
Masking:
• participant - no,
• provider - no,
• outcome - no.
Exclusions after randomisation: no.
Losses to follow-up: yes, temporary absence.
Participants Country: Egypt.
Endemicity: “trachoma endemic”. Percentage prevalence of active trachoma in study
villages was 20% for all ages.
Number of communities randomised: 2.
Number of people randomised: 2238.
Age: all ages.
Sex: not reported.
Clinical grading: Dawson 1981b.
Laboratory tests: LCR.
Inclusion criteria: all villagers present.




• Dose: 20 mg/kg up to 1 g.
• Duration: once a week for 3 weeks.
Women of childbearing age erythromycin for 14 days, 500 mg twice daily or 250 mg 4




• Duration: once daily for 6 weeks, trained village assistants were responsible for
administration.
Outcomes Primary: active trachoma.
Secondary: ocular C trachomatis infection.
Adverse effects: not reported.
Follow-up: 12 to 14 months.
Notes Study name: Azithromycin in Control of Trachoma.
Date study conducted: not reported.
Funding source: Quote: “This project was supported by a grant from the National In-
stitute of Allergy and Infectious Disease (PO1 A135682), and by Pfizer Labs (New York,
NY), the Edna McConnell Clark Foundation (New York, NY) and Abbott Laboratories
(Abbott Park, IL).”
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ACT 1999 Egypt (Continued)
Conflict of interest: not reported.
Trial registration ID: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “In each of the endemic areas, pairs
of villages were matched on the basis of
an initial rapid assessment of the trachoma
rate among children aged between 1 and 10
years. One member of each village pair was
randomly assigned mass treatment with
oral azithromycin, with the other receiv-
ing the topical tetracycline regimen; in each
village we generated a random number for
each and took the number closest to one to
be assigned azithromycin”
Allocation concealment (selection bias) Low risk Judgement comment: cluster-randomised
controlled trial, so not applicable
Blinding (performance bias and detection
bias)
Active trachoma
High risk Judgement comment: the treatments were
quite different: oral versus topical. No mea-
sures were reported to mask study partic-
ipants and personnel from knowledge of
which intervention a participant received
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “Laboratory staff were not aware of
the clinical and treatment status of study
participants”
Quote: “Identification numbers for labora-
tory samples differed from those used on
the ocular examination forms to conceal
village and treatment status from the labo-
ratory staff ”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Some individuals or families could
not be reached at scheduled treatment
times (they worked out of town, had moved
away on a temporary or permanent basis, or
were working in the fields when the teams
were present). There were some refusals at
all sites.”
Quote: ”little movement was documented“
Quote: ”Compliance was good for all
groups, except the tetracycline treatment
village in Egypt (table 2).“ (page 633).
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ACT 1999 Egypt (Continued)
From Table 2: the percentage receiving at
least 1 dose of azithromycin was 95%, and
the percentage receiving 28 applications of
tetracycline was 59.5%
Judgement comment: different follow-up
in intervention and control, and follow-up
in control group less than 80%. From Ta-
ble 6: 92% of azithromycin group and 86%
of tetracycline group had assessment of ac-
tive trachoma at baseline. At 1 year, 87%
of azithromycin group and 75% of tetracy-
cline group had data on active trachoma
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
Recruitment bias addressed? (cluster RCT
only)
Unclear risk Judgement comment: recruitment bias was
not specifically addressed in the report,
however the following statement was made:
“At all study sites we attempted to treat
every individual present in each village”
(Schachter page 631). The following data
were available in the report, which suggest
that compliance was very different in the 2
groups. This is almost certainly related to
the number of doses, but may indicate that
recruitment bias is a possibility
A = azithromycin group; T = tetracycline
group, numbers expressed as % of pre-
study census
Pre-study census: A: 1179 T: 1212.
At time of treatment: A: 1139 (97%) T:
1099 (91%).
Baseline clinical trachoma status: A: 1080
(92%) T: 1044 (86%)
Compliance (at least 1 dose azithromycin
or 28 applications of tetracycline): A: 95%
T: 60%
Baseline imbalances addressed? (cluster
RCT only)
Low risk Quote: ”In each of the endemic areas, pairs
of villages were matched on the basis of
an initial rapid assessment of the trachoma
rate among children aged between 1 and 10
years. One member of each village pair was
randomly assigned mass treatment with
oral azithromycin, with the other receiv-
ing the topical tetracycline regimen; in each
village we generated a random number for
each and took the number closest to one to
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ACT 1999 Egypt (Continued)
be assigned azithromycin“. (Schachter page
631). However, note in Egypt only 2 clus-
ters were randomised
Baseline comparability of clusters not re-
ported in Schachter, but “[...], we have
done multivariate analyses, which adjust
for clustering of individual within house-
holds and for co-variates that may affect
an individuals’ risk of being infected with
chlamydia (LCR positive) at 1 year. The as-
sumption underlying these models is that
after adjustment for covariates there are no
village characteristics, other than treatment
type, that affect the risk of positivity at 1
year after treatment” (Schachter page 632)
ACT 1999 Tanzania
Methods Unit of randomisation: community (1 matched pair).
Masking:
• participant - no,
• provider - no,
• outcome - no.
Exclusions after randomisation: none.
Losses to follow-up: yes, temporary absence.
Participants Country: Tanzania.
Endemicity: ”trachoma endemic“. Percentage prevalence of active trachoma in study
villages was 31% for all ages.
Number of communities randomised: 2.
Number of people randomised: 3261.
Age: all ages.
Sex: not reported.
Clinical grading: Dawson 1981b.
Laboratory tests: LCR.
Inclusion criteria: all villagers present.




• Dose: 20 mg/kg up to 1 g.
• Duration: once a week for 3 weeks.
Women of childbearing age were given erythromycin for 14 days, 500 mg twice daily or
250 mg 4 times daily (amoxicillin in case of intolerance)
Comparator: oxytetracycline (tetracycline).
• Administration: topical (supervised).
• Dose: 1%.
• Duration: once daily for 6 weeks, trained village assistants were responsible for
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ACT 1999 Tanzania (Continued)
administration.
Outcomes Primary: active trachoma.
Secondary: ocular C trachomatis infection.
Adverse effects: none.
Follow-up: 12 to 14 months.
Notes Study name: Azithromycin in Control of Trachoma.
Date study conducted: not reported.
Funding source: Quote: ”Financial support for the trial was received from Pfizer Ltd,
the Edna McConnell Clark Foundation, and the National Institutes of Health; the data
analysis was supported by the Freiwillige Akademische Gesellschaft and the
L. & Th. La Roche Stiftung.“
Conflict of interest: none declared.
Trial registration ID: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “In each of the endemic areas, pairs
of villages were matched on the basis of
an initial rapid assessment of the trachoma
rate among children aged between 1 and 10
years. One member of each village pair was
randomly assigned mass treatment with
oral azithromycin, with the other receiv-
ing the topical tetracycline regimen; in each
village we generated a random number for
each and took the number closest to one to
be assigned azithromycin”
Allocation concealment (selection bias) Low risk Quote: ”The villages were matched in pairs
of similar size, and azithromycin and tetra-
cycline were allocated randomly within
these pairs.“
Judgement comment: allocation conceal-
ment unlikely to have been an issue with
this design
Blinding (performance bias and detection
bias)
Active trachoma
High risk The treatments were quite different: oral
versus topical. No measures were reported
to mask study participants and personnel
from knowledge of which intervention a
participant received
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk “Laboratory staff were not aware of the clin-
ical and treatment status of study partici-
pants” and “Identification numbers for lab-
48Antibiotics for trachoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ACT 1999 Tanzania (Continued)
oratory samples differed from those used
on the ocular examination forms to conceal
village and treatment status from the labo-
ratory staff ” (page 632)
Incomplete outcome data (attrition bias)
All outcomes
High risk Some individuals or families could not be
reached at scheduled treatment times (they
worked out of town, had moved away on
a temporary or permanent basis, or were
working in the fields when the teams were
present). There were some refusals at all
sites (page 633)
From Table 6 (page 633): 78% of azithro-
mycin group and 88% of tetracycline group
had assessment of active trachoma at base-
line. At 1 year, 60% of azithromycin group
and 77% of tetracycline group had data on
active trachoma
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
Recruitment bias addressed? (cluster RCT
only)
Unclear risk Recruitment bias was not specifically ad-
dressed in the report, however the following
statement was made: “At all study sites we
attempted to treat every individual present
in each village” (Schachter page 631)
The following data were available in the
report, which suggest that recruitment bias
may have been a possibility
A = azithromycin group; T = tetracycline
group, numbers expressed as % of pre-
study census
Pre-study census: A: 2167 T: 1179.
At time of treatment: A: 2161 (100%) T:
1100 (93%).
Baseline clinical trachoma status: A: 1696
(78%) T: 1036 (88%)
Compliance (at least 1 dose azithromycin
or 28 applications of tetracycline): A: 89%
T: 90%
Baseline imbalances addressed? (cluster
RCT only)
Low risk Baseline comparability of clusters not re-
ported in Schachter, but “[...], we have
done multivariate analyses, which adjust
for clustering of individual within house-
holds and for co-variates that may affect
an individuals’ risk of being infected with
chlamydia (LCR positive) at 1 year. The as-
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ACT 1999 Tanzania (Continued)
sumption underlying these models is that
after adjustment for covariates there are no
village characteristics, other than treatment
type, that affect the risk of positivity at 1
year after treatment.” (Schachter page 632)
ACT 1999 The Gambia
Methods Unit of randomisation: community.
Masking:
• participant - no,
• provider - no,
• outcome - no.
Exclusions after randomisation: no.
Losses to follow-up: yes, temporary absence.
Participants Country: The Gambia.
Endemicity: ”trachoma endemic“. Percentage prevalence of active trachoma in study
villages was 16% for all ages and 36% for children less than 10 years.
Number of communities randomised: 8 (pair-matched).
Number of people randomised: 1753.
Age: all ages.
Sex: not reported.
Clinical grading: Dawson 1981b.
Laboratory tests: LCR.
Inclusion criteria: all villagers present.




• Dose: 20 mg/kg up to 1 g.
• Duration: 3 weeks.
• Treatment frequency: once a week, ”Compliance was determined by trained
volunteers who recorded the ingestion of tablets or application of ointment.“
Women of childbearing age erythromycin for 14 days, 500 mg twice daily or 250 mg 4




• Duration: 6 weeks.
• Treatment frequency: once daily, ”Compliance was determined by trained
volunteers who recorded the ingestion of tablets or application of ointment.“
Outcomes Primary: active trachoma.
Secondary: ocular C trachomatis infection.
Adverse effects: none.
Follow-up: 12 months
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ACT 1999 The Gambia (Continued)
Notes Study name: Azithromycin in Control of Trachoma.
Date study conducted: July 1994 to October 1994.
Funding source: Quote: ”Financial support for the trial was received from Pfizer Ltd,
the Edna McConnell Clark Foundation, and the National Institutes of Health; the data
analysis was supported by the Freiwillige Akademische Gesellschaft and the L. & Th. La
Roche Stiftung.“
Conflict of interest: Quote: ”none declared“.
Trial registration ID: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “In each of the endemic areas, pairs
of villages were matched on the basis of
an initial rapid assessment of the trachoma
rate among children aged between 1 and 10
years. One member of each village pair was
randomly assigned mass treatment with
oral azithromycin, with the other receiv-
ing the topical tetracycline regimen; in each
village we generated a random number for
each and took the number closest to one to
be assigned azithromycin”
Allocation concealment (selection bias) Low risk Quote: ”The villages were matched in pairs
of similar size, and azithromycin and tetra-
cycline were allocated randomly within
these pairs.“
Judgement comment: allocation conceal-
ment unlikely to have been an issue with
this design
Blinding (performance bias and detection
bias)
Active trachoma
High risk The treatments were quite different: oral
versus topical. No measures were reported
to mask study participants and personnel
from knowledge of which intervention a
participant received
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “Laboratory staff were not aware of
the clinical and treatment status of study
participants”
Quote: “Identification numbers for labora-
tory samples differed from those used on
the ocular examination forms to conceal
village and treatment status from the labo-
ratory staff ”
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ACT 1999 The Gambia (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk All clusters completed the trial in theory, al-
though 1 cluster allocated to azithromycin
had very poor follow-up (0% at 12 months)
.
Some individuals or families could not be
reached at scheduled treatment times (they
worked out of town, had moved away on
a temporary or permanent basis, or were
working in the fields when the teams were
present). There were some refusals at all
sites (Schachter page 633)
From Table 6 (Schachter page 633): 91%
of azithromycin group and 82% of tetra-
cycline group had assessment of active tra-
choma at baseline. At 1 year, 65% of
azithromycin group and 50% of tetracy-
cline group had data on active trachoma
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
Recruitment bias addressed? (cluster RCT
only)
Unclear risk Quote: “All residents who were present at
the pre-treatment survey were eligible for
participation in the trial.” (Fraser-Hurt)
Quote: “At all study sites we attempted to
treat every individual present in each vil-
lage” (Schachter page 631)
Baseline imbalances addressed? (cluster
RCT only)
Low risk Quote: “In each of the endemic areas, pairs
of villages were matched on the basis of
an initial rapid assessment of the trachoma
rate among children aged between 1 and 10
years. One member of each village pair was
randomly assigned mass treatment with
oral azithromycin, with the other receiv-
ing the topical tetracycline regimen; in each
village we generated a random number for
each and took the number closest to one to
be assigned azithromycin” (Schachter page
631)
“The villages were matched in pairs of sim-
ilar size, and azithromycin and tetracycline
were allocated randomly within these pairs.
” (Fraser-Hurt page 633)
Baseline comparability of clusters reported
(Fraser-Hurt Table 1 page 635). There were
some baseline imbalances, but these were
controlled for in the analysis: “Point esti-
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ACT 1999 The Gambia (Continued)
mates of the odds ratio for the comparison
of azithromycin with tetracycline, adjusted
for age, latrine ownership and, where ap-
propriate, trachoma status at baseline, were
obtained using logistic regression with in-
dividual records.” (Fraser-Hurt page 634)
Baseline comparability of clusters not re-
ported in Schachter, but “[...], we have
done multivariate analyses, which adjust
for clustering of individual within house-
holds and for co-variates that may affect
an individuals’ risk of being infected with
chlamydia (LCR positive) at 1 year. The as-
sumption underlying these models is that
after adjustment for covariates there are no
village characteristics, other than treatment
type, that affect the risk of positivity at 1
year after treatment.” (Schachter page 632)
Atik 2006
Methods Unit of randomisation: community (1 matched pair).
Masking:
• participant - no,
• provider - no,
• outcome - unclear.
Exclusions after randomisation: no.
Losses to follow-up: unclear.
Participants Country: Vietnam.
Endemicity: Quote: ”All 8 communes had approximately a 20% prevalence rate of active
trachoma based on rapid assessment.“
Number of communities randomised: 2 (8 included in study, 2 relevant to this review)
.
Number of people randomised: 1851.
Age: 6 months and older.
Sex: approximately 60% female.
Clinical grading: Thylefors 1987.
Laboratory tests: Amplicor-PCR assay (Roche Diagnostics, Branchburg, NJ) of con-
junctival samples
Inclusion criteria: all ages 6 months and older.
Exclusion criteria: none, but pregnant women received erythromycin.
Interventions Intervention: azithromycin.
• Administration: oral
• Dose: 20 mg/kg for children; 1 g for adults. Pregnant women received
erythromycin.
• Duration: baseline and 12 months.
All schoolchildren aged 5 through 15 years were examined; children who had active
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trachoma defined as follicular inflammation, intense inflammation, or both were consid-
ered index cases. Index cases and their household members were treated with azithromy-
cin. Non-index cases and non-household members who had active trachoma (follicular
inflammation, intense inflammation, or both) received topical tetracycline
Comparator: no azithromycin.
People with trachomatous trichiasis were identified and informed of the availability of
surgery. People with active trachoma (follicular inflammation, intense inflammation, or
both) received topical tetracycline




Notes Study name: none.
Date study conducted: November 2000 to November 2003.
Funding source: Quote: ”This work was supported by International Trachoma Initiative
grant ITI 01-040 (Dr Dean) and Public Health Service grant EY/AI12219 (Dr Dean),
from the National Institutes of Health.“
Conflict of interest: Quote: ”Financial Disclosures: None reported.“
Trial registration ID: ACTRN012606000360516 (www.anzctr.org.au/)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Three of 8 communes in Thanh
Hoa Province were randomly chosen using
a random number list.“
Quote: ”The assignment of the communes
to the various treatments was performed
randomly.“
Allocation concealment (selection bias) Low risk Quote: ”Three of 8 communes in Thanh
Hoa Province were randomly chosen using
a random number list.“
Quote: ”The assignment of the communes
to the various treatments was performed
randomly.“
Judgement comment: allocation conceal-
ment unlikely to have been an issue with
this design
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: ”the 3 randomly selected com-
munes were geographically isolated from
one another”
Judgement comment: it was not clear if the
participants were aware of the existence of
other potential interventions
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Quote: “At each time point of the study,
all participants were examined by an oph-
thalmologist and graded for trachoma in a
masked fashion using a modified grading
scale”
Judgement comment: the extent to which
the ophthalmologist might be aware of
what treatment the community had re-
ceived was not discussed
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “Samples were labelled with date
and a unique identification number to
maintain confidentiality and to process
samples in a masked fashion”
Incomplete outcome data (attrition bias)
All outcomes
High risk Judgement comment: both clusters com-
pleted the trial. Attrition was high and un-
equal between the 2 groups. Response rates
were not reported explicitly. The total pop-
ulation and the percentage graded for tra-
choma at baseline, 6 months, 12 months,
and 24 months are as follows (from Table
1 and Figure 2)
Azithromycin community: total = 659:
100%; 86%; 79%; 56%.
Untreated community: total = 1192;
100%; 89%; 83%; 72%.
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
Recruitment bias addressed? (cluster RCT
only)
Unclear risk Quote: “selected communes were geo-
graphically isolated from one another”
(page 1489); and “All commune residents
older than 6 months were included in the
study” (page 1489). However, no informa-
tion on response rates were given, so it is
unclear how many of the residents actually
took part in the study
Baseline imbalances addressed? (cluster
RCT only)
High risk Only 2 clusters included in the trial, so
no pair-matching. Baseline comparability
of clusters was reported with respect to sex
and trachoma only (Table 1 page 1491).
There was a higher baseline prevalence of
active trachoma in people aged > 15 years
in the control cluster (10.6% versus 3.6%,
P < 0.001) and a higher baseline prevalence
of active trachoma in children 5 to 15 years
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in the intervention cluster (9.2% versus 4.
7%, P = 0.033). Statistical adjustment was
made for sex, age, and having at least 1 per-
son with chlamydial infection in the house-
hold
Attiah 1973
Methods Unit of randomisation: individual.
Masking:
• participant - no,
• provider - yes,
• outcome - yes.
Exclusions after randomisation: no.
Losses to follow-up: none.
Unusual study design: random allocation stratified by disease severity (clinical signs,
11 strata)
Participants Country: Egypt.
Number of people randomised: 228.
Age: 6 to 12 years.
Sex: not reported.
Clinical grading: WHO 1962.
Laboratory tests: none.
Inclusion criteria: active trachoma or “undetermined case”.
Exclusion criteria: none.
Interventions Intervention 1: tetracycline derivative GS2989.
• Administration: topical.
• Dose: 0.25%.
• Duration: once every school day for 11 weeks, administered by trained public
health nurse.
Intervention 2: oxytetracycline (Terramycin).
• Administration: topical.
• Dose: not reported.
• Duration: once every school day for 11 weeks, administered by trained public
health nurse.
Comparator:: no treatment.
• Administration: not applicable.
• Dose: not applicable.
• Duration: not applicable.
Outcomes Primary: active trachoma.
Secondary: none.
Adverse effects: not reported.
Follow-up: 3 months.
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Notes Study name: none.
Date study conducted: February to May 1965.
Funding source: Quote: “We are grateful to Dr Ali Gaber, Medical Director, of Pfizer
Egypt, who kindly supplied the study with the GS-2989.”
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “the principle of double blindness
ensured in the experiment”
Quote: “The examiner had no knowledge
of the treatment assignment to the groups
or of the randomisation process used in the
trial”
Quote: “After three months treatment, the
results were checked using WHO criteria
without investigators knowing what treat-
ment applied”
Judgement comment: the report gave no
indication as to how the groups were
masked and whether the control group re-
ceived any placebo treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: reported 100% fol-
low-up. This is unusual and could indi-
cate that children who were not followed
up were not reported. However, 100% may
be feasible in a school situation. We have
left this as ’unclear’ because we cannot tell
which of the 2 options apply
Selective reporting (reporting bias) Low risk Clinical examination only and no sugges-
tion that any assessment of ocular infection
made
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Bailey 1993
Methods Unit of randomisation: Quote: “randomisation was by room, all active cases within a
room receiving the same treatment”
Masking:
• participant - no,
• provider - no,
• outcome - unclear.
Exclusions after randomisation: none.
Losses to follow-up: none.
Participants Country: The Gambia.
Number of communities randomised: not reported.
Number of people randomised: 194.
Age: 9 months to 60 years.
Sex: 51% male.
Clinical grading: Dawson 1981a.
Laboratory tests: IDEIA amplified enzyme-linked immunosorbent assay (Dako) for
genus-specific lypopolysaccharide antigen
Inclusion criteria: active trachoma.
Exclusion criteria: pregnant or lactating.
Interventions Intervention: azithromycin.
• Administration: oral.
• Dose: 20 mg/kg.
• Duration: single dose.
Comparator: tetracycline.*
• Administration: topical.
• Dose: 1% eye ointment.
• Duration: twice daily for 6 weeks, applied by patient’s mother.
*Those with ’severe disease’ also received oral erythromycin stearate 250 mg 4 times daily
for 2 weeks
Outcomes Primary and secondary: “resolution of disease” clinical signs and antigen positivity
Adverse effects: standard interview 3 days after treatment including questions about
gastrointestinal symptoms in the preceding 3 days and open questions about general
health
Follow-up: 26 weeks.
Notes Study name: none.
Date study conducted: ocular survey done in May 1992 followed by treatment and
follow-up for 26 weeks
Funding source: Quote: “This project was supported by a grant from the Edna Mc-
Connell Clark Foundation, New York, USA.”
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “Randomisation was by room, all
active cases within a room receiving the
same treatment”
Judgement comment: unclear how the ran-
dom allocation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “Randomisation was by room, all
active cases within a room receiving the
same treatment”
Judgement comment: unclear how alloca-
tion was concealed.
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “Subjects were examined [...] by a
trained observer (RLB) unaware of treat-
ment allocation”
Judgement comment: unclear how this
masking was maintained as no placebos
used for either tablets or ointment
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk No specific information on this, but as the
investigators attempted to mask the clini-
cal examinations, it is likely that the lab-
oratory analyses were masked as well, and
this would have been easier to do
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 194 participants randomised, 194 ex-
amined at 4 weeks; 194 examined at 8
weeks; 191 examined at 16 weeks; and 193
examined at 26 weeks (1 participant had
died by that point)
Selective reporting (reporting bias) Low risk Both outcomes (infection and clinical dis-
ease) were reported
Bowman 2000
Methods Unit of randomisation: individual.
Masking:
• participant - no,
• provider - no,
• outcome - yes.
Exclusions after randomisation: no.
Losses to follow-up: numbers recorded.
Unusual study design: trial aimed to compare treatments under operational and not
best-possible conditions
Participants Country: The Gambia.
Number of people randomised: 314.
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Age: 6 months to 10 years.
Sex: 50% male.
Clinical grading: Thylefors 1987.
Laboratory tests: none.
Inclusion criteria: clinical signs of active trachoma in at least 1 eye.
Exclusion criteria: not reported.
Interventions Intervention: azithromycin.
• Administration: oral.
• Dose: 20 mg/kg.
• Duration: single dose.
Comparator: tetracycline.
• Administration: topical.
• Dose: not reported.
• Duration: applied once by a nurse in front of the caregiver, and then twice daily
by caregiver for 6 weeks.
Outcomes Primary: active trachoma.
Secondary: none.
Adverse effects: not reported.
Follow-up: 6 months.
Notes Study name: none.
Date study conducted: recruitment April and May 1998, follow-up 6 months later.
Funding source: Quote: “Supported by Sight Savers International (GJJ, RJCB). The
azithromycin was donated by Pfizer.”
Conflict of interest: Quote: “Commercial relationships policy: N.”
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects with clinical signs of ac-
tive trachoma in at least one eye were ran-
domized, using a block design”
Judgment comment: although method of
generating sequence was not clearly re-
ported, inclusion of term ’block design’
suggests that an unpredictable sequence
was generated
Allocation concealment (selection bias) Low risk Quote: “Treatment codes in numbered
sealed envelopes were used by the nurse ad-
ministering treatment to allocate treatment
to the subject. The clinical assessors had no
knowledge of the randomisation sequence
or of the treatment received by previous
subjects. Similarly the nurse had no knowl-
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edge of the block randomisation procedure
and did not examine the children but ad-
ministered treatment according to the allo-
cation in the envelope.”
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “...graded by a clinical assessor
blind to the treatment allocation.”
Quote: “Patients were aware of their treat-
ments, and therefore inadvertent unmask-
ing of the clinical assessors at follow-up
by the patients was possible. There were
no reports of the occurring, however, and
the similar cure rate ratios for both clini-
cal and photographic outcome suggest that
unmasking and bias were not a significant
problem.“
Judgement comment: interventions were
different - oral dose of azithromycin syrup
versus topical tetracycline - so it was not
possible to prevent knowledge to caregivers
and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: analysis was not by
intention-to-treat, as 4 participants re-
ceived the wrong allocation and were anal-
ysed according to their received treatment,
not per their random allocation. However,
as this number was low, it is unlikely to have
biased the outcome. Of 154 children who
received tetracycline, 15 (10%) were not
followed at 6 months; of 160 who received
azithromycin, 11 (7%) missed follow-up.
No reason was given for loss to follow-up,
but as this was low and not substantially
different between groups it is unlikely to
have caused bias
Selective reporting (reporting bias) Low risk This study reported one of the primary
outcomes for this review: active trachoma.
There was no indication that the other out-
come for this review, C trachomatis infec-
tion, was collected but not reported.
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Cochereau 2007
Methods Unit of randomisation: individual.
Masking:
• participant - yes,
• provider - yes,
• outcome - yes.
Exclusions after randomisation: 1 person in eye drop group did not receive allocated
treatment.
Losses to follow-up: generally low (less than 5%), some imbalance between groups.
Protocol deviations mean that per-protocol analysis included 80% to 90% of randomly
allocated population
Participants Country: Guinea-Conakry (community) and Pakistan (boys schools only)
Number of people randomised: 670.
Age: 1 to 10 years.
Sex: 50% male.
Clinical grading: Thylefors 1987.
Laboratory tests: conjunctival swab analysed using PCR.
Inclusion criteria: active trachoma (TF+TI0 or TF+TI+ on simplified World Health
Organization (WHO) scale)
Exclusion criteria: Quote: ”trichiasis or corneal opacity; fibrosis with palpebral deforma-
tion; ocular abnormality; ocular infection; organic amblyopia; hypersensitivity to the in-
vestigational product; immunosuppressive conditions; systemic steroids, or ophthalmic
systemic antibiotics, or topical treatments, or systemic non-steroidal anti-inflammatory
drugs prior to the study.“
Interventions Intervention 1: azithromycin (eye drops 2 days) and placebo paediatric suspension (n
= 224)
• Administration: topical.
• Dose: 1.5% eye drops.
• Duration: twice daily for 2 days, administered by a member of the research team.
Intervention 2: azithromycin (eye drops 3 days) and placebo paediatric suspension (n
= 225)
• Administration: topical.
• Dose: 1.5% eye drops.
• Duration: twice daily for 3 days administered by a member of the research team.
Comparator: azithromycin (oral) and placebo eye drops (n = 221).
• Administration: oral.
• Dose: 20 mg/kg.
• Duration: single dose administered by a member of the research team.
Outcomes Primary: clinical cure in children with clinically active trachoma.
Secondary: ocular infection, tolerance.
Adverse effects: yes.
Follow-up: 2 months.
Notes Study name: none.
Date study conducted: January to May 2004.
Funding source: Quote: ”This clinical trial was sponsored by Laboratoires Thea, Cler-
mont-Ferrand, France.“
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Conflict of interest: Quote: ”IC, PG, AG, TA, TB and PYR have no financial interest
in Laboratoires Thea and the product Azyter. PP and LD are employees of Laboratoires
Thea.“
Trial registration ID: not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”The randomisation list used ran-
dom permuted blocks of six (SAS v 8.2).“
Allocation concealment (selection bias) Low risk Quote: “Within each village, patient num-
bers were allocated in ascending order us-
ing the next available number. Study drugs
were identified by patient number using the
randomisation list.”
Judgement comment: as placebo con-
trolled, it is likely that allocation was con-
cealed
Blinding (performance bias and detection
bias)
Active trachoma
Low risk Quote: “We used a double-dummy design
with placebo eye drops and placebo paedi-
atric suspension”
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “We used a double-dummy design
with placebo eye drops and placebo paedi-
atric suspension”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up data reported as follows (Figure
1, page 669). Some participants may have
more than 1 reason for not being followed
up
2-day eye drops group (n = 224):
• did not receive allocated treatment
(lost to follow-up) (1)
• moved to another region (2)
• probably did not fit inclusion criteria
(22)
• use of other medications (1)
• non-compliance (2)
• no follow-up at 2 months (1)
• number available for ITT analysis
(222, 99.1%)
• number available for per-protocol
analysis (199, 88.8%)
3-day eye drops group (n = 225):
• moved to another region (9)
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• probably did not fit inclusion criteria
(23)
• use of other medications (1)
• non-compliance (1)
• no follow-up at 2 months (7)
• participant request (1)
• adverse event (1)
• family member illness (1)
• number available for ITT analysis
(220, 97.8%)
• number available for per-protocol
analysis (190, 84.4%)
Oral azithromycin (n = 221)
• moved to another region (9)
• probably did not fit inclusion criteria
(33)
• non-compliance (2)
• no follow-up at 2 months (4)
• participant request (1)
• adverse event (1)
• family member illness (1)
• number available for ITT analysis
(214, 96.8%)
• number available for per-protocol
analysis (179, 81.0%)
Judgement comment: some imbalance in
per-protocol analysis, which was main way
outcomes were reported, however the im-
pact of this is unclear. Last observation car-
ried forward for missing data
Selective reporting (reporting bias) High risk Quote: “A conjunctival swabbing was taken
on days 0, 30 and 60 under strictly sterile
conditions and analyzed for Chlamydia tra-
chomatis using a polymerase chain reaction.
”
Judgement comment: the PCR used (name
of product used if a commercial assay, or
details of method if an in-house assay) are
not specified, and no data on PCR positiv-
ity are provided, other than the statement
“Positivity to Chlamydia was not confirmed
to be a prognostic factor by the stepwise
logistic regression analysis”
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Methods Unit of randomisation: individual.
Masking:
• participant - no,
• provider - no,
• outcome: unclear.
Exclusions after randomisation: yes, poor compliers.
Losses to follow-up: not given by group.
Unusual study design: family-based treatment (family members treated but not anal-
ysed). Data on whole conjunctiva and upper conjunctiva given. Patients with “active
trachoma in their whole conjunctiva” were included. Patients with active disease may
have been excluded. Some data available only in graphical form
Participants Country: Iran.
Number of people randomised: 147.
Age: pre-school (average 6 years).
Sex: 38% male.
Clinical grading: modification of Dawson 1975a.
Laboratory tests: culture (Darougar 1970).
Inclusion criteria: active trachoma, residence in study village.
Exclusion criteria: none.
Interventions Intervention 1: oxytetracycline.
• Administration: topical.
• Dose: 1%.
• Duration: twice daily for 7 consecutive days, every month for 12 months,
administered by field technician.
Intervention 2: doxycycline.
• Administration: oral.
• Dose: 5 mg/kg.




• Dose: not reported.
• Duration: 1 dose per month for 12 months, administered by field technician.
Outcomes Primary: active trachoma.
Secondary: culture (McCoy cells).
Adverse effects: not reported.
Follow-up: 4 and 12 months.
Notes Study name: none.
Date study conducted: not reported.
Funding source: Quote: “The research project was partially supported by grants from
the Dulverton Trust, the Wellcome Foundation, the Order of St John, and an anonymous
donor.”
Conflict of interest: not reported.
Trial registration ID: none.
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients with active trachoma were
divided into 3 groups according to a ran-
domisation schedule stratified for age, sex,
intensity of trachoma, and the number of
children with active trachoma in each fam-
ily.”
Judgement comment: unclear how the al-
location sequence was generated
Allocation concealment (selection bias) Unclear risk Judgement comment: no information
about allocation concealment, although
the study is described as “double-blind”
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Judgement comment: no information
about allocation concealment, although
the study is described as “double-blind”.
Treatments are different - topical versus oral
antibiotics versus vitamin tablets - so the
participants will not have been masked.
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Unclear risk Judgement comment: no information
about allocation concealment, although
the study is described as “double-blind”.
Treatments are different - topical versus oral
antibiotics versus vitamin tablets - so the
participants will not have been masked
Incomplete outcome data (attrition bias)
All outcomes
High risk Judgement comment: 147 participants in-
cluded; 18 excluded because of inadequate
treatment or follow-up; it was not reported
to which groups these 18 participants had
originally been allocated
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
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Methods Unit of randomisation: individual.
Masking:
• participant - yes,
• provider - yes,
• outcome - yes.
Exclusions after randomisation: no.
Losses to follow-up: not reported.
Unusual study design: 2 similar studies with few participants each. Numbers need to
be read from figures, some not very clear
Participants Country: USA (Native American).
Number of people randomised: 29.
Age: 12 to 21 years.
Sex: not reported.
Clinical grading: MacCallan 1936.
Laboratory tests: IFAT on conjunctival smears.




• Dose: 3 daily doses to total 3.5 g/day.
• Duration: 21 consecutive days.
Comparator: lactose-placebo.
• Administration: oral.
• Dose: not reported.
• Duration: 21 consecutive days.




Notes Study name: none.
Date of study conducted: September 1967 to April 1968.
Funding source: Quote: ”Supported by a grant (NB 00604) from the National Institutes
of Health, US Public Health Service and by a Research Career Development Award to
CRD“
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: unclear how the al-
location sequence was generated
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Allocation concealment (selection bias) Unclear risk Quote: ”At each school, a full-time nurse
personally administered all drugs and
placebos. All materials were coded, and the
identify of drug or placebo remained un-
known to subjects, nurse, and physicians
throughout the trials until all examination
results had been recorded”
Judgement comment: this statement sug-
gests that allocation was concealed, how-
ever it does not tell us who allocated the
treatment
Blinding (performance bias and detection
bias)
Active trachoma
Low risk Quote: “At each school, a full-time nurse
personally administered all drugs and
placebos. All materials were coded, and the
identify of drug or placebo remained un-
known to subjects, nurse, and physicians
throughout the trials until all examination
results had been recorded”
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “At each school, a full-time nurse
personally administered all drugs and
placebos. All materials were coded, and the
identify of drug or placebo remained un-
known to subjects, nurse, and physicians
throughout the trials until all examination
results had been recorded”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: 29 children took
part; all (100%) were followed up. The-
oretically they could have recruited more
and had some lost to follow-up that they
did not report, but it is also possible that
in a boarding school environment loss to
follow-up would be nil. As we cannot dis-
tinguish between these 2 possibilities, we
have assigned a judgement of unclear risk
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
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Methods Unit of randomisation: individual.
Masking:
• participant - yes,
• provider - yes,
• outcome - yes.
Exclusions after randomisation: no.
Losses to follow-up: not reported.
Unusual study design: 2 similar studies with few participants each. Numbers need to
be read from figures, some not very clear
Participants Country: USA (Native American).
Number of people randomised: 36.
Age: 12 to 21 years.
Sex: not reported.
Clinical grading: MacCallan 1936.
Laboratory tests: IFAT on conjunctival smears.




• Dose: 3.5 g/day.
• Duration: 21 consecutive days.
Comparator: lactose-placebo.
• Administration: oral.
• Dose: not reported.
• Duration: 21 consecutive days.




Notes Study name: none.
Date study conducted: September 1967 to March 1968.
Funding source: Quote: ”Supported by a grant (NB 00604) from the National Institutes
of Health, US Public Health Service and by a Research Career Development Award to
CRD“
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: unclear how the al-
location sequence was generated
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Dawson 1969 Stewart (Continued)
Allocation concealment (selection bias) Unclear risk Quote: ”At each school, a full-time nurse
personally administered all drugs and
placebos. All materials were coded, and the
identify of drug or placebo remained un-
known to subjects, nurse, and physicians
throughout the trials until all examination
results had been recorded”
Judgement comment: this statement sug-
gests that allocation was concealed, how-
ever it does not tell us who allocated the
treatment
Blinding (performance bias and detection
bias)
Active trachoma
Low risk Quote: “At each school, a full-time nurse
personally administered all drugs and
placebos. All materials were coded, and the
identify of drug or placebo remained un-
known to subjects, nurse, and physicians
throughout the trials until all examination
results had been recorded”
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “At each school, a full-time nurse
personally administered all drugs and
placebos. All materials were coded, and the
identify of drug or placebo remained un-
known to subjects, nurse, and physicians
throughout the trials until all examination
results had been recorded”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: 36 children took
part; all (100%) were followed up. The-
oretically they could have recruited more
and had some lost to follow-up that they
did not report, but it is also possible that
in a boarding school environment loss to
follow-up would be nil. As we cannot dis-
tinguish between these 2 possibilities, we
have assigned a judgement of unclear risk
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
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Dawson 1997
Methods Unit of randomisation: individual.
Masking:
• participant: for azithromycin,
• provider: no,
• outcome: yes.
Exclusions after randomisation: no.
Losses to follow-up: absence in village/not found.
Unusual study design: oral placebo for different azithromycin regimens, no placebo for
topical treatment. Epidemic of purulent conjunctivitis at 8/12 years; cut-off for positivity
not justified.
3 azithromycin regimens analysed together.
Participants Country: Egypt.
Number of people randomised: 168.
Age: 2 to 10 years (average age 4 years).
Sex: 60% male.
Clinical grading: Thylefors 1987.
Laboratory tests: Thylefors 1987; Dawson 1981b.
Inclusion criteria: active trachoma, 2 to 10 years, resident in a study village.
Exclusion criteria: missing baseline record.
Interventions Intervention: azithromycin.
• Administration: oral.
• Dose: 20 mg/kg.
• Duration: single dose; or single dose weekly for 3 weeks; or single dose monthly
for 6 months.
Comparator: oxytetracycline/polymyxin + oral placebo.
• Administration: topical.
• Dose: oxytetracycline 1%/polymyxin 10,000 units/gram.
• Duration: once daily for 5 consecutive days every 28 days for 6 times, applied by
trained medical personnel.
Outcomes Primary: active trachoma.
Secondary: elementary bodies ≤ 200 or > 200 on conjunctival smears.
Adverse effects: reported in Discussion only.
Follow-up: 12 months.
Notes Study name: none.
Date of study conducted: February 1992 to February 1993.
Funding source: not reported.
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
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Dawson 1997 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: ”A total of 168 children were ran-
domized to one of the four treatment
groups in blocks of eight“
Judgement comment: not enough informa-
tion to judge whether the sequence was un-
predictable
Allocation concealment (selection bias) Unclear risk Quote: ”This clinical trial was double-
masked, placebo-controlled, and random-
ized”
Judgement comment: no information
about allocation concealment given. Treat-
ment groups were different, e.g. no oint-
ment placebo, and different dosing sched-
ules for oral antibiotic
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “Ophthalmologists experienced in
the diagnosis of trachoma performed all ex-
aminations and were masked as to the treat-
ment used”
Judgement comment: no details of the
masking were given, and as the treatments
were different, the examiners could theo-
retically have been unmasked by their pa-
tients
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Unclear risk Judgement comment: no details of the
masking were given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “In most cases, children were lost to
follow-up at specific examinations because
they and their family were not in the village
or because the child could not be found on
the day of the examination.”
Judgement comment: follow-up rates at
12 months were good from 91% to 98%.
Ointment group 42/43, 1 oral dose 39/40,
3 oral doses 39/43, 6 oral doses 39/42. The
groups with a larger number of oral doses
had lower follow-up rates, but these were
only 4 and 3 children, respectively
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
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Foster 1966





Exclusions after randomisation: not reported.
Losses to follow-up: yes.
Participants Country: USA (Native American).
Number of people randomised: 457.
Age: 8 to 20 years.
Sex: not reported.
Clinical grading: Thygeson 1960.
Laboratory tests: none.
Inclusion criteria: active trachoma, studying in a study school.
Exclusion criteria: none.
Interventions Intervention: 1: sulfamethoxypyridazine (n = 112 analysed).
• Administration: oral.
• Dose: 0.5 g.
• Duration: once daily for 5 consecutive days every week for 3 weeks.
Intervention: 2: tetracycline (n = 106 analysed).
• Administration: topical.
• Dose: 1%.
• Duration: 3 times daily on 5 consecutive days every week for 6 weeks.
Comparator: no treatment (n = 107 analysed).
Outcomes Primary: active trachoma.
Secondary: none.
Adverse effects: not recorded.
Follow-up: 3 and 12 months.
Notes Study name: none.
Date study conducted: September 1963 to September 1964.
Funding source: Quote: “This work was supported in part by grants from Research to
Prevent Blindness, Inc., and from the National Institute of health (B604)”
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The active cases were assigned at
random to one of three treatment groups”
Judgement comment: not enough informa-
tion.
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Foster 1966 (Continued)
Allocation concealment (selection bias) Unclear risk Judgement comment: not enough informa-
tion. Allocation concealment not reported
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “The examiner had no knowledge
of the earlier findings or of the nature of the
treatment of the students being examined,
and the order of the examinations was ran-
domised”
Judgement comment: the treatments were
different, so the students will have known
which treatment they received (oral versus
topical antibiotic)
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “For the purpose of analysis, only
the 325 students who were examined on all
three occasions are included in Tables 3,4
and 5.”
Judgement comment: a total of 457 active
cases were identified, but results reported
for only 325 (71%) who had complete fol-
low-up. No information on follow-up by
group
Selective reporting (reporting bias) Low risk Judgement comment: only clinical out-
comes recorded, but no indication of any
assessment of ocular infection
Hoshiwara 1973
Methods Unit of randomisation: individual.
Masking:
• participant - yes,
• provider - yes,
• outcome - yes.
Exclusions after randomisation: no.
Losses to follow-up: poor compliance, lack of sample. Placebo with “strong beneficial
effect”
Participants Country: USA.
Number of people randomised: 120.
Age: 7 to 13 years (average 10 years).
Sex: not reported.
Clinical grading: Dawson 1969.
Laboratory tests: IFAT on scrapings of upper tarsal conjunctival epithelium.
Inclusion criteria: active disease, boarding at study school.
Exclusion criteria: none.
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• Dose: 2.5 to 4.0 mg/kg.
• Duration: once daily for 5 consecutive days every week up to 28 doses in 40 days.
Comparator: placebo.
• Administration: oral.
• Dose: not applicable.
• Duration: once daily for 5 consecutive days every week up to 28 doses in 40 days.
Outcomes Primary: active trachoma.
Secondary: TRIC-positive immunofluorescent inclusions.
Adverse effects: anorexia, nausea, vomiting, or diarrhoea.
Follow-up: 5 months.
Notes Study name: none.
Date study conducted: October 1971 to April 1972.
Funding source: Quote: “This investigation was supported by National Institutes of
Health grant EY 00186 and the Burroughs Welcome Fund. Doxycycline capsules were
supplied as Vibramycin and a placebo was supplied through Barabar Liebovityz MD
and doxycycline hyclate was supplied as Vibramycin hyclate through Kenneth Munnelly
PhD Pfizer Inc. Brooklyn NY.”
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Students with signs of active tra-
choma were randomly assigned placebo or
drug”
Judgement comment: not enough informa-
tion on sequence allocation
Allocation concealment (selection bias) Unclear risk Judgement comment: although the drugs
were identical in appearance and taste and
coded A/B (see below), it was not clear how
they were allocated, e.g. whether they were
sequentially numbered
Blinding (performance bias and detection
bias)
Active trachoma
Low risk Quote: “Doxycycline capsules (50 mg) and
a placebo of identical appearance and taste
were used. Medications were coded as Drug
A or Drug B, and the identity remained un-
known to subjects, physicians and nursing
personnel until the results of all examina-
tion had been recorded.“
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Hoshiwara 1973 (Continued)
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “Doxycycline capsules (50 mg) and
a placebo of identical appearance and taste
were used. Medications were coded as Drug
A or Drug B, and the identity remained un-
known to subjects, physicians and nursing
personnel until the results of all examina-
tion had been recorded.“
Judgement comment: laboratory analyses
will have been easier to mask effectively
Incomplete outcome data (attrition bias)
All outcomes
High risk Judgement comment: 120 students ran-
domised and 103 (86%) followed up: 54
placebo and 49 active treatment. However,
it is not clear what the original random al-
locations were
Quote: “The others had to be eliminated
because of definite gaps in intake of medi-
cation, because serum levels or drug could
not be documented, or because they were
unavailable for one or more follow-up ex-
aminations.“
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
NCT00618449
Methods Unit of randomisation: village.
Masking:
• participant - no,
• provider - no,
• outcome - no (active trachoma), yes (C trachomatis infection).
Exclusions after randomisation: not reported.
Losses to follow-up: not reported.
Notes: study is unpublished, but results available on clinicaltrials.gov/ct2/show/results/
NCT00618449. Investigators comment: “Prevalence of infection in communities was
less than predicted, as was return of infection post-treatment, thus hypothesis could not
be evaluated”
Participants Country: Niger.
Endemicity: Quote: “high prevalence of clinically active trachoma amongst children<=
age 10.” but “Prevalence of infection in communities was less than predicted”. Actual
prevalence not reported.
Number of communities randomised: 10.
Number of people randomised: not reported.
Age: average age 18 to 19 years.
Sex: 52% female.
Clinical grading: method not specified.
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NCT00618449 (Continued)
Laboratory tests: nucleic acid amplification test.
Inclusion criteria: people living in selected villages, unclear how villages were selected
but have high prevalence of clinically active trachoma > 15% in children in the village.
Exclusion criteria: history of allergy to ANY macrolide antibiotic; severe nausea or
diarrhoea after the first dose of azithromycin; inability to tolerate oral therapy; pre-
existing serious illness
Interventions Intervention: azithromycin (2 doses) (n = 679 people).
• Administration: oral.
• Dose: 20 mg/kg up to 1 g.
• Duration: Day 0 and Day 30.
Comparator: azithromycin (single dose) (n = 668 people).
• Administration: oral.
• Dose: 20 mg/kg up to 1 g.
• Duration: Day 0.
Outcomes Primary: infection with C trachomatis diagnosed by use of nucleic acid amplification
tests.
Adverse effects: serious (death, life-threatening, inpatient hospitalisation, ongoing or
significant incapacity or interferes substantially with normal life functions, birth defects)
Follow-up: 1 month and 1 year post-treatment.
Notes Study name: Impact of Two Alternative Dosing Strategies for Trachoma Control in
Niger
Date study conducted: January 2008 to May 2009.
Funding source: not reported.
Conflict of interest: not reported.
Trial registration ID: NCT00618449.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Judgement comment: not reported.
Allocation concealment (selection bias) Low risk Judgement comment: not reported, but
cluster-RCT.
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Not reported
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
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NCT00618449 (Continued)
Selective reporting (reporting bias) High risk Judgement comment: study unpublished,
but results reported on ClinicalTrials.gov.
Active trachoma not reported
Recruitment bias addressed? (cluster RCT
only)
Unclear risk Not reported
Baseline imbalances addressed? (cluster
RCT only)
Unclear risk Not reported
Peach 1986
Methods Unit of randomisation: community, but analysed as individuals.
Masking:
• participant - no,
• provider - no,
• outcome: no.
Exclusions after randomisation: no.
Losses to follow-up: yes.
Note: 1 arm of a larger trial with components face washing and face washing plus
antibiotics. Communities randomly allocated, but trial was analysed and reported as
if it was individually randomised, so no information provided on clusters. We have
considered it as analysed, i.e. grouped it with the individually randomised studies
Participants Country: Australia (Aboriginal children).
Number of people randomised: 641.
Age: children 5 to 14 years (plus 5% under 5 and 5% over 14).
Sex: not reported.
Clinical grading: local version with at least 1 follicle or some papillary hypertrophy
being positive.
Laboratory tests: none.
Inclusion criteria: follicular trachoma.
Exclusion criteria: none.
Interventions Intervention: oily tetracycline.
• Administration: topical.
• Dose: daily for 5 days once a month.
• Duration: 3 months.
Comparator: no treatment.
Outcomes Primary: active trachoma.
Secondary: none.
Adverse events: not reported.
Follow-up: 3 months.
Notes Study name: none.
Date study conducted: not reported.
Funding source: not reported.
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Peach 1986 (Continued)
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Accordingly, whole communities
were randomly allocated to one of thre
treatment groups or to the fourth (non-
treatment) group”
Judgement comment: generation of the al-
location sequence not described
Allocation concealment (selection bias) Low risk Quote: “Accordingly, whole communities
were randomly allocated to one of thre
treatment groups or to the fourth (non-
treatment) group”
Judgement comment: allocation conceal-
ment not described.
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “The trachoma workers did not
know what treatment program, if any, had
been allocated to a particular community
and communities were visited in the same
order in which they had initially been
screened.“
Judgement comment: topical antibiotics
versus observation. Communities will have
known which treatment group they were
allocated to
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Children lost to follow-up were
assumed to have follicles and were included
in the analysis on that basis”
Judgement comment: 22/211 (10%) were
lost to follow-up in control communities.
34/374 (9%) lost to follow-up in treated
communities. These were not large losses to
follow-up, and the assumption that they all
have active trachoma is a conservative one,
which is why we have assigned a judgement
of low risk
Selective reporting (reporting bias) Low risk Judgement comment: only clinical out-
comes reported, but no indication of any
collection of data on microbiological out-
comes
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PRET Niger
Methods Unit of randomisation: community (grappe, government health unit).
Masking:
• participant - no,
• provider - no,
• outcome - no.
Exclusions after randomisation: none.
Losses to follow-up: none.
Notes: 2x2 factorial design, random sample of 100 sentinel children and 40 people aged
15 years or older were followed up in each community, mesoendemic region
Participants Country: Niger.
Endemicity: selected on the basis of at least 10% prevalence of active trachoma. Reported
prevalence of trachomatous inflammation in children 0 to 5 years was 28%.
Number of communities randomised: 24.
Number of people randomised: 12,991.
Age: sentinel children were aged 0 to 5.
Sex: approximately 52% female.
Clinical grading: Thylefors 1987.
Laboratory tests: Amplicor PCR.
Inclusion criteria:
Communities:
• Population between 250 and 600 at the most recent government census.
• Prevalence of 10% or more of active trachoma in children aged 0 to 60 months.
Interventions All intervention groups received azithromycin, as follows.
• Administration: oral.
• Dose: 20 mg/kg, up to 1 g in suspension (children) or tablets (adults, or children
able to swallow tablets).
• Quote: “Children under 6 months of age and those known to be allergic to
macrolides were offered tetracycline ointment (1%) to be applied to both eyes two
times per day for 6 weeks.”
Intervention 1: azithromycin (standard coverage 80% to 90%) (n = 12 communities,
people analysed = 1016 children at baseline, 772 children at 36 months)
• Duration: single dose at 4 time points (i.e. annually): 0, 12, 24, and 36 months.
• Quote: “(azithromycin)... was distributed during a single day, aiming for a
coverage target of 80% or greater of children and adults.”
Intervention 2: azithromycin (enhanced coverage > 90%) (n = 12 communities, people
analysed = 1196 children at baseline, 906 children at 36 months)
• Duration: single dose at 4 time points (i.e. annually): 0, 12, 24, and 36 months.
• Quote: “...communities received up to three follow-up visits to achieve coverage
of 90% or greater of children and adults.”
Intervention 3: azithromycin (annual all ages) (n = 24 communities).
• Duration: single dose at 4 time points (i.e. annually): 0, 12, 24, and 36 months.
• Quote: “In annually treated communities, study participants aged ≥6 months
received a directly observed dose of oral azithromycin”.
Intervention 4: azithromycin (twice yearly MDA in children 0 to 12 years) (n = 24
communities)
• Duration: single dose at 7 time points (i.e. twice yearly): 0, 6, 12, 18, 24, 30, and
36 months.
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PRET Niger (Continued)
• Quote: “only study participants aged 6 months to 12 years were offered
treatment.”
Outcomes (from trial register entry)
Primary:
• Community prevalence of trachoma and ocular C trachomatis infection at 5 years.
Secondary:
• Community costs of mass treatment (5 years).
• Community costs of incident infection (5 years).
• Macrolide resistance in pneumococcus (3 years).
• Anthropometry in children 5 years old or younger (1 to 3 years after baseline).
• Prevalence of anaemia in children 5 years old or younger (1 to 3 years after
baseline).
• Rates of health clinic visits overall, for infectious diseases, diarrhoea, malaria,
respiratory disease, and antibiotics (1, 2, and 3 years after baseline).
• Mortality in children (over study period).
• Mortality in adults (over study period).
Adverse events: not reported.
Follow-up: every 6 months for 3 years.
Quote: “a random sample of 100 children aged 0-5 years per community (or all children
if a given community had fewer than 100 children) was selected from the most recent
census for examination.”
Quote: for comparison of annual versus bi-annual “In both arms, childhood examinations
and swabs were biannual, while adult swabs were at baseline, 6, 12, and 36 months by
design”
Notes Study name: Partnership for the Rapid Elimination of Trachoma.
Date study conducted: May 2010 to August 2013.
Funding source: Quote: “This trial was funded by the Bill & Melinda Gates Foundation”
Conflict of interest: Quote: “All authors: No reported conflicts.”
Trial registration ID: NCT00792922.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Communities were randomised by
stratified block randomisation within each
CSI by high or low trachoma prevalence in
children. Within a given CSI, communi-
ties above the median trachoma prevalence
were considered to be ‘high’, and those be-
low the median were considered to be ‘low’.
The random allocation sequence was gen-
erated by TCP using R V.2.12 (R Foun-
dation for Statistical Computing, Vienna,
Austria; http://www. r- project. org).”
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PRET Niger (Continued)
Allocation concealment (selection bias) Low risk Judgement comment: not discussed, but as
this was a cluster-RCT unlikely to have cre-
ated selection bias
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Judgement comment: not discussed.
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Unclear risk Judgement comment: not discussed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: all clusters followed
up. Similar numbers of children sampled
in each cluster
Selective reporting (reporting bias) Unclear risk Judgement comment: some mismatch be-
tween the trial registry outcomes and what
was actually reported, but unclear whether
this will affect the conclusions of this re-
view
Recruitment bias addressed? (cluster RCT
only)
Unclear risk Judgement comment: not discussed.
Baseline imbalances addressed? (cluster
RCT only)
Low risk Judgement comment: communities ap-
peared to be balanced with respect to age,
sex, and prevalence of trachoma. Random
allocation was stratified by trachoma preva-
lence
PRET Tanzania
Methods Unit of randomisation: community (geographically distinct subvillages, averaging 1500
people)
Masking:
• participant - no,
• provider - no,
• outcome - no.
Exclusions after randomisation: none.
Losses to follow-up: none.
Notes: 2x2 factorial trial. Mesonendemic communities - prevalence of trachoma >=
20%. Quote: “The studies define communities as the smallest population unit for which
health services are organized and trachoma control programs are implemented.”
Participants Country: Tanzania.
Endemicity: prevalence of active trachoma in children aged less than 5 years was ap-
proximately 30%
Number of communities randomised: 32.
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PRET Tanzania (Continued)
Number of people randomised: not reported.
Age: all ages treated, sentinel children followed up aged 0 to 5.
Sex: % female ranged from 48% to 50% in 4 arms of the study (in sentinel children at
baseline assessment).
Clinical grading: Thylefors 1987.
Laboratory tests: Amplicor PCR.
Inclusion criteria:
Communities:
• Less than 5000 people with an estimated active trachoma prevalence of between
20% and 50% for mesoendemic communities and less than 20% for hypoendemic
communities.
Sentinel children:
• Aged 5 years or less at the time of census.
• Resided in an eligible community (defined as either living in the community since
birth, or moved in with parents or guardians).
• Had no ocular condition that precluded trachoma grading or prevented obtaining
an ocular specimen.
• Had an identifiable guardian capable of providing consent to participate.
Interventions All intervention groups received azithromycin, as follows.
• Administration: oral.
• Dose: 20 mg/kg, up to 1 g in suspension (children) or tablets (adults, or children
able to swallow tablets). Children below 6 months were given topical tetracycline.
Intervention 1: azithromycin (standard coverage 80% to 90%) (n = 16 communities,
people analysed = not reported)
• Duration: single dose at 4 time points (i.e. annually): 0, 12, 24, and 36 months.
• Quote: “For 80-90.0% coverage, CDDs (Community Drug Distributors) provide
mass treatment in the community for 2 days, with additional follow-up allowed to
achieve at least 80% coverage. Treatment is available at a central site the first day, with
follow-up to individual homes the second day and, if needed, subsequent days”.
Intervention 2: azithromycin (enhanced coverage > 90%) (n = 16 communities, people
analysed = not reported)
• Duration: single dose at 4 time points (i.e. annually): 0, 12, 24, and 36 months.
• Quote: “To reach >90.0% coverage, treatment is available at a central site for 1 to
2 days with household follow-up for 5 to 7 days as necessary to achieve > 90%
coverage.”
Intervention 3: azithromycin (annual MDA for 3 years) (n = 8 communities).
• Duration: single dose at 4 time points (i.e. annually): 0, 12, 24, and 36 months.
• Quote: “In annually treated communities, study participants aged ≥6 months
received a directly observed dose of oral azithromycin”.
Intervention 4: azithromycin (MDA cessation rule) (n = 8 communities).
• Duration: single dose at 0 months and thereafter only if infection prevalence was
greater than 0% at 6- or 18-month visit.
• MDA to be stopped early if prevalence of ocular C trachomatis was less than 5%.
Outcomes Outcome measures as recorded in trials register entry (clinicaltrials.gov/show/
NCT00792922, accessed 14 May 2014)
Primary outcome measure:
• Community prevalence of trachoma and ocular C trachomatis infection at 5 years.
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PRET Tanzania (Continued)
Secondary outcome measures:
• Community costs of mass treatment (5 years).
• Community costs of incident infection (5 years).
Follow-up: every 6 months for 3 years.
Notes Study name: Partnership for the Rapid Elimination of Trachoma.
Date study conducted: February 2010 and September 2011.
Funding source: Bill and Melinda Gates Foundation.
Conflict of interest: Authors reported no conflict of interest.
Trial registration ID: NCT00792922.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “In each study site, communities
were randomly allocated by the study statis-
tician in a 1:1:1:1 ratio to trial arms using
the 2X2 factorial design”.
Quote: “A constrained randomization was
used to reduce the likelihood of a bad ran-
domization outcome by balancing on es-
timated (pre-study) trachoma prevalence
and geographic location of villages as co-
variates19 and to assign a sufficient number
of communities to each of the 2X2 cells in
the factorial design (Table 1). A SAS macro
was developed (Version 9.0, SAS Institute,
Cary, NC) for this purpose.”
Allocation concealment (selection bias) Low risk Judgement comment: cluster-RCT, so not
applicable.
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “Only the study statistician and
mass treatment team were aware of the
community assignment; survey teams and
census teams were masked”.
Quote: “The survey team was masked to
the allocation of the communities into the
two arms. Team members were not shown
allocation schemes and surveys did not oc-
cur in order of treatment allocation. It was
theoretically possible that survey personnel
may have been unmasked once the cessa-
tion rule took effect, but cessation did not
occur in the study.”
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PRET Tanzania (Continued)
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “The survey team was masked to
the allocation of the communities into the
two arms. Team members were not shown
allocation schemes and surveys did not oc-
cur in order of treatment allocation. It was
theoretically possible that survey personnel
may have been unmasked once the cessa-
tion rule took effect, but cessation did not
occur in the study.”
Quote: “The laboratory at Johns Hopkins
University which processed the specimens
for infection was also masked to treatment
allocation. The specimen labels did not re-
veal treatment allocation, and all infection
data were managed by the study statistician
and study data managers who had no access
to the study teams. Community members
were not told their laboratory results be-
cause all members of the community were
eligible to receive the intervention. There-
fore, infection outcome in this trial was
double masked”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on numbers examined in
each community.
Selective reporting (reporting bias) Unclear risk Primary outcomes reported; secondary
outcomes not yet reported
Unclear why results for only 16 commu-
nities reported, but planned study design
included 48 communities
Results for comparison of coverage not yet
reported.
Recruitment bias addressed? (cluster RCT
only)
Low risk Not mentioned but probably unlikely.
Baseline imbalances addressed? (cluster
RCT only)
Low risk Yes. Allocation constrained and baseline
characteristics reported
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PRET The Gambia
Methods Unit of randomisation: community (Census Enumeration Area, quote: “several small
villages, be equivalent to a medium sized village, or be part of a large village and have
populations averaging 600-800 persons.”)
Masking:
• participant - yes,
• provider - yes,
• outcome: yes.
Exclusions after randomisation: none.
Losses to follow-up: none.
Notes: Quote: “The studies define communities as the smallest population unit for which
health services are organized and trachoma control programs are implemented.”
Participants Country: The Gambia.
Endemicity: prevalence of active trachoma in children 5 years or younger was 6.5%
Number of communities randomised: 48 communities.
Number of people randomised: random sample of 100 sentinel children followed up.
Age: sentinel children were aged 0 to 5.
Sex: approximately 50% female.
Clinical grading: Thylefors 1987.
Laboratory tests: Amplicor PCR.
Eligible communities had a trachoma prevalence estimated to be greater than 5%
To participate as a sentinel child, the child was:
• aged 5 years or less at the time of census;
• resided in an eligible community (defined as either living in the community since
birth, or moved in with parents or guardians);
• had no ocular condition that precluded trachoma grading or prevented obtaining
an ocular specimen;
• had an identifiable guardian capable of providing consent to participate.
Interventions 2x2 factorial design
• Annual MDA with “standard coverage” 80% to 90% (n = 24 communities)
versus “enhanced coverage” > 90% (n = 24 communities).
• Annual MDA for 3 years (n = 24 communities) versus annual MDA for 3 years
only if evidence of follicular trachoma or infection (“graduation”) (n = 24
communities).
Intervention: community treatment with single dose azithromycin 20 mg/kg, up to 1
g in a single dose of either suspension (children) or tablets (adults, or children able to
swallow tablets). Pregnant women and children below 6 months of age were given topical
tetracycline
Intervention: oily tetracycline daily for 5 days once a month for 3 months
• Administration: oral.
• Dose: oily tetracycline daily for 5 days once a month.
• Duration: 3 months.
Outcomes Outcome measures as recorded in trials register entry (clinicaltrials.gov/show/
NCT00792922, accessed 14 May 2014)
Primary outcome measure:
• Community prevalence of trachoma and ocular C trachomatis infection at 5 years.
Secondary outcome measures:
• Community costs of mass treatment (5 years).
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• Community costs of incident infection (5 years).
• Mortality in children aged 1 to 5 years (over study period).
• Cause-specific mortality in children aged 1 to 5 years (over study period).
• Mortality in adults in the study area (over study period).
• Cause-specific mortality in adults in the study area (over study period).
• Morbidity among children aged 1 to 5 years as assessed by height for age, weight
for age, weight for height, body mass index, and Hackett spleen size (30 months after
baseline).
• Serotype distribution, antibiotic sensitivity profile, and MLST type of
Streptococcus pneumoniae carried in the nasopharynx of study children (30 months after
baseline).
Follow-up: every 6 months for 3 years.
Notes Study name: Partnership for the Rapid Elimination of Trachoma.
Date study conducted: 2008 to 2011.
Funding source: Bill and Melinda Gates Foundation.
Conflict of interest: authors reported no conflict of interest.
Trial registration ID: NCT00792922.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “All 102 EAs in the 4 districts were
randomly assigned by the study statistician
to one of the four study arms: 1) Stan-
dard-SR; 2) Standard-36; 3) Enhanced-SR;
4) Enhanced-36 under the restriction that
all EAs that represented segments of the
same village were in the same randomiza-
tion group and would receive the same
combination of delivery strategies. The re-
striction process also aimed for balance of
strategy by district and overall. From these
EAs a random selection of 48 ‘study EAs’
for sampling was made such that 12 study
EAs per arm and per district were selected
(three EAs per arm per district) and such
that each large settlement was represented
by only one of its segment EAs selected at
random.”
Allocation concealment (selection bias) Low risk Judgement comment: cluster-randomised
study so not applicable
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “Only the study statistician and
mass treatment team were aware of the
community assignment; survey teams and
census teams were masked”.
87Antibiotics for trachoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PRET The Gambia (Continued)
Quote: “The participants and census, ex-
amination and treatment teams were un-
aware of which EAs were allocated to which
coverage arm.”
Quote: “The survey teams did not have ac-
cess to the coverage assignment of the com-
munities. The NEHP treatment team were
not part of the survey and were unaware of
treatment allocation on the first day they
treated an EA. Laboratory personnel were
masked to EA, coverage and treatment al-
location. At time points after six months,
concealment of stopping rule allocations
from participants and treatment teams was
not possible due to the design of the inter-
vention.”
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “Only the study statistician and
mass treatment team were aware of the
community assignment; survey teams and
census teams were masked”
Judgement comment: the participants and
census, examination, and treatment teams
were unaware of which enumeration areas
(EA) were allocated to which coverage arm
Quote: “The survey teams did not have ac-
cess to the coverage assignment of the com-
munities. The NEHP treatment team were
not part of the survey and were unaware of
treatment allocation on the first day they
treated an EA. Laboratory personnel were
masked to EA, coverage and treatment al-
location. At time points after six months,
concealment of stopping rule allocations
from participants and treatment teams was
not possible due to the design of the inter-
vention.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No communities withdrew from the study.
Quote: “A total of 5036 children aged 0-5
years were examined in The Gambia with
only 3 missing values for clinical sign data.
”
No loss to follow-up of EAs . However, no
data on attrition or exclusions at child level.
Raw data only available for a breakdown at
district level, and not by intervention group
(where only percentages are provided, even
in the supplementary tables)
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Selective reporting (reporting bias) Unclear risk Primary outcomes reported. Secondary
outcomes not reported as yet
Recruitment bias addressed? (cluster RCT
only)
Low risk Not mentioned but unlikely.
Baseline imbalances addressed? (cluster
RCT only)
Unclear risk Quote: “A comparison of baseline char-
acteristics of each group of communities
showed no imbalances in population size,
percentage of households with no latrine,
percentage more than 30 minutes from wa-
ter, or average education of head of house-
hold (Table 1). The baseline prevalence of
TF and of infection with Ct was low and
did not differ by study arm or allocation
(Table 2).”
Resnikoff 1995
Methods Unit of randomisation: village.
Masking:
• participant - no,
• provider - no,
• outcome - no.
Exclusions after randomisation: no information.
Losses to follow-up: no information.
Notes: 2x2 factorial design with health education intervention.
Participants Country: Mali.
Endemicity: prevalence of active trachoma ranged from 15% to 22%.
Number of communities randomised: 4 villages randomly allocated to 4 different
interventions. 2 villages only eligible for inclusion in this review
Number of people randomised: 1810.
Age: 1 to 5 years.
Sex: not reported.
Clinical grading: Thylefors 1987.
Laboratory tests: none.
Inclusion criteria: all inhabitants.
Exclusion criteria: none.
Interventions Intervention: 1% oxytetracycline eye drop solution (Innolyre).
• Administration: topical.
• Dose: 1 drop 4 times daily for 7 days a month, directly supervised by village
workers.
• Duration: 6 months.
Comparator: no treatment.
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Outcomes Primary: active trachoma (cure and incidence of new cases).
Secondary outcomes: none.
Follow-up: 3 and 6 months.
Notes Study name: none.
Date study conducted: March to September 1994.
Funding source: not reported.
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Four types of treatment were de-
fined, then attributed by randomization”
Judgement comment: not enough informa-
tion.
Allocation concealment (selection bias) Low risk Not reported, but as cluster-RCT not likely
to be a problem.
Blinding (performance bias and detection
bias)
Active trachoma
High risk This was not reported, so we have assumed
that it did not occur, as treatment was com-
pared to no treatment. The study was de-
scribed as “open controlled clinical trial”
(page 103)
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “At the initial examination, 1810
subjects were enrolled and examined” (page
104). Of these, 424 were from the commu-
nity treated with topical antibiotics (village
2) and 476 were from the control commu-
nity (village 4) (Table 2, page 109)
Quote: “A total of 347 subjects with ac-
tive trachoma were included in the clinical
trial. Two hundred and sixty five (76%) of
these subjects were successfully followed for
6 months and were included in the analysis
of the results.” (page 105)
Judgement comment: the distribution of
these cases by village is not reported. Using
Figure 1 (page 109) we can estimate that
there were 89 cases of active trachoma in
treatment community and 90 cases in con-
trol community. The “cure rate” in treat-
ment village was 82% (estimated 73 peo-
ple cured) and 36% in control community
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(estimated 33 people cured). No informa-
tion was given on possible reasons for loss
to follow-up
Selective reporting (reporting bias) Low risk Only clinical outcomes reported, but no in-
dication that microbiological data collected
Recruitment bias addressed? (cluster RCT
only)
Unclear risk Quote: “With the permission of adminis-
trative and traditional authorities, all in-
habitants of these four villages were sur-
veyed” (page 102).
No other information on recruitment, in
particular no indication as to response rates
of the survey in the villages concerned
Baseline imbalances addressed? (cluster
RCT only)
High risk Quote: “Four villages, matched for size and
epidemiological, economic and social con-
ditions, were included in the study. All vil-
lages were situated the same distance from
the health centre and each village possessed
a school and was equipped with boreholes.
” (page 102) (NB: 2 of these villages con-
cerned health education; data from these
not included in this review)
Quote: “The age and sex distribution was
identical in all four villages” (page 103). Ta-
ble 2 (page 109) shows the sex distribution
(46% male in treatment community and
51% male in control community). No data
on age distribution
Baseline prevalence of active trachoma
(Figure 1, page 109) just over 20% in treat-
ment community and just under 20% in
control community
Shukla 1966
Methods Unit of randomisation: individual.
Masking:
• participant - no,
• provider - no,
• outcome - unclear.
Exclusions after randomisation: no.
Losses to follow-up: none.
Notes: 4-armed trial with factorial design.
Participants Country: India.
Number of people randomised: 349.
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Age: 5 to 13 years.
Sex: not reported.
Clinical grading: WHO 1962.
Laboratory tests: none.
Inclusion criteria: active trachoma, schooling at a study school.
Exclusion criteria: none.
Interventions Intervention 1: sulfafurazole + sulfadimethoxine.
• Administration: topical + oral.
• Dose: 15%/100 mg/kg.




• Dose: 100 mg/kg.




• Duration: twice daily for 5 consecutive days every month for 5 months.
Comparator: no treatment.
Outcomes Primary: active trachoma.
Secondary: none.
Adverse events: not reported.
Follow-up: 5 months.
Notes Study name: none.
Date study conducted: October 1963 (recruitment).
Funding source: Quote: “We are grateful to the Indian Council of Medical Research for
adequate facilities and to Dr. B. Hegde, of Roche Products Lid., for the liberal supply of
Gantrisin drops and Madribon tablets.”
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The cases were randomly divided
into four more or less identical groups”
Judgement comment: not enough informa-
tion to judge.
Allocation concealment (selection bias) Unclear risk Allocation concealment not mentioned.
Judgement comment: not enough informa-
tion to judge.
92Antibiotics for trachoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Shukla 1966 (Continued)
Blinding (performance bias and detection
bias)
Active trachoma
High risk Judgement comment: no information
given, and treatments different in the vari-
ous groups, so study unlikely to have been
masked. However, study is described as
“double-blind study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: apparently 100%
follow-up with exception of 1 group B1 at
5 months where 35/41 seen
Selective reporting (reporting bias) Low risk Judgement comment: only clinical out-
comes reported, but no indication that mi-
crobiological data collected
Tabbara 1996
Methods Unit of randomisation: individual.
Masking:
• participant - no,
• provider - no,
• outcome - yes.
Exclusions after randomisation: no.
Losses to follow-up: 8/64.
Notes: case definition not clear (probable diagnosis of trachoma based on cytology,
definitive diagnosis of trachoma based on microscopical assessment of scrapings)
Participants Country: Saudi Arabia.
Number of people randomised: 64.
Age: 6 to 14 years (average 11 years).
Sex: not reported.
Clinical grading: Dawson 1981b.
Laboratory tests: conjunctival scrapings for inclusion bodies/cells/organisms/mucus;
IFAT for free elementary bodies




• Dose: 20 mg/kg.




• Duration: twice daily for 5 consecutive days per week over 6 weeks, administered
by teacher.
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Outcomes Primary: active trachoma.
Secondary: intraepithelial cell inclusion bodies, free elementary bodies.
Adverse events: none.
Follow-up: 4, 8, 12, and 24 weeks.
Notes Study name: none.
Date study conducted: not reported.
Funding source: not reported.
Conflict of interest: Quote: ”The authors have no proprietary interest in any of the
materials used in this study.“
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”The patients were assigned ran-
domly ...“
Judgement comment: not enough informa-
tion to judge.
Allocation concealment (selection bias) Unclear risk Not reported.
Judgement comment: not enough informa-
tion to judge.
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “The examiner was unaware of the
treatment allocation at the time of the ex-
amination”
Judgement comment: study was described
as “single-masked”. Patients were aware of
therapy because oral versus topical treat-
ment. No information on whether the
masking was effective - e.g. did the patients
tell the examiners which treatment they had
received?
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “Conjunctival scrapings were ob-
tained from each patient before initiation
of therapy”
Quote: “The slides were coded and masked
to the reader”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: it was not clear how
many people were randomised to treat-
ment/control, but reported percentages
suggest that it was 32 in each group
8 weeks: treatment 2/32 (6.3%) and con-
trol 5/32 (15.6%) lost to follow-up
94Antibiotics for trachoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tabbara 1996 (Continued)
12 weeks: treatment 1/32 (3.1%) and con-
trol 3/32 (9.4%) lost to follow-up
24 weeks: treatment 2/32 (6.3%) and con-
trol 6/32 (18.8%) lost to follow-up
Higher loss to follow-up in control group,
but actual numbers not very large. No in-
dication as to reason for not being seen. We
have assigned a judgement of unclear risk
because the effect of these missing data is
uncertain
Selective reporting (reporting bias) Low risk Both outcomes of relevance to this review
were reported.
TANA
Methods Unit of randomisation: community (subkebeles, government-defined units).
Masking:
• participant - no,
• provider - no,
• outcome - yes.
Exclusions after randomisation: none.
Losses to follow-up: no communities lost to follow-up.
Notes: study had 6 treatment arms, but 4 of these (12 communities in each) relevant to
this review. The other 2 treatment groups evaluated intensive latrine construction and
are beyond the remit of this review
Participants Country: Ethiopia.
Endemicity: prevalence of active trachoma in children aged 0 to 9 years was approxi-
mately 70%
Number of communities randomised: 48.
Number of people randomised: 66,404.
Age: 32% aged 0 to 9 years
Sex: 48% female
Clinical grading: Thylefors 1987.
Laboratory tests: Amplicor PCR assay (Roche Diagnostics, Branchburg,
NJ, USA)
Inclusion criteria: people resident in these communities. Different members of the pop-
ulation were treated according to the treatment schedule being tested (see interventions
below).
Exclusion criteria: none.
Interventions All intervention groups received azithromycin, as follows.
• Administration: oral.
• Dose: adults 1 g, children 20 mg/kg, directly observed, unless contraindicated by
allergy or pregnancy.
• Duration: single dose.
• Children younger than 1 year and pregnant women were offered a 6-week course
of topical tetracycline 1% (not directly observed).
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Intervention 1: annual treatment of people 1 year and above (12 subkebeles, 15,902
people)
• Duration: 3 years.
Intervention 2: twice-yearly treatment of people 1 year and above (12 subkebeles, 17,
288 people)
• Duration 3.5 years.
Intervention 3: quarterly treatment of children age 1 to 10 years (12 subkebeles, 14,
716 people)
• Duration: 1 year.
Intervention 4: delayed treatment group (12 subkebeles, 18,498 people).
• Duration: 1 year.
In a follow-up study, communities were randomised to continuation or discontinuation
of yearly or twice-yearly treatment
Outcomes The following information about outcomes was obtained from the trial registration
information on ClinicalTrials.gov
Primary outcome measures:
• The average prevalence of ocular chlamydia infection in communities in an arm
as determined by pooled nucleic acid amplification test (at 42 months for Aim 1, at 12
months for Aim 2, post-treatment relative to pre-treatment for Aim 3) [ Time Frame:
42 months ].
Secondary outcome measures:
• Clinical active trachoma in community, as determined by the WHO simplified
grading system [ Time Frame: 42 months ].
• Childhood (>= 1 year of age) mortality, analysed as 1 to 5, 6 to 10 years of age,
and total [ Time Frame: 42 months ].
• Macrolide resistance in pneumococcus (% resistance over time, clustered by
randomisation unit) [ Time Frame: 42 months ].
Notes Study name: Trachoma Amelioration in Northern Amhara (TANA). Follow-up study
name: Tripartite International Research for the Elimination of Trachoma (TIRET)
Date study conducted: May 2006 to November 2009.
Funding source: Quote: “The National Institutes of Health (NEI U10 EY016214,
NEI K12EX017269, NEI K23 EYO19881-01, and NCRR/OD UCSF-CTSI Grant
Number KL2 RR024130) was the main supporter of this trial. We thank the International
Trachoma Initiative for their generous donation of azithromycin, the Bernard Osher
Foundation, That Man May See, the Harper Inglis Trust, the Bodri Foundation, the
South Asia Research Fund, and Research to Prevent Blindness”
Conflict of interest: Quote: “We declare that we have no conflicts of interest”
Trial registration ID: NCT00322972. Follow-up study: NCT01202331.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The 72 subkebeles were randomly
assigned to one of six groups of 12 sub-
kebeles each, forming three separate tra-
choma-specific comparisons (generation by
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KJR with RANDOM() and SORT() in Ex-
cel [version 2003], implementation by BA,
concealed until assignment).”
Allocation concealment (selection bias) Low risk Quote: “The 72 subkebeles were randomly
assigned to one of six groups of 12 sub-
kebeles each, forming three separate tra-
choma-specific comparisons (generation by
KJR with RANDOM() and SORT() in Ex-
cel [version 2003], implementation by BA,
concealed until assignment).”
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “Censuses for all study communi-
ties were undertaken by trained health-care
personnel who were blinded to study group
and to the prevalence of ocular chlamydial
infection”
Judgement comment: no mention of mask-
ing of clinical observers
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “Laboratory person-
nel were blinded to individual, community,
and treatment-group identifications. Since
dilution effects and underestimation due to
pooling could theoretically occur, all com-
munities had to be processed in an identical
way, and complete masking of laboratory
personnel had to be maintained.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Random sample selected for measurement
of ocular infection. 637/720 (88%) chil-
dren seen in “children-treated” group; 618/
720 (86%) children seen in control group
(delayed treatment); and 600/720 (83%)
children seen in mass treatment group.
Equivalent measures for children >= 11
years and adults: 561/720 (78%); 550/720
(76%); 599/720 (83%)
Selective reporting (reporting bias) Low risk Data on active trachoma not reported but
supplied by author.
Recruitment bias addressed? (cluster RCT
only)
Low risk No information reported, however we be-
lieve that this is unlikely because in all arms
treatment was offered at the same time as
assessment
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Baseline imbalances addressed? (cluster
RCT only)
Low risk Pre-treatment age, sex, ocular and clinical
infection in children reported at baseline
for treated communities and 12 months for
untreated communities. No major imbal-
ances reported
TEF
Methods Unit of randomisation: community.
Masking:
• participant - no,
• provider - no,
• outcome - no (active trachoma), yes (C trachomatis infection).
Exclusions after randomisation: no.
Losses to follow-up: numbers recorded.
Participants Country: Ethiopia.
Endemicity: mean prevalence of ocular infection in children aged 1 to 5 years was 43%
Number of communities randomised: 16.
Number of people randomised: 5410.
Age: not reported.
Sex: not reported.
Clinical grading: Thylefors 1987.
Laboratory tests: Amplicor PCR (Roche Diagnostics, Branchburg, NJ).
Inclusion criteria: everyone 1 year and older.
Exclusion criteria: none.
Pregnant women and children younger than 1 year were offered 6-week course of topical
1% tetracycline (applied twice daily to both eyes and not directly observed)
Interventions All intervention groups received azithromycin as follows.
• Administration: oral.
• Dose: 1 g in adults, 20 mg/kg in children.
• Duration: single dose, directly observed.
Pregnant women, children younger than 1 year, and those allergic to macrolides were
offered a 6-week course of topical 1% tetracycline ointment (applied twice daily to both
eyes, not directly observed)
Intervention 1: annual treatment people age 1 year and above (8 communities)
Intervention 2: twice-yearly treatment people age 1 year and above (8 communities)
Intervention 3: single treatment people age 1 year and above.
Comparator: delayed treatment.
Outcomes On trials register, as follows.
• Primary: the prevalence of ocular chlamydia infection in a village as determined
by PCR.
• Secondary: clinical active trachoma, as determined by the WHO simplified
grading system, by village.
Presence of ocular chlamydial infection in children aged 1 to 5. A random sample of
adults was tested at 18 months
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Follow-up: 2, 6, 12, 18, and 24 months after treatment.
Notes Study name: Trachoma Elimination Follow-up.
Date study conducted: March 2003 to April 2005 (from clinical trials registration)
Funding source: Quote: “This work was supported by the International Trachoma
Initiative, the Bernard Osher Foundation, That Man May See, the Peierls Foundation,
the Bodri Foundation, the Harper Inglis Trust, the South Asia Research Fund, Research
to Prevent Blindness, and grants U10 EY016214 and R21 AI 55752 from the National
Institutes of Health.”
Conflict of interest: none reported.
Trial registration ID: NCT00221364.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eight villages were randomly as-
signed to receive annual treatments and 8
to receive biannual treatments (generation
by the RAND command in Excel by T.M.
L., implementation including enrollment
and assignment of participants by M.M.)”
Allocation concealment (selection bias) Low risk Not reported, but not an issue in cluster-
RCTs.
Blinding (performance bias and detection
bias)
Active trachoma
Low risk Quote: “Fieldworkers who performed an-
tibiotic distributions and clinical assess-
ments were aware of treatment schedules.
Laboratory personnel were masked to indi-
vidual, village, and treatment group iden-
tifications.”
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Low risk Quote: “Fieldworkers who performed an-
tibiotic distributions and clinical assess-
ments were aware of treatment schedules.
Laboratory personnel were masked to indi-
vidual, village, and treatment group iden-
tifications.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All communities completed the study.
84% of children completed survey in an-
nual treatment group compared to 78% in
bi-annual treatment group. Most common
reasons for non-participation were: absence
from village, moved to another village, and
death
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Selective reporting (reporting bias) High risk Secondary outcome on active trachoma not
reported.
Recruitment bias addressed? (cluster RCT
only)
Unclear risk Quote: “All children 1-5 years of age
were identified through the census and re-
quested to come to a central location with
a guardian.” (page 129)
No information given on rates of response
to this request for participation
Baseline imbalances addressed? (cluster
RCT only)
Unclear risk Annually treatment arm villages had a
higher average prevalence of ocular in-
fection (43%) compared to bi-annually
treated villages (32%), but differences not
statistically significant
Wilson 2018
Methods Unit of randomisation: communities (subvillage balozis).
Masking:
• participant - no,
• provider - no,
• outcome - no.
Exclusions after randomisation: none.
Losses to follow-up: no communities lost to follow-up, follow-up could not be assessed
for individuals, as random samples of children were assessed at baseline and follow-up.
Notes: 96 communities randomised, unclear how many people in the communities, but
20 children per community assessed
Participants Country: Tanzania.
Endemicity: prevalence of active trachoma was approximately 5% in children aged 1 to
9 years.
Number of communities randomised: 96.
Number of people randomised: unclear, approximately 1600 children aged 1 to 9 years
assessed for trachoma.
Age: 1 to 9 years.
Sex: 48% male.
Clinical grading: Thylefors 1987.
Laboratory tests: swab specimen of right eye, C trachomatis diagnosed by use of nucleic
acid amplification test.
Inclusion criteria:
• Communities: not been treated with azithromycin since 2009 and were predicted
from prior prevalence surveys to have TF between 5% and 9.9%.
• People: mass treatment, but only children aged 1 to 9 years with parental consent
were assessed for trachoma.
Exclusion criteria:
• Pregnant women and infants under the age of 6 months were instead offered
tetracycline eye ointment for daily use for up to 6 weeks.
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• Dose: 20 mg/kg up to 1 g.
• Duration: single dose.
Comparator: no treatment.
Outcomes Primary: not stated.
Secondary: not stated.
Outcomes assessed: clinical trachoma, ocular infection, antibody response.
Adverse effects: yes.
Follow-up: 12 months.
Notes Study name: none.
Date study conducted: October to December 2012.
Funding source: Quote: “Funding for this project was provided by the Bill and Melinda
Gates Foundation (project OPP1022543).”
Conflict of interest: Quote: “The authors report no conflict of interest. The authors
alone
are responsible for the writing and content of this article.”
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Balozis were randomly assigned to
the intervention and control arms.”
Judgement: not enough information to
make a judgement.
Allocation concealment (selection bias) Low risk Cluster-RCT.
Blinding (performance bias and detection
bias)
Active trachoma
High risk Judgement comment: masking not re-
ported and interventions different
Blinding (performance bias and detection
bias)
Ocular Chlamydia trachomatis infection
Unclear risk Judgement comment: masking not re-
ported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: similar numbers of
children seen at baseline and 12 months in
both arms
Selective reporting (reporting bias) Unclear risk Judgement comment: no access to proto-
col, trial does not appear to be registered.
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Wilson 2018 (Continued)
Recruitment bias addressed? (cluster RCT
only)
Unclear risk Judgement comment: difficult to assess
with the information available.
Baseline imbalances addressed? (cluster
RCT only)
Unclear risk Judgement comment: clusters appeared to
be similar except with respect to distance
from water source - more communities in
the no-treatment arm were less than 30
minutes from a water source (39% versus
35% in the treatment arm), and median
percentage with active trachoma was higher
in the no-treatment arm (6.0% versus 4.
3% in the treatment arm), however differ-
ence was not statistically significant
Woolridge 1967
Methods Unit of randomisation: individual.
Masking:
• participant - no,
• provider - no,
• outcome - yes.
Exclusions after randomisation: unclear.
Losses to follow-up: unclear.
Notes: combined vaccine and therapy trial.
Participants Country: Taiwan.
Number of people randomised: 322.
Age: primary school age.
Sex: not reported.
Clinical grading: Modified McCallan classification.
Laboratory tests: none.





• Duration: twice daily for 6 consecutive days per week for 6 weeks.
Comparator: no treatment.
Outcomes Primary: active trachoma.
Secondary: none.
Adverse effects: not assessed.
Follow-up: 3 years.
Notes Study name: none.
Date study conducted: February 1962 to October 1964.
Funding source: Quote: “This study was supported in part by a United States Public
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Woolridge 1967 (Continued)
Health Service Research Grant”
Conflict of interest: not reported.
Trial registration ID: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Those that received treatment
were chosen by random number”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Active trachoma
Unclear risk Quote: “The ophthalmologists making the
eye examinations at no time knew to which
vaccine or treatment group the subject be-
longed nor what his previous diagnosis had
been”
Quote: “Placebo therapy was not em-
ployed” (page 1578).
No discussion as to whether the ophthal-
mologists might have been unmasked be-
cause the participants knew their treatment
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk No information on completeness of follow-
up.
Selective reporting (reporting bias) Low risk Active trachoma only reported, but no in-
dication that any data were collected on C
trachomatis infection.
IFAT: immunofluorescent antibody test
ITT: intention-to-treat
LCR: ligase chain reaction
MDA: mass drug administration
MLST: multilocus sequence typing
PCR: polymerase chain reaction
RCT: randomised controlled trial
TRIC: trachoma inclusion conjunctivitis
WHO: World Health Organization
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdou 2007 Not a randomised controlled trial. Prevalence study only
Assaad 1968 Not a randomised controlled trial (quasi-randomised)
Astle 2006 Not a randomised controlled trial. Prevalence study only
Babbar 1982 Not a randomised controlled trial. No comparator group
Biebesheimer 2009 Not a randomised controlled trial. No comparator group
Bietti 1967 Not a randomised controlled trial (review)
Broman 2006 Not a randomised controlled trial
Cerulli 1983 Not a randomised controlled trial (no evidence of randomisation)
Chumbley 1988 Not a randomised controlled trial
Coulibaly 2013 Not a relevant intervention or comparator. Co-administered treatment for onchocerciasis, difficult to distinguish
effects of azithromycin
Daghfous 1974 Not a randomised controlled trial (no evidence of randomisation)
Daghfous 1985 Not a randomised controlled trial (no evidence of randomisation)
Darougar 1980b Not a relevant intervention or comparator. Topical therapy only
Darougar 1981 Not a relevant intervention or comparator. Topical therapy only
Dawson 1967a Not a randomised controlled trial (quasi-randomised)
Dawson 1967b Not a randomised controlled trial (quasi-randomised)
Dawson 1968 Not a randomised controlled trial (no evidence of randomisation)
Dawson 1971 Not a randomised controlled trial (quasi-randomised)
Dawson 1972a Not a randomised controlled trial (no evidence of randomisation)
Dawson 1972b Not a randomised controlled trial (no evidence of randomisation)
Dawson 1974a Not a randomised controlled trial (no evidence of randomisation)
Dawson 1974b Not a randomised controlled trial (quasi-randomised)
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(Continued)
Dawson 1975b Not a randomised controlled trial (quasi-randomised)
Dawson 1981b Not a relevant intervention or comparator. Topical therapy only
Dawson 1982 Not a randomised controlled trial (children were matched by severity, age, and sex)
Edwards 2006 Not a relevant intervention or comparator. Health education intervention
Gower 2006 Not randomised controlled trial
Gupta 1966 Not a randomised controlled trial (no evidence of randomisation)
Gupta 1968 Not a relevant intervention or comparator. No comparison group receiving placebo or no treatment
Guzey 2000 Inclusion criteria of participants non-specific. They had bilateral trachoma or showed symptoms (not described)
Hasan 1976 Not a relevant intervention or comparator. No comparison group receiving placebo or no treatment
Humet 1989 No eye outcome measured
Isenberg 2002 Study not carried out in a trachoma endemic area.
Ji 1986 No trial report
Kamiya 1956 Not a relevant intervention or comparator. Lack of comparison villages
Khandekar 2006 Not a randomised controlled trial
Litricin 1968 Not a relevant intervention or comparator. No comparison group
Mesfin 2006 Not a randomised controlled trial
Mohan 1982 Not a randomised controlled trial
MORDOR 2018 Trial of azithromycin to reduce childhood mortality; participants did not have trachoma
Nabli 1988 Not a relevant intervention or comparator. No comparison group
NCT00286026 Study was not conducted because the prevalence of infection in the screened population was too low
NCT00347607 Not a relevant intervention or comparator. Trial of different approaches to surveillance
NCT00347776 Randomised controlled trial evaluating effect of antibiotic treatment on recurrence of trichiasis
NCT01178762 Not a randomised controlled trial
NCT01767506 Not a relevant intervention or comparator. Additional benefit of treating newcomers
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NCT02211729 Trial of azithromycin as an adjunct to seasonal malaria chemoprevention, participants did not have trachoma
Ngondi 2006a Not a randomised controlled trial
Ngondi 2006b Not a relevant intervention or comparator. No antibiotic/no antibiotic comparison
Nisbet 1979 Not a relevant intervention or comparator. No comparator group
Obikili 1988 Not a relevant intervention or comparator. No comparator group
Putschky 2006 No eye outcome measured.
Reinhards 1959 Not a relevant intervention or comparator. No comparison group
Resnikoff 1994 Not a relevant intervention or comparator. No comparison group
Schachterle 2014 Not a randomised controlled trial
Schemann 2007 Not a relevant intervention or comparator. Comparison of different treatment targeting strategies, therefore
does not meet inclusion criteria of review
Tabbara 1988 Randomisation was by eye and not patient. It was not possible to determine the individual patient outcome
Toufic 1968 Not a randomised controlled trial
Wadia 1980 Not a relevant intervention or comparator. No comparison group
Werner 1977 Not a randomised controlled trial
West 2006 Test efficacy of insecticide
Whitcher 1974 Not a randomised controlled trial
Zhang 2006 Not a relevant intervention or comparator. No appropriate control group
Characteristics of studies awaiting assessment [ordered by study ID]
Last 2015
Methods Cluster-randomised controlled trial
Participants 1714 children aged 1 to 9 years
Interventions Single versus 2 doses (Day 1 and Day 7) of oral azithromycin
Outcomes Active trachoma and ocular infection
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Last 2015 (Continued)
Notes Published as abstract only
Characteristics of ongoing studies [ordered by study ID]
NCT03523156
Trial name or title Trachoma Elimination Study by Focused Antibiotic (TESFA)
Methods Cluster-randomised controlled trial
Participants Country: Ethiopia
19,200
Interventions • Azithromycin targeted treatment: community-wide MDA followed by 2 rounds targeted to children
age 6 months to 9 years 1 to 2 weeks apart.
• Azithromycin mass treatment: annual community-wide MDA.
Outcomes (From ClinicalTrials.gov)
“Primary Outcome Measures
• Prevalence of Chlamydia trachomatis (CT) infection [ Time Frame: Month 12 ]The community-level
prevalence of CT infection in children aged 6 months to 9 years will be compared between study arms.
Secondary Outcome Measures :
• Change in prevalence of trachomatous inflammation-follicular (TF) [ Time Frame: Baseline, Week 4,
Month 12, Month 24 ]The prevalence of trachomatous inflammation-follicular (TF) among all household
members will be noted at each visit and compared between study arms.
• Change in prevalence of trachomatous inflammation-intense (TI) [ Time Frame: Baseline, Week 4,
Month 12, Month 24 ]The prevalence of trachomatous inflammation-intense (TI) among all household
members will be noted at each visit and compared between study arms
• Change in Chlamydia trachomatis (CT) infection in children [ Time Frame: Baseline, Month 12,
Month 24 ]The change in prevalence of Chlamydia trachomatis (CT) infections in children ages 6 months to
9 years will be compared between study arms. Analysis will be conducted which will include all three of
these time-points to compare infection prevalence between the comparison arms
• Prevalence of Chlamydia trachomatis (CT) infection among adults [ Time Frame: Month 12 ]The
prevalence of Chlamydia trachomatis (CT) infection among adults will be compared between study arms.
• Cost [ Time Frame: Month 24 ]The cost of the enhanced intervention will be compared to the cost of
the standard-of-care intervention.
• Cost-effectiveness [ Time Frame: Month 24 ]The cost-effectiveness of the enhanced intervention will
be compared to the cost of the standard-of-care intervention. The incremental cost effectiveness analysis
ratio approach will be used. Effectiveness is defined as the percent CT reduction from baseline to 24 months
and the outcome of this analysis will be the cost per percent of CT infection reduction.
• Correlation between Chlamydial Infection and trachomatous inflammation-follicular (TF) and
trachomatous inflammation-intense (TI) [ Time Frame: Baseline, Week 4, Month 12, Month 24 ]We will
conduct cluster level analysis using cluster level Ct and clinical data including TF and TI.
• Cluster-level Chlamydial load [ Time Frame: Baseline, Week 4, Month 12, Month 24 ]Infectious load
for all individual specimens from 6 months to 9 year-old children who test positive for CT will be measured
for chlamydia load. Chlamydial load will be noted at each visit and compared between study arms.”
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NCT03523156 (Continued)
Starting date December 2018
Estimated study completion date: December 2020
Contact information Contact: Kelly Callahan, MPH ecallah@emory.edu
Notes clinicaltrials.gov/ct2/show/NCT03523156
SWIFT 2017
Trial name or title Sanitation, Water, and Instruction in Face-washing for Trachoma (SWIFT)




• Targeted antibiotic treatment.
• Mass antibiotics.
TAITU-B
• Targeted antibiotic treatment.
• Delayed antibiotics.
Targeted antibiotic treatment: communities will receive targeted antibiotic treatments for children testing
positive for ocular chlamydia at 3, 6, 9, and 12 months after baseline testing. After testing for ocular chlamydia
at 12 months, any children testing positive at this time point will receive antibiotic treatments at 15, 18, 21,
and 24 months. Children 6 months and up will be offered azithromycin 20 mg/kg; those under 6 months
will be offered tetracycline
Delayed mass antibiotics: Delayed mass antibiotic treatment: Communities will receive no mass azithromycin
treatment during the study period. Communities in this treatment group have previously received at least 8
rounds of mass azithromycin treatment. These clusters will be enrolled in an antibiotics treatment program
(azithromycin or tetracycline) after the completion of the study
Mass antibiotics: Mass antibiotic treatment: Communities will receive mass azithromycin treatment of all
individuals aged 6 months and up (20 mg/kg for children, 1 g for adults); those younger than 6 months,
pregnant, or allergic to macrolide antibiotics will be offered a 2-week course of tetracycline
Outcomes (From ClinicalTrials.gov)
“Primary Outcome Measures
• Village-specific ocular chlamydia among 0-5 children over time (first trial: WUHA) [ Time Frame: 12,
24, 36 months ]Multiple time points will be used in a mixed effects regression model of the village-specific
ocular chlamydia prevalences over time in 0-5 year olds as assessed by PCR.
• Ocular chlamydia among 8-12 year olds (second trial: TAITU-A) [ Time Frame: 24 months ]Cluster-
specific prevalence of ocular chlamydia among individuals aged 8-12 years, compared between the targeted
azithromycin arm and the mass azithromycin arm.
• Incident ocular chlamydia in 0-5 year-olds (third trial: TAITU-B) [ Time Frame: 24 months
]Incidence of new ocular chlamydia infection in 0-5 year-olds, compared between the targeted azithromycin
arm and the delayed mass azithromycin arm.
• Trial-based cost-effectiveness of intervention (intervention costs per percent of chlamydia reduction) [
Time Frame: 24 months for TAITU, 36 months for WUHA ]The short term analysis is designed to provide
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SWIFT 2017 (Continued)
insight into whether each intervention (WASH or targeted antibiotics) is effective for our primary trial
outcome of reducing ocular chlamydial infection in children. The time horizon of these analyses will be the
duration of each trial.
Secondary Outcome Measures
• Quantitative PCR chlamydia load [ Time Frame: 12, 24, 36 months ]
• Follicular trachoma scores; age-stratified (0-5, 6-9, 10 and up for WUHA; 0-5, 8-12 for TAITU) [
Time Frame: 12, 24, 36 months ]
• Inflammatory trachoma scores; age-stratified (0-5, 6-9, 10 and up for WUHA; 0-5, 8-12 for TAITU) [
Time Frame: 12, 24, 36 months ]
• Ocular chlamydia; age-stratified (0-5, 6-9, 10 and up for WUHA; 0-5, 8-12 for TAITU) [ Time
Frame: 12, 24, 36 months ]
• Nasopharyngeal pneumococcal macrolide resistance [ Time Frame: 12, 24, 36 months ]Using standard
microbiological techniques, the lab will process the swabs using media selective for Streptococcus
pneumoniae, and then test for antibiotic resistance. Nasopharyngeal macrolide resistance in age 0-5 will be
modeled at the village level, using treatment arm as a covariate.
• Proportion of the population with clean faces at the village level [ Time Frame: 12, 24, 36 months ]
• Childhood growth (height) [ Time Frame: 12, 24, 36 months ]
• Childhood growth (weight) [ Time Frame: 12, 24, 36 months ]
• Soil-transmitted helminth prevalence [ Time Frame: 12, 24, 36 months ]
• Soil-transmitted helminth density [ Time Frame: 12, 24, 36 months ]
• Prevalence of chlamydia and other antigen positivity from serological tests [ Time Frame: 12, 24, and
36 months ]
• Prevalence of stool-based antigen (diarrheal pathogens, soil transmitted helminths) positivity from
serological tests [ Time Frame: 12, 24, and 36 months ]”
Starting date November 2015
Estimated study completion date: July 2019
Contact information Contact: Dionna M Fry, MPH; dionna.fry@ucsf.edu
Contact: Jeremy D Keenan, MD, MPH; jeremy.keenan@ucsf.edu
Notes clinicaltrials.gov/ct2/show/NCT02754583
MDA: mass drug administration
PCR: polymerase chain reaction
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D A T A A N D A N A L Y S E S
Comparison 1. Any antibiotic versus control (individuals)




participants Statistical method Effect size
1 Active trachoma at 3 months 9 1961 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.69, 0.89]
2 Active trachoma at 12 months 4 1035 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.55, 1.00]
3 Active trachoma at 3 months
(subgroup analysis)
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Oral antibiotic 6 599 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.67, 0.97]
3.2 Topical antibiotic 6 1478 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.72, 0.92]
4 Active trachoma at 12 months
(subgroup analysis)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Oral antibiotic 3 429 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.76, 1.00]
4.2 Topical antibiotic 4 724 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.71, 0.88]
5 Ocular C trachomatis infection
at 3 months
4 297 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.63, 1.04]
6 Ocular C trachomatis infection
at 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7 Ocular C trachomatis infection at
3 months (subgroup analysis)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Oral antibiotic 4 259 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.66, 1.11]
7.2 Topical antibiotic 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.02, 1.37]
8 Ocular C trachomatis infection at
12 months (subgroup analysis)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Oral antibiotic 1 91 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.10, 1.23]
8.2 Topical antibiotic 1 85 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.04]
Comparison 2. Oral versus topical antibiotics (individuals)




participants Statistical method Effect size
1 Active trachoma at 3 months 6 953 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.16]
2 Active trachoma at 12 months 5 886 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.75, 1.15]
3 Ocular C trachomatis infection
at 3 months
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Ocular C trachomatis infection
at 12 months
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 3. Oral azithromycin versus topical tetracycline (individuals)




participants Statistical method Effect size
1 Active trachoma at 3 months 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Active trachoma at 12 months 2 447 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.59, 0.99]
3 Ocular C trachomatis infection
at 3 months
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Ocular C trachomatis infection
at 12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Oral azithromycin versus control (communities)




participants Statistical method Effect size
1 Active trachoma at 12 months 1 1247 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.52, 0.65]
2 Ocular C trachomatis infection
at 12 months
2 2139 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.31, 0.43]
Comparison 5. Oral azithromycin versus topical tetracycline (communities)




participants Statistical method Effect size
1 Active trachoma at 3 months 3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Active trachoma at 12 months 3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Ocular C trachomatis infection
at 3 months
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Ocular C trachomatis infection
at 12 months
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Any antibiotic versus control (individuals), Outcome 1 Active trachoma at 3
months.
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 1 Active trachoma at 3 months








Attiah 1973 (1) 84/152 58/76 13.0 % 0.72 [ 0.60, 0.88 ]
Darougar 1980 (2) 61/79 34/45 12.4 % 1.02 [ 0.83, 1.25 ]
Dawson 1969 Sherman (3) 1/15 1/14 0.2 % 0.93 [ 0.06, 13.54 ]
Dawson 1969 Stewart (4) 6/18 15/18 2.8 % 0.40 [ 0.20, 0.79 ]
Foster 1966 (5) 165/218 88/107 16.1 % 0.92 [ 0.82, 1.03 ]
Hoshiwara 1973 (6) 28/49 44/54 9.8 % 0.70 [ 0.53, 0.92 ]
Peach 1986 (7) 216/340 138/189 16.0 % 0.87 [ 0.77, 0.98 ]
Shukla 1966 (8) 113/223 36/42 13.5 % 0.59 [ 0.49, 0.71 ]
Woolridge 1967 (9) 139/202 103/120 16.0 % 0.80 [ 0.71, 0.90 ]
Total (95% CI) 1296 665 100.0 % 0.78 [ 0.69, 0.89 ]
Total events: 813 (Antibiotic), 517 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 29.38, df = 8 (P = 0.00027); I2 =73%
Test for overall effect: Z = 3.81 (P = 0.00014)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
(1) Antibiotic: topical tetracycline derivative GS2989 or topical oxytetracycline (terramycin). Control: no treatment
(2) Antibiotic: topical oxytetracycline or oral doxycycline. Control: vitamin pills
(3) Antibiotic: oral trisulphapyrimidines. Control: lactose-placebo.
(4) Antibiotic: oral trisulphapyrimidines. Control: lactose-placebo.
(5) Antibiotic: oral sulphamethoxypyridazine or topical tetracycline. Control: no treatment.
(6) Antibiotic: oral doxycycline. Control: placebo.
(7) Antibiotic: topical tetracycline. Control: no treatment.
(8) Antibiotic: topical sulphafurazole and/or oral sulphadimethoxine. Control: no treatment.
(9) Antibiotic: topical tetracycline. Control: no treatment.
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Analysis 1.2. Comparison 1 Any antibiotic versus control (individuals), Outcome 2 Active trachoma at 12
months.
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 2 Active trachoma at 12 months








Darougar 1980 (1) 43/82 33/47 22.7 % 0.75 [ 0.57, 0.99 ]
Foster 1966 (2) 145/218 68/107 25.9 % 1.05 [ 0.88, 1.24 ]
Shukla 1966 (3) 91/217 35/42 24.9 % 0.50 [ 0.41, 0.62 ]
Woolridge 1967 (4) 121/202 95/120 26.5 % 0.76 [ 0.65, 0.88 ]
Total (95% CI) 719 316 100.0 % 0.74 [ 0.55, 1.00 ]
Total events: 400 (Antibiotic), 231 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 29.16, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
(1) Antibiotic: topical oxytetracycline or oral doxycycline. Control: vitamin pills
(2) Antibiotic: oral sulphamethoxypyridazine or topical tetracycline. Control: no treatment.
(3) Antibiotic: topical sulphafurazole and/or oral sulphadimethoxine. Control: no treatment.
(4) Antibiotic: topical tetracycline. Control: no treatment.
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Analysis 1.3. Comparison 1 Any antibiotic versus control (individuals), Outcome 3 Active trachoma at 3
months (subgroup analysis).
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 3 Active trachoma at 3 months (subgroup analysis)









Darougar 1980 (1) 32/42 34/45 21.7 % 1.01 [ 0.80, 1.28 ]
Dawson 1969 Sherman (2) 1/15 1/14 0.5 % 0.93 [ 0.06, 13.54 ]
Dawson 1969 Stewart (3) 6/18 15/18 5.9 % 0.40 [ 0.20, 0.79 ]
Foster 1966 (4) 86/112 88/107 28.7 % 0.93 [ 0.82, 1.07 ]
Hoshiwara 1973 (5) 28/49 44/54 19.3 % 0.70 [ 0.53, 0.92 ]
Shukla 1966 (6) 53/83 36/42 23.9 % 0.74 [ 0.61, 0.91 ]
Subtotal (95% CI) 319 280 100.0 % 0.81 [ 0.67, 0.97 ]
Total events: 206 (Antibiotic), 218 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 12.52, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 2.26 (P = 0.024)
2 Topical antibiotic
Attiah 1973 (7) 84/152 58/76 15.8 % 0.72 [ 0.60, 0.88 ]
Darougar 1980 (8) 29/37 34/45 13.0 % 1.04 [ 0.82, 1.32 ]
Foster 1966 (9) 79/106 88/107 19.2 % 0.91 [ 0.79, 1.04 ]
Peach 1986 (10) 216/340 138/189 20.9 % 0.87 [ 0.77, 0.98 ]
Shukla 1966 (11) 29/62 36/42 10.3 % 0.55 [ 0.41, 0.73 ]
Woolridge 1967 (12) 139/202 103/120 20.9 % 0.80 [ 0.71, 0.90 ]
Subtotal (95% CI) 899 579 100.0 % 0.82 [ 0.72, 0.92 ]
Total events: 576 (Antibiotic), 457 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 15.77, df = 5 (P = 0.01); I2 =68%
Test for overall effect: Z = 3.30 (P = 0.00097)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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(1) Antibiotic: oral doxycycline. Control: vitamin pills
(2) Antibiotic: oral trisulphapyrimidines. Control: lactose-placebo.
(3) Antibiotic: oral trisulphapyrimidines. Control: lactose-placebo.
(4) Antibiotic: oral sulphamethoxypyridazine. Control: no treatment.
(5) Antibiotic: oral doxycycline. Control: placebo.
(6) Antibiotic: oral sulphadimethoxine. Control: no treatment.
(7) Antibiotic: topical tetracycline derivative GS2989 or topical oxytetracycline (terramycin). Control: no treatment
(8) Antibiotic: topical oxytetracycline. Control: vitamin pills
(9) Antibiotic: topical tetracycline. Control: no treatment.
(10) Antibiotic: topical tetracycline. Control: no treatment.
(11) Antibiotic: topical sulphafurazole. Control: no treatment.
(12) Antibiotic: topical tetracycline. Control: no treatment.
Analysis 1.4. Comparison 1 Any antibiotic versus control (individuals), Outcome 4 Active trachoma at 12
months (subgroup analysis).
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 4 Active trachoma at 12 months (subgroup analysis)
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral antibiotic
Darougar 1980 24/44 33/47 21.7 % 0.78 [ 0.56, 1.08 ]
Foster 1966 80/112 68/107 47.4 % 1.12 [ 0.93, 1.35 ]
Shukla 1966 36/77 35/42 30.9 % 0.56 [ 0.43, 0.74 ]
Subtotal (95% CI) 233 196 100.0 % 0.87 [ 0.76, 1.00 ]
Total events: 140 (Antibiotic), 136 (Control)
Heterogeneity: Chi2 = 17.63, df = 2 (P = 0.00015); I2 =89%
Test for overall effect: Z = 1.90 (P = 0.057)
2 Topical antibiotic
Darougar 1980 19/38 33/47 11.4 % 0.71 [ 0.49, 1.03 ]
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Foster 1966 65/106 68/107 26.2 % 0.96 [ 0.78, 1.19 ]
Shukla 1966 35/62 35/42 16.2 % 0.68 [ 0.52, 0.88 ]
Woolridge 1967 121/202 95/120 46.2 % 0.76 [ 0.65, 0.88 ]
Subtotal (95% CI) 408 316 100.0 % 0.79 [ 0.71, 0.88 ]
Total events: 240 (Antibiotic), 231 (Control)
Heterogeneity: Chi2 = 5.58, df = 3 (P = 0.13); I2 =46%
Test for overall effect: Z = 4.33 (P = 0.000015)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
Analysis 1.5. Comparison 1 Any antibiotic versus control (individuals), Outcome 5 Ocular C trachomatis
infection at 3 months.
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 5 Ocular C trachomatis infection at 3 months








Darougar 1980 (1) 8/82 7/47 7.1 % 0.66 [ 0.25, 1.69 ]
Dawson 1969 Sherman (2) 7/15 10/14 15.9 % 0.65 [ 0.35, 1.23 ]
Dawson 1969 Stewart (3) 11/18 14/18 32.4 % 0.79 [ 0.50, 1.22 ]
Hoshiwara 1973 (4) 24/49 29/54 44.6 % 0.91 [ 0.62, 1.33 ]
Total (95% CI) 164 133 100.0 % 0.81 [ 0.63, 1.04 ]
Total events: 50 (Antibiotic), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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(1) Antibiotic: topical oxytetracycline or oral doxycycline. Control: vitamin pills
(2) Antibiotic: oral trisulphapyrimidines. Control: lactose-placebo.
(3) Antibiotic: oral trisulphapyrimidines. Control: lactose-placebo.
(4) Antibiotic: oral doxycycline. Control: placebo.
Analysis 1.6. Comparison 1 Any antibiotic versus control (individuals), Outcome 6 Ocular C trachomatis
infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 6 Ocular C trachomatis infection at 12 months
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darougar 1980 (1) 4/82 9/47 0.25 [ 0.08, 0.78 ]
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
(1) Antibiotic: topical oxytetracycline or oral doxycycline. Control: vitamin pills
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Analysis 1.7. Comparison 1 Any antibiotic versus control (individuals), Outcome 7 Ocular C trachomatis
infection at 3 months (subgroup analysis).
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 7 Ocular C trachomatis infection at 3 months (subgroup analysis)
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral antibiotic
Darougar 1980 7/44 7/47 11.5 % 1.07 [ 0.41, 2.80 ]
Dawson 1969 Sherman 7/15 10/14 17.6 % 0.65 [ 0.35, 1.23 ]
Dawson 1969 Stewart 11/18 14/18 23.8 % 0.79 [ 0.50, 1.22 ]
Hoshiwara 1973 24/49 29/54 47.0 % 0.91 [ 0.62, 1.33 ]
Subtotal (95% CI) 126 133 100.0 % 0.85 [ 0.66, 1.11 ]
Total events: 49 (Antibiotic), 60 (Control)
Heterogeneity: Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
2 Topical antibiotic
Darougar 1980 1/38 7/47 100.0 % 0.18 [ 0.02, 1.37 ]
Subtotal (95% CI) 38 47 100.0 % 0.18 [ 0.02, 1.37 ]
Total events: 1 (Antibiotic), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.098)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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Analysis 1.8. Comparison 1 Any antibiotic versus control (individuals), Outcome 8 Ocular C trachomatis
infection at 12 months (subgroup analysis).
Review: Antibiotics for trachoma
Comparison: 1 Any antibiotic versus control (individuals)
Outcome: 8 Ocular C trachomatis infection at 12 months (subgroup analysis)
Study or subgroup Antibiotic Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral antibiotic
Darougar 1980 3/44 9/47 100.0 % 0.36 [ 0.10, 1.23 ]
Subtotal (95% CI) 44 47 100.0 % 0.36 [ 0.10, 1.23 ]
Total events: 3 (Antibiotic), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
2 Topical antibiotic
Darougar 1980 1/38 9/47 100.0 % 0.14 [ 0.02, 1.04 ]
Subtotal (95% CI) 38 47 100.0 % 0.14 [ 0.02, 1.04 ]
Total events: 1 (Antibiotic), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.054)
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours control
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Analysis 2.1. Comparison 2 Oral versus topical antibiotics (individuals), Outcome 1 Active trachoma at 3
months.
Review: Antibiotics for trachoma
Comparison: 2 Oral versus topical antibiotics (individuals)
Outcome: 1 Active trachoma at 3 months








Bowman 2000 (1) 48/152 68/139 16.4 % 0.65 [ 0.48, 0.86 ]
Darougar 1980 (2) 32/42 29/37 19.0 % 0.97 [ 0.77, 1.23 ]
Dawson 1997 (3) 76/118 28/42 18.3 % 0.97 [ 0.75, 1.24 ]
Foster 1966 (4) 86/112 79/106 24.0 % 1.03 [ 0.89, 1.20 ]
Shukla 1966 (5) 53/83 29/62 15.4 % 1.37 [ 1.00, 1.86 ]
Tabbara 1996 (6) 13/31 12/29 6.8 % 1.01 [ 0.56, 1.85 ]
Total (95% CI) 538 415 100.0 % 0.97 [ 0.81, 1.16 ]
Total events: 308 (Oral antibiotic), 245 (Topical antibiotic)
Heterogeneity: Tau2 = 0.03; Chi2 = 13.21, df = 5 (P = 0.02); I2 =62%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours oral Favours topical
(1) Oral antibiotic: azithromycin. Topical antibiotic: tetracycline.
(2) Oral antibiotic: doxycycline. Topical antibiotic: oxytetracycline.
(3) Oral antibiotic: azithromycin. Topical antibiotic: oxytetracycline/polymyxin and oral placebo.
(4) Oral antibiotic: sulphamethoxypyridazine. Topical antibiotic: tetracycline.
(5) Oral antibiotic: sulphadimethoxine. Topical antibiotic: sulphafurazole.
(6) Oral antibiotic: azithromycin. Topical antibiotic: tetracycline.
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Analysis 2.2. Comparison 2 Oral versus topical antibiotics (individuals), Outcome 2 Active trachoma at 12
months.
Review: Antibiotics for trachoma
Comparison: 2 Oral versus topical antibiotics (individuals)
Outcome: 2 Active trachoma at 12 months








Bowman 2000 (1) 32/149 45/139 16.4 % 0.66 [ 0.45, 0.98 ]
Darougar 1980 (2) 24/44 19/38 15.2 % 1.09 [ 0.72, 1.66 ]
Dawson 1997 (3) 60/117 24/42 20.3 % 0.90 [ 0.65, 1.23 ]
Foster 1966 (4) 80/112 65/106 28.3 % 1.16 [ 0.96, 1.41 ]
Shukla 1966 (5) 36/77 35/62 19.8 % 0.83 [ 0.60, 1.14 ]
Total (95% CI) 499 387 100.0 % 0.93 [ 0.75, 1.15 ]
Total events: 232 (Oral antibiotic), 188 (Topical antibiotic)
Heterogeneity: Tau2 = 0.03; Chi2 = 9.13, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours oral Favours topical
(1) Oral antibiotic: azithromycin. Topical antibiotic: tetracycline.
(2) Oral antibiotic: doxycycline. Topical antibiotic: oxytetracycline.
(3) Oral antibiotic: azithromycin. Topical antibiotic: oxytetracycline/polymyxin and oral placebo.
(4) Oral antibiotic: sulphamethoxypyridazine. Topical antibiotic: tetracycline.
(5) Oral antibiotic: sulphadimethoxine. Topical antibiotic: sulphafurazole.
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Analysis 2.3. Comparison 2 Oral versus topical antibiotics (individuals), Outcome 3 Ocular C trachomatis
infection at 3 months.
Review: Antibiotics for trachoma
Comparison: 2 Oral versus topical antibiotics (individuals)
Outcome: 3 Ocular C trachomatis infection at 3 months
Study or subgroup Oral antibiotic Topical antibiotic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darougar 1980 (1) 7/44 1/38 6.05 [ 0.78, 46.95 ]
Dawson 1997 (2) 5/119 3/41 0.57 [ 0.14, 2.30 ]
Tabbara 1996 (3) 6/30 4/26 1.30 [ 0.41, 4.11 ]
0.1 0.2 0.5 1 2 5 10
Favours oral Favours topical
(1) Oral antibiotic: doxycycline. Topical antibiotic: oxytetracycline.
(2) Oral antibiotic: azithromycin. Topical antibiotic: oxytetracycline/polymyxin and oral placebo.
(3) Oral antibiotic: azithromycin. Topical antibiotic: tetracycline.
Analysis 2.4. Comparison 2 Oral versus topical antibiotics (individuals), Outcome 4 Ocular C trachomatis
infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 2 Oral versus topical antibiotics (individuals)
Outcome: 4 Ocular C trachomatis infection at 12 months
Study or subgroup Oral antibiotic Topical antibiotic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darougar 1980 (1) 3/44 1/38 2.59 [ 0.28, 23.88 ]
Dawson 1997 (2) 8/105 5/33 0.50 [ 0.18, 1.43 ]
0.1 0.2 0.5 1 2 5 10
Favours oral Favours topical
(1) Oral antibiotic: doxycycline. Topical antibiotic: oxytetracycline.
(2) Oral antibiotic: azithromycin. Topical antibiotic: oxytetracycline/polymyxin and oral placebo.
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Analysis 3.1. Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 1 Active
trachoma at 3 months.
Review: Antibiotics for trachoma
Comparison: 3 Oral azithromycin versus topical tetracycline (individuals)
Outcome: 1 Active trachoma at 3 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bowman 2000 48/152 68/139 0.65 [ 0.48, 0.86 ]
Dawson 1997 76/118 28/42 0.97 [ 0.75, 1.24 ]
Tabbara 1996 15/31 12/29 1.17 [ 0.66, 2.06 ]
0.1 0.2 0.5 1 2 5 10
Favours azithromycin Favours tetracycline
Analysis 3.2. Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 2 Active
trachoma at 12 months.
Review: Antibiotics for trachoma
Comparison: 3 Oral azithromycin versus topical tetracycline (individuals)
Outcome: 2 Active trachoma at 12 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bowman 2000 32/149 45/139 56.9 % 0.66 [ 0.45, 0.98 ]
Dawson 1997 60/117 24/42 43.1 % 0.90 [ 0.65, 1.23 ]
Total (95% CI) 266 181 100.0 % 0.76 [ 0.59, 0.99 ]
Total events: 92 (Oral azithromycin), 69 (Topical tetracycline)
Heterogeneity: Chi2 = 1.50, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours azithromycin Favours tetracycline
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Analysis 3.3. Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 3 Ocular
C trachomatis infection at 3 months.
Review: Antibiotics for trachoma
Comparison: 3 Oral azithromycin versus topical tetracycline (individuals)
Outcome: 3 Ocular C trachomatis infection at 3 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dawson 1997 5/119 3/41 0.57 [ 0.14, 2.30 ]
Tabbara 1996 6/30 4/26 1.30 [ 0.41, 4.11 ]
0.1 0.2 0.5 1 2 5 10
Favours azithromycin Favours tetracycline
Analysis 3.4. Comparison 3 Oral azithromycin versus topical tetracycline (individuals), Outcome 4 Ocular
C trachomatis infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 3 Oral azithromycin versus topical tetracycline (individuals)
Outcome: 4 Ocular C trachomatis infection at 12 months
Study or subgroup Oral azithromycin Topical tetracycline Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dawson 1997 8/105 5/33 0.50 [ 0.18, 1.43 ]
0.1 0.2 0.5 1 2 5 10
Favours azithromycin Favours tetracycline
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Analysis 4.1. Comparison 4 Oral azithromycin versus control (communities), Outcome 1 Active trachoma
at 12 months.
Review: Antibiotics for trachoma
Comparison: 4 Oral azithromycin versus control (communities)
Outcome: 1 Active trachoma at 12 months
Study or subgroup Oral azithromycin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TANA 258/634 429/613 100.0 % 0.58 [ 0.52, 0.65 ]
Total (95% CI) 634 613 100.0 % 0.58 [ 0.52, 0.65 ]
Total events: 258 (Oral azithromycin), 429 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 9.90 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours azithromycin Favours control
Analysis 4.2. Comparison 4 Oral azithromycin versus control (communities), Outcome 2 Ocular C
trachomatis infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 4 Oral azithromycin versus control (communities)
Outcome: 2 Ocular C trachomatis infection at 12 months
Study or subgroup Oral azithromycin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TANA 88/600 282/618 75.3 % 0.32 [ 0.26, 0.40 ]
TEF 51/513 82/408 24.7 % 0.49 [ 0.36, 0.68 ]
Total (95% CI) 1113 1026 100.0 % 0.36 [ 0.31, 0.43 ]
Total events: 139 (Oral azithromycin), 364 (Control)
Heterogeneity: Chi2 = 4.76, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 11.23 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours azithromycin Favours control
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Analysis 5.1. Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 1
Active trachoma at 3 months.
Review: Antibiotics for trachoma
Comparison: 5 Oral azithromycin versus topical tetracycline (communities)
Outcome: 1 Active trachoma at 3 months








ACT 1999 Egypt 141/1050 199/775 0.52 [ 0.43, 0.64 ]
ACT 1999 Tanzania 343/1535 200/1042 1.16 [ 1.00, 1.36 ]
ACT 1999 The Gambia 38/818 48/782 0.76 [ 0.50, 1.15 ]
0.01 0.1 1 10 100
Favours azithromycin Favours tetracycline
Analysis 5.2. Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 2
Active trachoma at 12 months.
Review: Antibiotics for trachoma
Comparison: 5 Oral azithromycin versus topical tetracycline (communities)
Outcome: 2 Active trachoma at 12 months








ACT 1999 Egypt 149/1031 178/910 0.74 [ 0.61, 0.90 ]
ACT 1999 Tanzania 333/1351 191/925 1.19 [ 1.02, 1.40 ]
ACT 1999 The Gambia 58/675 82/522 0.55 [ 0.40, 0.75 ]
0.01 0.1 1 10 100
Favours azithromycin Favours tetracycline
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Analysis 5.3. Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 3
Ocular C trachomatis infection at 3 months.
Review: Antibiotics for trachoma
Comparison: 5 Oral azithromycin versus topical tetracycline (communities)
Outcome: 3 Ocular C trachomatis infection at 3 months








ACT 1999 Egypt 10/1026 34/756 0.22 [ 0.11, 0.44 ]
ACT 1999 Tanzania 64/1510 64/1028 0.68 [ 0.49, 0.95 ]
ACT 1999 The Gambia 52/749 96/704 0.51 [ 0.37, 0.70 ]
0.01 0.1 1 10 100
Favours azithromycin Favours tetracycline
Analysis 5.4. Comparison 5 Oral azithromycin versus topical tetracycline (communities), Outcome 4
Ocular C trachomatis infection at 12 months.
Review: Antibiotics for trachoma
Comparison: 5 Oral azithromycin versus topical tetracycline (communities)
Outcome: 4 Ocular C trachomatis infection at 12 months








ACT 1999 Egypt 30/1013 56/901 0.48 [ 0.31, 0.74 ]
ACT 1999 Tanzania 108/1327 73/909 1.01 [ 0.76, 1.35 ]
ACT 1999 The Gambia 53/636 66/490 0.62 [ 0.44, 0.87 ]
0.01 0.1 1 10 100
Favours azithromcyin Favours tetracycline
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A D D I T I O N A L T A B L E S
Table 1. Individually randomised studies: participants




1 Attiah 1973 Egypt Active trachoma or
“undetermined
case”
228 6 to 12 years Not reported
2 Bailey 1993 The Gambia Active trachoma 194 9 months to 60
years
51%
3 Bowman 2000 The Gambia Active trachoma 314 6 months to 10
years
50%
4 Cochereau 2007 Guinea and Pak-
istan
Active trachoma 670 1 to 10 years 50%










Active trachoma 36 12 to 21 years Not reported
8 Dawson 1997 Egypt Active trachoma 168 2 to 10 years 60%
9 Foster 1966 USA (Indian
boarding school)
Active trachoma 457 8 to 20 years Not reported
10 Hoshiwara 1973 USA (Indian
boarding school)
Active trachoma 120 7 to 13 years Not reported




641 5 to 14 years Not reported
12 Shukla 1966 India Active trachoma 349 5 to 13 years Not reported
13 Tabbara 1996 Saudi Arabia Active trachoma 64 6 to 14 years Not reported
14 Woolridge 1967 Taiwan Active trachoma 322 Primary school age Not reported
*Dawson 1969 Sherman and Dawson 1969 Stewart were reported in the same paper.
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Antibiotic Dose Duration Frequency Interven-
tion
Dose Duration Frequency













































































































once placebo - 21 consecu-
tive days
-
Oral versus topical antibiotic
129Antibiotics for trachoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Individually randomised studies: comparisons (Continued)
Bailey 1993 azithromy-
cin (oral)
































































20 mg/kg single dose -
*Also compared to oxytetracycline (Terramycin) once every school day for 11 weeks.
**Also compared to doxycycline (oral) 5 mg/kg single dose every month for 12 months.
***Also compared to sulfadimethoxine (oral) 100 mg/kg bi-weekly or weekly dose for 5 months and sulfafurazole (topical) 15% twice
daily for 5 consecutive days, every month for 5 months.
****Also compared to azithromycin (topical) 1.5% twice daily for 3 days.
Table 3. Individually randomised studies: outcomes
Study Active trachoma Ocular infection
Classification
scheme
3 months 12 months Laboratory as-
sessments
3 months 12 months
1 Attiah 1973 WHO 1962
√
No follow-up No laboratory
tests
- -
2 Bailey 1993 Dawson 1981
√ √
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Table 3. Individually randomised studies: outcomes (Continued)
3 Bowman 2000 Thylefors 1987
√ √







































(20 weeks) No follow-up No laboratory
tests
- -


























(5 months) No follow-up
11 Peach 1986 At least 1 folli-




No follow-up No laboratory
tests
- -
12 Shukla 1966 WHO 1962
√
(5 months) No follow-up No laboratory
tests
- -
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IFAT: immunofluorescence antibody test
PCR: polymerase chain reaction
*Followed up to three years.
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Table 4. Cluster-randomised studies: participants (Continued)
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Table 4. Cluster-randomised studies: participants (Continued)
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LCR: ligase chain reaction
TF: trachomatous inflammation-follicular
Table 5. Cluster-randomised studies: comparisons
Intervention Comparator
Comparison Antibiotic* Frequency Antibiotic* Frequency
Studies with a no-treatment or delayed-treatment comparator group
Resnikoff 1995 tetracycline ** every month for 6 months no treatment -
TEF azithromycin once only; annually for 3
years; twice a year for 3 years
delayed treatment -
TANA azithromycin every 3 months for 3 years delayed treatment -
Wilson 2018 azithromycin once only delayed treatment -
Studies of azithromycin versus tetracycline
ACT 1999 Egypt; ACT
1999 Tanzania; ACT
1999 The Gambia***
azithromycin once a week for 3 weeks tetracycline once daily for 6 weeks
Atik 2006**** azithromycin single dose at baseline and
12 months.
Non-index cases received
All patients with active
trachoma received topical
tetracycline and surgery of-
-
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Table 5. Cluster-randomised studies: comparisons (Continued)
tetracycline, and surgery of-
fered where appropriate
fered where appropriate
Studies of different frequencies of azithromycin






azithromycin annually for 3 years (en-
hanced coverage)




azithromycin twice a year for 3 years azithromycin annually for 3 years
PRET Tanzania; PRET
The Gambia
azithromycin annually for 3 years azithromycin cessation rule
*Azithromycin was given as a single oral dose at 20 mg/kg up to 1 g (adults); tetracycline was given topically 1%.
**One drop four times daily for seven days.
***Once a week for three weeks.
****Treatment of people with active trachoma and their household members only.
*****Only children were treated twice yearly.
Table 6. Cluster-randomised studies: outcomes
Study Follow-up Active trachoma Ocular infection Resistance Adverse effects
1 ACT 1999 Egypt 12 to 14 months Dawson 1981 Conjunctival swabs
assessed using LCR.
Not studied Not reported
2 ACT 1999
Tanzania
12 to 14 months Dawson 1981 Conjunctival swabs
assessed using LCR.
Not studied Not reported
3 ACT 1999 The
Gambia
12 months Dawson 1981 Conjunctival swabs
assessed using LCR.
Not studied Not reported





Not studied Not reported




Not studied Reported (no ad-
verse events)
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Table 6. Cluster-randomised studies: outcomes (Continued)




























9 Resnikoff 1995 6 months Thylefors 1987 No laboratory tests Not studied Not reported













S pneumoniae Reported (no seri-
ous adverse events)




Not studied Reported (no seri-
ous adverse events)
LCR: ligase chain reaction
PCR: polymerase chain reaction
Table 7. Adverse effects: individually randomised studies
Study Antibiotic (number of people treated) Report
1 Attiah 1973 Oxytetracycline (77)
Tetracycline derivative GS2989 (75)
No comment on adverse effects in report
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Table 7. Adverse effects: individually randomised studies (Continued)
2 Bailey 1993 Azithromycin (97)
Topical tetracycline with oral ery-
thromycin in severe cases (97)
Table 2 on page 454 reports adverse ef-
fects. Abdominal pain reported more of-
ten in azithromycin group (26% ver-
sus 16%, P = 0.09). Other effects:
diarrhoea, vomiting, fever, headache,
body pain, other similar between study
groups
“There were no serious adverse reac-
tions and both treatments were well tol-
erated. All symptoms resolved sponta-
neously and none required treatment.”
1 study participant died, probably due
to malaria. He had received topical tetra-
cycline
3 Bowman 2000 Azithromycin (160)
Tetracycline (154)
No comment on adverse effects in report
4 Cochereau 2007 Azithromycin topical 2-day regimen
(222) 3-day (220) and oral azithromy-
cin (214)
“Ocular adverse events were reported
in 10.8%, 8.9% and 13.1% of pa-
tients in the 2-day, 3-day and oral treat-
ment groups respectively. Systemic ad-
verse events were reported in 2.6%, 10.
2% and 9.0% of patients. None of the
adverse events were treatment-related
events. One patient (3-day group) had a
serious unrelated adverse events (death
due to head injury).” (page 670)
5 Darougar 1980 Doxycycline (44)
Oxytetracycline (38)
No comment on adverse effects in report
6 & 7 Dawson 1969 Sherman
Dawson 1969 Stewart
Trisulfapyrimidines (33) “No untoward reactions to sulfon-
amides were noted” (page 587)
8 Dawson 1997 Oxytetracycline/polymyxin (43)
Azithromycin (125)
“In this trial, azithromycin was well tol-
erated and only two children (of 125
treated) complained of nausea” (page
367)
9 Foster 1966 Sulfamethoxypyridazine (112)
Tetracycline (106)
“3/155 students who received sul-
famethoxypyridazine had adverse reac-
tions to the drug. One girl developed a
severe purpura associated with marked
thrombocytopenia. She recovered fol-
lowing withdrawal of the drug and
administration of corticosteroids. Two
cases of diagnosed drug rash necessi-
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Table 7. Adverse effects: individually randomised studies (Continued)
tated discontinuance of the drug. The
nephrotic syndrome developed in one
boy three months after completion of
sulphonamide therapy, but the relation-
ship of this development to therapy was
not determined. No reactions or rashes
occurred in the other two treatment
groups” (page 453) (note: Table 3/Table
4 report 112 children treated with sul-
famethoxypyridazine)
10 Hoshiwara 1973 Doxycycline (49) “Anorexia, nausea, vomiting or diarrhea
occurred in three children between the
15th and 25th days of medication. Two
of these children were receiving doxycy-
cline, and the disturbances lasted only
a single day in each child, in spite of
continuing medication. Between day 21
and 28 of medication, transient macu-
lar rashes and one-day illness with low-
grade fever and anorexia occurred in
four children. Two of them had received
drug, and two placebo. It is likely that
an intercurrent, unrelated illness was
responsible. Gross enamel dysplasia or
tooth discoloration was not observed on
examination 20 weeks after the end of
medication.” (page 222)
11 Peach 1986 Tetracycline (932) No comment on adverse effects in report
12 Shukla 1966 Sulfafurazole (140)
Sulfadimethoxine (161)
No comment on adverse effects in report
13 Tabbara 1996 Azithromycin (31)
Tetracycline (29)
“No adverse effects were noted” (page
844); and “The safety of a single oral
dose of azithromycin has been demon-
strated in this study. Similar to other
clinical studies, no adverse effects de-
veloped in any of the patients in the
azithromycin group” (page 845)
14 Woolridge 1967 Tetracycline (726)
Sulfonamide (526)
“No more than trivial reactions were ob-
served in any of these three studies, to
vaccine, to oil adjuvant, to eye ointment
or to sulfa drug.” (page 1581)
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MDA: mass drug administration
TMP-SMX: trimethoprim-sulfamethoxazole
*All the studies were cluster-randomised trials, and AZ was delivered to the whole community (mass drug administration).
Table 9. Antibiotic resistance to Streptococcus pneumoniae
Study* Follow-
up**
















































2 - - - - - - -
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2 - - - - - - -
TANA Baseline 11 - - - - - - -












12 months 12 58/93 62.3 12 11/98 11.6 5.6 3.1 to 9.9
TEF 24 months 8 34/120 28.2 8 1/120 0.9 34.0 4.7 to 244
TEF 36 months 8 92/120 76.8 8 0/119 0 183.4 11.5 to 2922
TEF 42 months 8 37/120 30.6 8 - - - -
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Table 9. Antibiotic resistance to Streptococcus pneumoniae (Continued)
TEF 54 months 8 25/120 20.8 8 - - - -
CLINDAMYCIN
TANA Baseline 11 2/110 1.5 - - - - -












12 months 12 14/83 16.9 12 4/98 3.9 4.1 1.4 to 12.1
PENICILLIN
TANA Baseline 11 0/110 0 - - - - -












12 months 12 0/83 0 12 1/98 1.0 0.39 0.02 to 9.52
TEF 24 months 8 1/120 0.9 8 0/120 0 3.0 0.12 to 72.9
TEF 36 months 8 0/120 0 8 0/119 0 - -
TEF 42 months 8 0/120 0 8 - - - -
TEF 54 months 8 0/120 0 8 - - - -
TETRACYCLINE
TANA Baseline 11 11/110 10.0 - - - - -
145Antibiotics for trachoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 9. Antibiotic resistance to Streptococcus pneumoniae (Continued)












12 months 12 29/83 35.5 12 21/98 21.5 1.6 1.01 to 2.6
TEF 24 months 8 44/120 36.5 8 23/120 18.9 1.9 1.2 to 3.0
TEF 36 months 8 82/120 68.7 8 19/119 15.7 4.3 2.8 to 6.6
TEF 42 months 8 69/120 57.2 8 - - - -
TEF 54 months 8 46/120 38.7 8 - - - -
TRIMETHOPRIM-SULFAMETHOXAZOLE
TEF 24 months 8 0/120 0 8 3/120 2.7 0.14 0.01 to 2.7
TEF 36 months 8 9/120 7.9 8 8/119 6.7 1.1 0.5 to 2.8
TEF 42 months 8 11/120 8.8 8 - - - -
TEF 54 months 8 8/120 6.8 8 - - - -
n/N: number of isolates with resistance/total number of isolates
AZ: azithromycin
MDA: mass drug administration
*Studies were all cluster-randomised controlled trials. PRET The Gambia compared AZ once a year for 3 years with AZ once a year
for 1 year; TANA compared AZ every 3 months for 12 months with no AZ; TEF compared AZ twice a year for 3 years with no AZ.
**Follow-up is months after baseline (i.e. first MDA) unless otherwise indicated.
***TANA and TEF reported average percentages across communities, and these are the percentages reported in this table. We estimated
n/N using these percentages and additional information in the text of the paper. Figures for n/N were used to calculate the risk ratio
and 95% confidence interval in RevMan 5. There may be minor discrepancies due to rounding between the raw numbers, percentages
and risk ratios. The 95% confidence intervals for the risk ratio are are not adjusted for the cluster design.
¶ Denominator is isolates with pneumococcal carriage only.
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Table 10. Antibiotic resistance to Staphylococcus aureus
Study* Follow-
up**




































































2 25/30 83.3 6 6/25 24.0 3.5 1.7 to 7.1
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2 24/102 23.5 6 - - - -
148Antibiotics for trachoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.






























2 20/30 66.7 6 3/25 12.0 5.6 1.9 to 16.5
n/N: number of isolates with resistance/total number of isolates
AZ: azithromycin
MDA: mass drug administration
*Studies were all cluster-randomised controlled trials. PRET The Gambia compared AZ once a year for three years with AZ once a
year for one year.
**Follow-up is months after baseline (i.e. first mass drug administration) unless otherwise indicated.
***The 95% confidence intervals for the risk ratio are are not adjusted for the cluster design.
¶ Denominator is isolates with S.aureus carriage only.
Table 11. Antibiotic resistance to Escherichia coli
Study* Follow-
up**












Baseline 4 20/163 16.3 4 20/96 20.8 0.6 0.3 to 1.04
PRET
Tanzania
1 month 4 79/129 61.2 4 25/134 18.7 3.3 2.3 to 4.8
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Table 11. Antibiotic resistance to Escherichia coli (Continued)
PRET
Tanzania
3 months 4 56/133 42.1 4 20/126 15.9 2.7 1.7 to 4.2
PRET
Tanzania




























Baseline 4 32/123 26.0 4 22/96 22.9 1.2 0.6 to 2.2
PRET
Tanzania
1 month 4 98/129 76.0 4 38/134 28.4 8.0 4.6 to 13.9
PRET
Tanzania
3 months 4 73/133 54.9 4 30/126 23.8 3.9 2.3 to 6.6
PRET
Tanzania






Baseline 4 51/300 17.0 4 35/205 17.1 1.0 0.6 to 1.6
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6 months 4 61/191 31.9 4 20/118 16.9 2.3 1.3 to 4.1
n/N: number of isolates with resistance/total number of isolates
AZ: azithromycin
*Studies were all cluster-randomised controlled trials. PRET Tanzania compared AZ once a year for three years with no AZ.
**Follow-up is months after baseline (i.e. first mass drug administration) unless otherwise indicated.
***The 95% confidence intervals for the risk ratio are not adjusted for the cluster design.
¶ Denominator is isolates with E.coli carriage only.
Table 12. Adverse effects: cluster-randomised studies
Study Antibiotic (number of communities
and people treated)
Report
1, 2 & 3 ACT 1999 Egypt; ACT 1999
Tanzania; ACT 1999 The Gambia
Azithromycin (6 communities, approx-
imately 3800)
Tetracycline (6 communities, approxi-
mately 2400)
No comment on adverse effects in re-
port




No comment on adverse effects in re-
port
5 NCT00618449 Azithromycin (1139) Reported no adverse events on clini-
cal trials register (clinicaltrials.gov/ct2/
show/results/NCT00618449)
6 PRET Niger Azithromycin (48 communities, ap-
proximately 6000)
No comment on adverse effects in re-
port, but “a data and safety monitoring
committee met annually to review re-
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Table 12. Adverse effects: cluster-randomised studies (Continued)
sults and serious adverse events”
7 PRET Tanzania Azithromycin (32 communities, ap-
proximately 12,000)
“There were no serious adverse events
reported in either arm.”
8 PRET The Gambia Azithromycin (48 communities, 29,
091)
No comment on adverse effects in re-
port
9 Resnikoff 1995 Oxytetracycline (346) No comment on adverse effects in re-
port
10 TANA Azithromycin (over 16,000) “We recorded no reported serious ad-
verse events attributed to study medi-
cation. 96 deaths were recorded in sub-
kebeles in the children-treated group
and 126 deaths recorded in those in
the control group. At 12 months a sur-
vey was undertaken to assess adverse
effects in the treated population (n=
671, 96 side-effects reported). [.. ] 56
(11.3%) patients reported abdominal
pain, vomiting, and nausea, whereas
diarrhoea, constipation and related is-
sues accounted for 16 (2.4%) of com-
plaints. Four (0.6%) patients reported
haemorrhoid or other as side effects”
(House and colleagues, page 1115). “In
a trachoma-endemic area, mass distri-
bution of oral azithromycin was asso-
ciated with reduced mortality in chil-
dren” (Porco and colleagues, conclu-
sion of abstract)
11 TEF Azithromycin (16 communities, 4790) “There were no serious adverse events
due to the study medicine reported”
12 Wilson 2018 Azithromycin (48 communities, un-
clear how many people)
“No serious adverse events were associ-
ated with MDA.”
MDA: mass drug administration
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Table 13. Azithromycin (single-dose) every 3 months for 12 months: mean community prevalence of infection with C
trachomatis at 12 months
Intervention: children aged 1 to 10 years offered
single-dose oral azithromycin every 3 months (n
= 12 communities)
Comparator: everyone aged 1 year and older of-
fered single-dose oral azithromycin at first visit
(baseline) (n = 12 communities)
Prevalence % 95% confidence inter-
val
Prevalence % 95% confidence inter-
val
Children aged 1 to 10
years
3.6 0.8 to 6.4 14.6 7.2 to 22.1
Children and adults aged
11 years and older
8.2 5.1 to 11.4 6.2 2.9 to 9.4
Table 14. Azithromycin (single-dose) every 6 months compared with annual treatment: mean community prevalence of
infection with C trachomatis
Intervention: everyone aged 1 year and older
offered single-dose oral azithromycin every 6
months
Comparator: everyone aged 1 year and older of-
fered single-dose oral azithromycin annually
Prevalence % 95% confidence inter-
val
Prevalence % 95% confidence inter-
val
PRET Niger
Children aged 0 to 5
years
Follow-up: 36 months
3.8 2.2 to 6.0 5.8 3.2 to 9.0
PRET Niger
Adults aged 15 years
or older Follow-up: 36
months
0.0 0 to 7 0.3 0 to 7
TANA
Children aged 0 to 9
years
Follow-up: 12 months
1.7 0.7 to 2.6 6.2 2.9 to 9.4
TANA
Children aged 0 to 9
years
Follow-up: 24 months
1.5 0.2 to 2.8 2.3 0.8 to 3.8
TANA
Children aged 0 to 9
years
Follow-up: 36 months
0.2 0.0 to 0.6 1.5 0.1 to 3.0
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Table 14. Azithromycin (single-dose) every 6 months compared with annual treatment: mean community prevalence of
infection with C trachomatis (Continued)
TANA
Children and adults aged
10 years and older
Follow-up: 12 months
1.7 0.7 to 2.6 6.2 2.9 to 9.4
TANA
Children and adults aged
10 years and older
Follow-up: 24 months
1.5 0.2 to 2.8 2.3 0.8 to 3.8
TANA
Children and adults aged
10 years and older
Follow-up: 36 months
0.2 0.0 to 0.6 1.5 0.1 to 3.0
TEF
Children aged 1 to 5
years
Follow-up: 12 months
1.3 0.3 to 2.6 10.9 0.1 to 21.8
TEF
Children aged 1 to 5
years
Follow-up: 24 months
0.9 0.0 to 2.1 6.8 1.2 to 12.4
PRET Niger: 24 communities in each group; only children aged 0 to 12 years treated in intervention group.
TANA: 12 communities in each group.
TEF: 8 communities in each group.
Table 15. Antimicrobial resistance in non-randomised studies
Citation and loca-
tion













2 months 956/978 residents
examined at base-
line; 56 with eye in-
fection; 43 isolates
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fore and after treat-
ment.
1 to 5 years Azithromycin
Doxycycline
18 months af-















after mass drug ad-
ministration.
0 to 9 years Azithromycin
Doxycycline
12 months after 3
years of mass treat-
ment
Compared resis-
tance to C trachoma-
tis in children with/
without continuing
infection and found



























• 6/38 at 2 to 3
weeks;













10 days and 6
months
At 180 days, 5% of






0% of children with









0 to 7 years Azithromycin
Penicillin
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vey 1 year after
mass distribution of
azithromycin
1 to 10 years Azithromycin
Trimethoprim/
sulfamethoxazole









vey 6 months after
the 3rd annual treat-
ment with azithro-
mycin or tetracy-
cline or no treat-
ment
1 to 10 years Azithromycin
Trimethoprim/
sulfamethoxazole
12 months 5/163 (3%) isolates
were resis-
tant to azithromy-
cin in the azithro-
mycin-treated com-
munities compared
with 0 in 126 chil-
dren in tetracycline-
treated com-
















vey 4 years after
mass distribution of
azithromycin
1 month to 59
months




and 16.6% of the
S pneumoniae, S au-
reus, and E coli iso-
lates, respectively.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Trachoma
#2 MeSH descriptor Chlamydia trachomatis
#3 trachoma* or tracoma*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Anti-Bacterial Agents
#6 antibiotic*
#7 MeSH descriptor Azithromycin
#8 azithrom*cin*
#9 MeSH descriptor Tetracycline
#10 tetracycline*
#11 MeSH descriptor Chlortetracycline
#12 chlortetracycline*
#13 MeSH descriptor Macrolides
#14 macrolide*
#15 (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#16 (#4 AND #15)
Appendix 2. MEDLINE Ovid search strategy
1 randomized controlled trial.pt.









11 9 not (9 and 10)
12 8 not 11
13 exp trachoma/
14 trac?oma$.tw.
15 exp chlamydia trachomatis/
16 or/13-15 (14120)











28 16 and 27
29 12 and 28
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
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Appendix 3. Embase Ovid search strategy
1 exp randomized controlled trial/
2 exp randomization/
3 exp double blind procedure/
4 exp single blind procedure/
5 random$.tw.
6 or/1-5
7 (animal or animal experiment).sh.
8 human.sh.
9 7 and 8
10 7 not 9
11 6 not 10
12 exp clinical trial/
13 (clin$ adj3 trial$).tw.




18 exp experimental design/
19 exp crossover procedure/
20 exp control group/
21 exp latin square design/
22 or/12-21
23 22 not 10
24 23 not 11
25 exp comparative study/
26 exp evaluation/
27 exp prospective study/
28 (control$ or prospectiv$ or volunteer$).tw.
29 or/25-28
30 29 not 10
31 30 not (11 or 23)
32 11 or 24 or 31
33 exp trachoma/
34 trac?oma$.tw.
35 exp chlamydia trachomatis/
36 or/33-35











48 36 and 47
49 32 and 48
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Appendix 4. ISRCTN search strategy
(trachoma OR tracoma) AND antibiotics
Appendix 5. ClinicalTrials.gov search strategy
(trachoma OR tracoma) AND Antibiotics
Appendix 6. WHO ICTRP search strategy
Condition = trachoma OR tracoma AND Interventions = antibiotics
Appendix 7. Changes made to data in the 2011 update of the review
Current review Original review Comments
Treatment Control Treatment Control









































48 152 68 139 56 158 83 156 People with missing data








53 83 29 62 53 83 34 42 Error in data extraction in
original review
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15 31 12 29 15 32 12 32 In the original review, peo-
ple who were not followed up
were included in the denomi-
nator. This makes the assump-
tion that people who were not

































































Data for the ACT trial in the original review were not exactly the same as the published data and included
unpublished outcomes. The original review authors had access to individual patient data that were not
available to the current authors. In the absence of access to the original data, we felt it was unwise to make
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any changes to the data included in the review.
W H A T ’ S N E W
Date Event Description
4 January 2019 New citation required and conclusions have changed Issue 9, 2019: Review substantively updated. New author-
ship.
4 January 2019 New search has been performed Issue 9, 2019: Electronic searches updated and 4 new trials
included. New outcome on antimicrobial resistance added
H I S T O R Y
Protocol first published: Issue 3, 1999
Review first published: Issue 1, 2002
Date Event Description
31 March 2008 Amended Converted to new review format.
1 February 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Original version of the review: Denise Mabey (DM) screened the search results, graded selected trials, extracted some data, and wrote
the review. DM was the guarantor for the review. Nicole Fraser-Hurt (NF) graded selected trials, extracted the data, and contributed
to the writing of the review. Christine Powell screened the search results and worked on the update of the review.
Major update of review and change of authors 2011: JE and AWS screened the search results; assessed risk of bias of all included studies;
extracted data from newly included trials; and substantially rewrote the text of the review.
Major update of review and change of authors 2019: JE and EHE screened the search results; assessed risk of bias of all included studies;
extracted data from newly included trials; and substantially rewrote the text of the review. Other authors reviewed and contributed to
the manuscript and collected data on non-randomised studies for the Discussion.
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D E C L A R A T I O N S O F I N T E R E S T
Previous versions of this review
The Edna McConnell Clark Foundation supported Denise Mabey and Nicole Fraser-Hurt for one half-day a week over a 10-month
period to undertake the original review. SightSavers International in part funded JE’s salary to update the review in 2011.







EHE: The International Trachoma Initiative (ITI) pays for EHE’s salary. ITI is a program of The Task Force for Global Health, and
receives funding from Pfizer Inc. Neither ITI nor Pfizer Inc. had any role in the review’s research questions and design; in the collection,
analysis and interpretation of data; in the writing of the review; or in the decision to submit for publication.
Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV) signed off the review for publication. Peter Tugwell,
Senior Editor and Nuala Livingstone, Associate Editor for the Cochane Musculoskeletal, Oral, Skin and Sensory (MOSS) Network
reviewed a draft prior to publication. This was to avoid a potential conflict of interest as one of the authors (JE) is the joint Co-
ordinating Editor for CEV.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• The Edna McConnell Clark Foundation, USA.
• Christian Blind Mission, Germany.
• Sightsavers International, UK.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
Objectives
When this review was first published in 2002 (Mabey 2002), the aim was to investigate the strength of evidence that antibiotics were
more effective than placebo in reducing disease and to compare the effects of oral azithromycin with topical tetracycline.
These objectives were modified when the review was updated in 2011 (Evans 2011). It was decided to consider individually randomised
and cluster-randomised trials separately, as the new author team felt that they were addressing different questions and were likely to
be measuring different effects. The individually randomised studies address the question: what is the effect of antibiotic treatment on
individuals? The cluster-randomised trials address the question: what is the effect of antibiotic treatment on communities? The effect
of treatment in individuals in treated communities may be different because as well as the individual-level effect, there may be an
additional impact via reduction in transmission. The following two objectives were identified.
1. What is the effect of antibiotic treatment of individuals on active trachoma and ocular C trachomatis infection?
2. What is the effect of community treatment with antibiotics on the prevalence of active trachoma and ocular C trachomatis infection?
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We further expanded the objectives for the current update, including the effect of different treatment frequencies and adding antimi-
crobial resistance as an outcome.
(1) What is the effect of antibiotic treatment of the individual on active trachoma and ocular C trachomatis infection?
• What is the effect of antibiotic treatment versus no treatment?
• What is the effect of oral versus topical antibiotic?
• What is the effect of oral azithromycin compared to topical tetracycline?
(2) What is the effect of community treatment with antibiotics on the prevalence of active trachoma and ocular C trachomatis infection?
• What is the effect of mass administration of antibiotic compared to no treatment?
• What is the effect of mass administration of oral azithromycin versus topical tetracycline?
• What is the effect of annual versus different treatment frequencies?
(3) What are the adverse effects of antibiotic treatment?
• What are the adverse effects at the individual level?
• What is the effect of mass administration of oral azithromycin or topical tetracycline on resistance in (i) C trachomatis and (ii)
other bacteria?
Other changes
In the 2011 update (Evans 2011), we implemented Cochrane’s tool for assessing risk of bias and updated some aspects of the methods
- such as assessment of heterogeneity - that were not discussed in detail in the original protocol.
N O T E S
This review was first published as Mabey D, Fraser-Hurt N. Antibiotics for trachoma. Cochrane Database of Systematic Reviews 2002,
Issue 1. Art. No.: CD001860. DOI: 10.1002/14651858.CD001860.pub2. The 2011 and current updated versions of the review were
written by a new review team.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Chlamydia trachomatis; Administration, Oral; Administration, Topical; Anti-Bacterial Agents [administration & dosage; ∗therapeutic
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